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Dolutegravir (DTG), the second-generation Integrase Inhibitor (InSTI) and Cobicistat 
(COBI), the new pharmacological booster, were approved for the treatment of HIV in 
2013-14. DTG changed the landscape of HIV therapy, raising standards for efficacy, 
safety and genetic barrier. It is now recommended as first line therapy in most major 
including universal guidelines and is the anchor drug for a number of new simplified 
ARV strategies. Meanwhile, COBI offers the opportunity to reduce pill burden in 
patients who require a boosted protease inhibitor, thanks to its co-formulation with 
atazanavir (ATV) and darunavir (DRV). It also has a lesser drug interaction profile 
than ritonavir (RTV), secondary to a lack of enzyme induction. Licensing data is often 
limited to highly selected study participants under strict trial conditions. The objectives 
of this thesis are therefore to address gaps in knowledge on the pharmacological 
behaviour of DTG and COBI in important real-life patient groups and clinical 
scenarios, including older people living with HIV (PLWH), women taking 
contraception, poorly adherent patients, DTG/DRV/COBI dual therapy candidates and 
genetically distinct populations. Five intensive pharmacokinetic (PK) studies were 
carried out, recruiting healthy volunteers and PLWH from four UK-based centers. 
Pharmacogenetic sampling from each DTG study was used in a final study to explore 
the impact of genetic variability in drug disposition genes on the PK of DTG. 
 
The intensive PK of DTG was described for the first time in PLWH aged 60 years and 
over, showing a significantly higher DTG Cmax (25%) versus younger subjects (median 
age 36yrs). Discontinuation rate secondary to neuro-psychiatric adverse events was 
4.6% and seemed to relate to elevated drug concentrations, but the Cmax increase was 
not associated with measured sleep or cognitive changes over six months in those who 
did continue the drug. The PK forgiveness of DTG and COBI-boosted elvitegravir 
(EVG), ATV and DRV was then characterised in healthy volunteers, showing a 72-
hour therapeutic PK tail for DTG, 36hrs for EVG, 30hrs for ATV and 24hrs for DRV 
when boosted with COBI. The PK impacts of DTG co-administration with DRV/COBI 
and of ethinylestrodiol/levonogestrel (EE/LNG) with ATV/COBI were also 
investigated. Findings showed minimal changes in DTG/DRV/COBI concentrations 
when administered together and a 25% decrease in EE C24 with no significant changes 
in LNG when EE/LNG was co-administered with ATV/COBI. Finally, a 
pharmacogenetic association between DTG PK and variants in the ABCG2, UGT1A1 
and NRI1/2 genes was demonstrated, particularly when combined. 
 
The data presented in this thesis provides clinicians with key information on the 
pharmacology and safety of DTG and COBI in important patient groups and clinical 
scenarios. The significance and clinical validity of the data is discussed and an 
argument is made to support future research in DTG dose optimisation. 
 The pharmacokinetics, pharmacodynamics and pharmacogenetics of dolutegravir and cobicistat in 
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1.1. HIV AND ITS PHARMACOLOGY  
By the end of 2016, approximately 36.7 million people were living with HIV/AIDS 
worldwide. As of July 2017, 20.9 million were accessing antiretroviral therapy (ART) 
globally.1 This is a formidable accomplishment for a disease that was uniformly fatal 
three decades ago.2 The critical contributor to this achievement has been the 
remarkably fast moving field of HIV pharmacotherapy.2, 3 Early and sustained 
antiretroviral (ARV) use now suppresses the virus and enables people living with HIV 
(PLWH) to enjoy long and healthy lives with negligible risks of sexual or perinatal 
HIV transmission.4-6 In the wake of these advancements, UNAIDS set the now well-
recognized 2020 fast track targets: 90-90-90, aiming for 90% of PLWH knowing their 
status, 90% accessing ART and 90% achieving viral suppression worlwide.7 This 
equates to almost 30 million people on ARV treatment and highlights the importance 
of meticulously characterising the pharmacokinetic (PK), pharmacodynamic (PD) and 
pharmacogenetic properties of the drugs involved in this ARV scale up.  
 
This chapter provides a brief overview of the HIV viral structure, replication cycle and 
drug targets followed by a detailed review of the pharmacology and pharmacogenetics 
of the two significant agents approved in 2013-14 for the treatment of HIV, 
dolutegravir (DTG) and cobicistat (COBI). Gaps in the literature addressed by the 
research presented in this thesis are highlighted and the chapter ends with the research 
objectives and structure of the thesis. 
1.1.1. An unprecedented epidemic 
Whilst 1981 saw the first cases of the HIV/AIDS pandemic reported in the US,8-11 the 
first verified report of AIDS dates back to 195912 and was retrospectively diagnosed 
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in blood samples collected from a man living in Kinshasa, now the Democratic 
Republic of Congo, by researchers studying the links between glucose-6-phosphatase 
deficiency, malaria and sickle cell disease.12-15 It is widely accepted that HIV-1 and 
HIV-2 are the result of zoonotic transfers of viruses from infected primates in central 
and equatorial Africa,15-17 and bush meat hunting, urbanisation and mass vaccination 
programs have all being implicated in the subsequent pathogenic evolution and 
propagation of the virus.15, 17-20 Phylogenetic and evolutionary studies of HIV-1 place 
the first cross-species transmission of chimpanzee Simian Immunodeficiency Virus 
(SIVcpz) into humans in the early 20th century14-17 and evidence supports the hypothesis 
that SIV must have crossed over into humans multiple times with limited virulence 
and capacity for spread across humans prior to the start of the current pandemic.14-17 
In spite of this, it wasn’t until 1987, that the human disease saw its first therapeutic 
agent approved.21-23 Today, over 30 individual agents are approved by the Food and 
Drugs Administration (FDA), including more than 10 co-formulated combinations. 
1.1.2. Viral structure, replication cycle and drug targets 
HIV viruses are lentiviruses, a family of retroviruses for which humans and non-
human primates are the only hosts.2 HIV-1 was first isolated and described in 1983 
and HIV-2 in 1986.19, 24, 25 The hallmarks of retrovirus infection are reverse 
transcription and integration,26 both of which are distinct and established therapeutic 
targets.  HIV-1 is not just one virus, it comprises four distinct lineages, termed groups 
M, N, O, and P, each of which results from an independent cross-species transmission 
event. Group M (group major) is responsible for more than 90% of all HIV/AIDS cases 
and has ~11 suspected or confirmed clades (A-K), resulting from differing 
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evolutionary pressures and adaptations.17, 27, 28 Clades A, B and C form the bulk of the 
epidemic.19 
Figure 1.1: HIV-1 genomic and structural organisation (adapted and with permission from Thomas 
Splettstoesser [www.scistyle.com] and Hoffman et al. HIV book, 2011).  
Figure 1.1 depicts the HIV-1 viral structure and genome organisation. Each individual 
virion consists of two copies of 9300 base pair-ribonucleic acid (RNA) genome, 
contained in a conical nucleocapsid core, itself surrounded by a lipid bilayer envelope 
(derived from host plasma membrane).2, 26, 29, 30 Overall, the HIV genome contains nine 
genes that encode fifteen viral proteins, that are either structural (found in all 
retroviruses) or nonstructural ("accessory", unique to HIV).31 The HIV life cycle and 
the individual steps targeted by the ARV agents currently approved or in development 
are illustrated in figure 1.2. The HIV-1 life cycle presents many potential opportunities 
for therapeutic intervention and some would argue that only a few have been exploited 
to date,32 albeit successfully. However, still, ARVs prevent infection of susceptible 
cells but do not eradicate the virus in cells that already harbour the integrated proviral 
DNA.2 The establishment of proviral DNA inside the host genome means that the viral 
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genome is replicated whenever cellular division takes place and will persist in the host 
even in the absence of active viral replication, which is known as the HIV reservoir.33  
Figure 1.2: HIV life cycle in a human cell, timing of early events post-cell infection and current drug 
targets (adapted from Prof Stanley Bruhl, University of Amsterdam)  
Triple therapy has been the cornerstone of HIV treatment since 1996. The currently 
used antiretroviral drugs are:34  
i. 6 nucleoside reverse transcriptase inhibitors (NRTIs): abacavir (ABC), zidovudine 
(ZDV), the cytosine analogues lamivudine (3TC) and emtricitabine (FTC), and the 







ii. 4 nonnucleoside reverse transcriptase inhibitors (NNRTIs): efavirenz (EFV), 
rilpivirine (RPV), etravirine (ETR) and doravirine (DOR) 
iii. 3 protease inhibitors (PIs) pharmacologically boosted by ritonavir (RTV) or 
cobicistat (COBI): lopinavir (LPV), atazanavir (ATV) and darunavir (DRV) 
iv. 4 integrase strand transfer inhibitors (InSTIs): raltegravir (RAL), elvitegravir 
(EVG), dolutegravir (DTG) and bictegravir (BIC) 
 
A full timeline of FDA approvals of ARV drugs for human use is described in table 
1.1. Trade names can be found in appendix 1. 
1.2. A NEW ERA: THE INTEGRASE INHIBITORS 
1.2.1. The HIV integrase structure 
The HIV-1 integrase enzyme (IN) belongs to the retrotransposon family of proteins 
and is present in the initial infectious virion (40-100 copies). In vitro, it is the only 
viral or host enzyme necessary and sufficient to promote insertion of a donor DNA 
into a heterologous target DNA, at any phosphodiester bond.35-37 The prototypical 
HIV-1 IN is a 288-amino-acid protein and is divided into three major domains (figure 
1.3): an N-terminal domain, a catalytic core domain and a C-terminal domain:35-39  
1. The Amino (N)-terminal domain, sometimes referred to as a "zinc finger", is 
composed of the conserved HHCC, His and Cys residues; a motif that serves to 
bind zinc.40, 41 The function of the N-terminal domain is not completely clear, but 
it is thought to involve IN multimerisation (into dimers and tetramers) and viral 
DNA binding. 
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Table 1.1: FDA Antiretroviral drugs approval timeline. Abbreviations: GSK: GlaxoSmithKline, Gilead: Gilead Sciences, BMS: Bristol Myers Squibb, Merck: Merck Sharp & 
Dohme, HLA: Hoffman La Roche, Trim: Trimeris, Thera: Theratechnologies Inc., Abbott: Abbott Laboratories, Agouron: Agouron Pharmaceuticals.
1980-1984 1981  
First AIDS reports in United States 
1985-1989 1987 
Zidovudine (AZT; GSK) 
   
1990-1994 1991 
Didanosine (ddI; BMS) 
Saquinavir (SQV; HLR) 
1992 
Zalcitabine (ddC; HLR) 
 
1994 
Stavudine (d4T; BMS) 
 
1995-1999 1995 
Lamivudine (3TC; GSK) 
 
1996  
Indinavir  (IDV; Merk) 
Nevirapine (NVP; BI) 
Ritonavir (RTV; Abbott) 
1997 
Combivir (AZT/3TC; GSK) 
Delavirdine (DLV; Pfizer) 
Nelfinavir (NFV; Agouron) 
1998/1999 
Abacavir (ABC; GSK) 
Efavirenz (EFV; BMS) 
Amprenavir (APV; GSK) 
2000-2004 2000  
Lopinavir/r (LPV/r; GSK) 
Trizivir (AZT/ABC/3TC;GSK) 
2001 
Tenofovir DF (Gilead) 
2003 
Atazanavir (ATV; BMS) 
Emtracitabine (FTC; Gilead) 
Enfuvirtide (T-2z; HLR/Trim) 
Fosamprenavir 
2004 
Kivexa (ABC/3TC; GSK) 
Truvada (TDF/FTC; Gilead) 
2005-2009 2005 
Tipranavir (TPV; BI) 
2006 
Atripla (TDF/FTC/EFV; Gilead) 
Darunavir (DRV; Tibotec) 
2007 
Maraviroc (MVC; Pfizer) 
Raltegravir (RAL; BMS) 
2008 
Etravirine (ETV; Tibotec) 
2010-2014 2011 
Eviplera (TDF/FTC/RPV; Gilead) 




Dolutegravir (DTG; GSK) 
2014 
Cobicistat (COBI; Gilead) 
Elvitegravir (EVG; Gilead) 




Evotaz (ATV/COBI; BMS) 
Genoya (TAF/FTC/EVG/COBI; Gilead) 
Rezolsta (DRV/COBI; Janssen) 
2016 
Descovy (TAF/FTC; Gilead) 
Odefsey (TAF/FTC/RPV; Gilead) 
2017 
Juluca (RPV/DTG; GSK) 
2018 
Biktarvy (TAF/FTC/BIC; Gilead) 
Cimduo (TDF/3TC; Mylan) 
Symfi (TDF/3TC/EFV; Mylan) 
Ibalizumab (IBA; Thera) 
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2. The catalytic core domain contains the D,D-35-E triad motif, which constitutes the 
catalytic active site essential to coordinate a pair of Mg2+ ions (or divalent metal 
cations) and carry out the IN enzymatic function. This motif is typical of 
polynucleotidyl transferases.36 The core domain also contains key residues involved 
in target and viral DNA binding. Recognition of the target site is thought to be 
controlled by the core domain.37, 42 
 
3. Finally, the C-terminal domain is mostly involved in IN multimerisation and DNA 
binding.43, 44 
 
Figure 1.3: Domain organisation of the human immunodeficiency virus type 1 (HIV-1) integrase 
enzyme, common to all retroviral integrases (adapted from Ciuffi et al. 2016).37 
The IN enzyme orchestrates several sequence-specific events required for successful 
stable integration, which occurs in 3 major phases:  
1. Assembly with the viral DNA, endonucleolytic processing of the 3’ ends of the viral 
DNA and nuclear translocation  
2.  Strand transfer or joining of the viral and cellular DNA  
3. DNA repair by the host DNA repair machinery 





Catalysis and DNA binding  
DNA binding 
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Figure 1. 4: Model of nuclear import and integration coupling. Interaction with Transportin-3 and 
RanBP2 shuttles the Pre-Integration Complex (PIC) through the nuclear pore and towards gene dense 
regions favored for HIV integration. The Ledgf/p75, co-factor then targets integration to active 
transcription sites. Abbreviations: F G, phenylalanine-glycine repeat sequences of nuclear pore proteins. 
Adapted from Ocwieja et al.2011  
Figure 1.5: HIV DNA integration sequence (from Ciuffi et al. 2016) 
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1.2.2. The Integrase Inhibitors (InSTIs) 
The integrase gene and enzyme of HIV were recognized as a potential therapeutic 
target susceptible to inhibition by oligonucleotides and synthetic peptides as early as 
1995.45, 46 However, the seminal study describing the first promising small compound 
targeting the integrase was published in 2000.47 Structures of intasome/drug 
complexes (from prototype foamy virus and more recently the HIV virus itself) have 
revealed that InSTIs bind to the catalytic core domain of the integrase and compete 
with host DNA binding (figure 1.6).47-49  
 
InSTIs are the most recently introduced ARVs. There are three established InSTIs 
licensed for HIV treatment naïve and experienced patients: raltegravir (RAL), 
elvitegravir (EVG) and dolutegravir (DTG).50 A fourth, bictegravir (BIC), was very 
recently (spring 2018) approved by the FDA for use in treatment-naive patients or 
patients with HIV-1 RNA <50 copies/mL for ≥3 months, no history of treatment 
failure, and no resistance to regimen components.51 InSTIs have changed the clinical 
landscape of HIV therapy significantly. Data from large clinical trials have showed 
that, as a drug family, they are equivalent or superior to existing treatments in efficacy, 
display favorable pharmacokinetics and show greater safety and tolerability than PIs 
and NNRTIs.52 They also benefit from paucity of drug-drug interactions (DDI), no 
cross-resistance to other drug classes, rapid HIV RNA reduction, action against HIV-
2 and availability in single tablet regimens (STR). In a 2013 comprehensive review, 
Messiaen et al. constructed forest plots of the modified intention to treat (mITT) 
analyses in 16 trials illustrating the integrase inhibitors’ superiority over other agents 
very clearly (figure 1.7 A-C) (data from the DTG VIKING 3&4 studies and the BIC 
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licensing studies are absent). The authors concluded that in first-line therapy, InSTIs 
are superior to other regimens and, additionally, that InSTI use after virological failure 
is supported but with caution when replacing a high genetic barrier drug in treatment-
experienced patients switching from successful treatment.52 
Figure 1.6: Integrase strand transfer inhibitors and the crystal structure of prototype human foamy virus 
integrase, complexed to dsDNA and raltegravir (from Hare et al. 2010, with permission). Abbreviations: 
N-term: amino-terminal; C-term: carboxy-terminal; GSK1349572: dolutegravir.
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Figure 1.7: Forest plot showing the meta-analysis of mITT data extracted from 
studies in patients who are A)therapy naive patient B) ART experienced in case of 
virological failure and C) ART experienced switching with suppressed viral loads. 
The black line indicates OR = 1, signifying no benefit of the INI arm compared to 
the non-INI arm. The dotted line shows the odds ratio of all included studies. The 
individual odds ratios as well as the proportionate weight in the overall analysis 
are shown in the right column. mITT = modified intention-to-treat; ART = 
antiretroviral treatment; INI = integrase inhibitor; (N)NRTI = (non-)nucleoside 
reverse transcriptase inhibitor; PI = protease inhibitor; OR = odds ratio 
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InSTIs now monopolise (DHHS/IAS-USA) or dominate (EACS/BHIVA)53-56 first-
line treatment in guidelines (table 1.2). They have even been credited for a marked 
increase seen in viral suppression and maintenance of undetectability overall.57 Table 
1.2 shows the recommendations for first line therapy in major 2018 HIV treatment 
guidelines. 
Table 1.2: North American and European 2018 guidelines for first line therapy in treatment-naïve HIV 
infected individuals. Abbreviations: DHHS: Department of Health and Human Service; IAS-USA: 
International Aids Society USA; EACS: European AIDS Clinical Society. In bold: single tablet 
regimen. 
Whilst the InSTI compounds share the same mode of action, they exhibit different PK, 
PD and DDI profiles. PK characteristics for each agent are tabulated in table 1.3.  
 
The second generation InSTI, DTG, is discussed below including licensing data, 
emerging real life experience, novel strategies and use in special populations.58 COBI 
is then discussed in the context of EVG licensing, the other second generation InSTI 
and in the context of its subsequent co-formulation with ATV and DRV.  
DHHS IAS-USA EACS 
BIC/TAF/FTC DTG/ABC/3TC DTG/ABC/3TC 
DTG/ABC/3TC DTG + TAF/FTC DTG + (TAF or TDF)/FTC 





TDF)/FTC RAL + TAF/FTC RAL + (TAF or TDF)/FTC 
RAL + (TAF or 
TDF)/FTC  RPV + (TAF or TDF)/FTC 
  DRV/ (RTV or COBI) + (TAF or TDF)/FTC 
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Table 1.3: Pharmacokinetic properties of integrase inhibitors (reported mean values in adults with 
normal renal and hepatic function). Abbreviations: AUC: Area Under the Curve; t1/2 elim: half-life of 
elimination; ND: not determined; UGT: UDP glucuronosyltransferase; IQ: inhibitory Quotient 
(Ctrough/IC90 or IC95), EC50/90 concentration producing a 50/90% effect (reduction of HIV RNA) in vivo, 
IC50/90/95 protein binding–adjusted concentration inhibiting viral replication by 50/90/95% in vitro. 
1.2.3. Dolutegravir 
1.2.3.1. DTG efficacy and PK   
Approved individually in 2013 and in combination with two NRTIs as part of triple 
therapy in 2014, DTG was the first InSTI to be dosed once daily (OD) without 
boosting. It exhibits high efficacy, a predictable and favourable PK profile 
characterised by relatively low variability in licencing trials (C24h, 25–26% CV) and 
excellent safety and tolerability profiles.57-62 Overall, it stands relatively ahead of other 
ARVs and has now replaced EFV as first line agent in the World Health Organisation 
(WHO)  guidelines, meaning it is likely to play a major role in the worldwide ARV 
scale up in coming years.62-66 Additionally, a generic STR consisting of 
TDF/3TC/DTG is now available in some low to middle income countries (LMIC) at a 
median price of US$75 per person-year, making a DTG-containing regimen more 
PARAMETER RAL EVG DTG BIC 
Oral bioavailability % ND ND ND >70 
Effect of food on AUC ñ13–212% ñ36-91 % ñ33-36% ñ24% 
Plasma t1/2, elim, h 9 9-14 14 18 
Plasma protein binding, % 76–83 98–99 ≥98.9% 99 




CYP3A4 =  
UGT1A1 
Renal excretion of parent drug, % 9 6.7 <1% 1 
Cmax (ng/mL) 2170 1700 3670 9340 
AUC (h*ng/mL) 6910 23000 53600 140 000 
Cmin (ng/mL) 68.6 450 1110 3510 
In vitro PA-IC90/95 (ng/mL) 14.7 (IC95) 44.9 (IC95) 64 (IC90) ND 
In vivo EC90 (ng/mL) ND 126 324 ND 
IQ 8 10 17 16.2 
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affordable than EFV-containing regimens and enabling progress towards universal 
access to HIV treatment.66-68  
In the licencing phase, DTG was examined in five pivotal Phase III clinical trials, 
where it met criteria for superiority to EFV and to DRV/RTV in treatment naïve 
patients and to RAL in treatment experienced patients with at least two-class resistance 
but InSTI naïve. DTG also retained activity against some InSTI resistant viruses when 
dosed 50mg twice daily. Table 1.4 summarises all five studies.69-73 DTG dosing 
depends on patient-specific factors:74 
• 50 mg once daily if patients are treatment naïve or treatment-experienced and 
InSTI-naïve 
• 50 mg twice daily if patients also are taking a potent UGT1A/CYP3A inducer 
• 50 mg twice daily if patients are InSTI experienced with associated InSTI 
resistance substitutions, or are suspected to be InSTI-resistant. 
 
It is available alone as an individual tablet (Tiviquay®)50 and co-formulated with 
abacavir/lamivudine (Triumeq®).75 It is rapidly absorbed, achieving maximal blood 
concentration 2-4 hours after ingestion and has a terminal half-life of 12 hours, 
allowing OD administration without pharmacological enhancement.59, 60, 76 There is 
minimal urinary excretion as it is metabolised predominantly through hepatic 
glucuronidation by UDP-glucuronosyltransferase 1A1 (UGT1A1) with a small 
contribution from cytochrome P450 3A4 (CYP3A4).76, 77 DTG is detected in 
compartments such as CSF and cervicovaginal fluid at concentrations above that 
expected to confer continued antiviral efficacy and is therefore presumed to distribute 
widely.78-80 Absorption of DTG is not pH dependent, food does increase the area-
under-the-curve moderately (AUC ñ33-66%) but it can be taken with or without.81  
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Trial name Design 
D
uration 
N Regimen Subject characteristics Summary of results Comments 













OD DTG 50mg 
+ABC/3TC  
ARV naïve 
Female: DTG 16%, EFV 11% 
VL >100,000 cpm: DTG 27%, EFV 24% 
CD4 <200 cells/mL: DTG 14%, EFV 15% 
EFV: n=412 (in ITT analysis) 
DTG: n=403 (in ITT analysis) 
Efficacy (FDA snapshot):  
• Wk 48 HIV-1 RNA< 50 cpm: DTG 88% vs EFV 81%  
• Wk 96 HIV-1 RNA< 50 cpm: DTG 80% vs EFV 72%  
• Wk 144 HIV-1 RNA< 50 cpm: DTG 71% vs EFV 67%  
Criteria met for DTG superiority  
Superior efficacy primarily driven by fewer Discontinuations 
due to AE AEs: DTG 3%; EFV 11% 
CD4 increase at W144: DTG: 267, EFV 208 cells/ mm3 
Safety 
Insomnia only AE more reported DTG arm: 15 vs 10% 
GI symptoms and nasopharyngitis: 15-20% in both arms 
DTG: insomnia 10%, headache 6%, dizziness 7% 
No treatment-emergent 
InSTI or NRTI resistance in 
DTG arm through to W144. 
In the EFV arm, 6 ppts 
developed NNRTI DRMs 
(K101E, K103K/N, and 
G190G/A) and 1 NRTI 
DRM (K65K/R) at time of 
failure 
 










OD DRV/r 800/100mg 
vs 
 
OD DTG 50mg 
 
Each + TDF/FTC or 
ABC/3TC 
ARV naïve 
Female: DRV 17%, DTG 13% 
VL >100,000 cpm: DRV 25%, DTG 25% 
CD4 <200 cells/mL: DRV 10%, DTG 10% 
DRV: n=242 (in mITT analysis) 
DTG: n=242 (in mITT analysis) 
Efficacy (FDA snapshot):  
• Wk 48 HIV-1 RNA< 50 cpm: DTG 90% vs DRV 83%  
• Wk 96 HIV-1 RNA< 50 cpm: DTG 80% vs DRV 68% 
Criteria met for DTG superiority  
Virological non-response: DTG 5%, RAL10% 
Discontinuation due to AE: DTG 2%, DRV 4% 
CD4 increase at W48: DTG: 210, DRV 210 cells/ mm3 
Safety 
W96: The most common drug-related adverse events were 
diarrhoea DTG 10% vs DRV 24%, nausea DTG 13% vs DRV 
14%, and 
DTG: insomnia 9%, headache DTG 7% vs DRV 15%, 
depression 5% 
dizziness 6% 
Greatest difference in Wk96 
viral suppression seen in pts 
with high viral load at 

















OD DTG 50mg 
 
Each + TDF/FTC or 
ABC/3TC 
ARV naïve 
Female: RAL 15%, DTG 14% 
VL >100,000 cpm: RAL 28%, DTG 28% 
CD4 <200 cells/mL: RAL 13%, DTG 12% 
RAL: n=411 (in ITT analysis) 
DTG: n=411 (in ITT analysis) 
Efficacy (FDA snapshot):  
• Wk 48 HIV-1 RNA <50 cpm: DTG 88% vs RAL 85%  
• Wk 96 HIV-1 RNA <50 cpm: DTG 81% vs RAL 76% 
Criteria met for DTG non-inferiority  
Virological non-response: DTG 5%, RAL10% 
Discontinuation due to AE: 2% in each group 
CD4 increase at W96: DTG: 276, RAL 264 cells/ mm3 
Safety 
Similar AEs in both groups, (up to 13%) including nausea, 
headache, nasopharyngitis, and diarrhoea. 
DTG: headache 12% 
Backbone similar in both 
arms: 60% TDF/FTC and 
40% ABC/3TC. 
 
No DRM seen in the DTG 
arm  
In the RAL arm:  

















OD DTG 50mg 
 
Each + 2 additional 
ARVs with at least one 
fully active. 
ARV experienced but InSTI naïve 
At least 2 class resistance 
 
Female: RAL 30%, DTG 34% 
VL >50,000 cpm: RAL 30%, DTG 30% 
PI/r in regimen: RAL 84%, DTG 85% 
RAL: n=361 (in ITT analysis) 
DTG: n=354 (in ITT analysis) 
Efficacy (FDA snapshot):  
• Wk 48 HIV-1 RNA <50 cpm: DTG 71% vs RAL 64%  
Criteria met for DTG superiority  
Discontinuations due to AE: DTG 3%, RAL 4% 
CD4 increase at W96: DTG: 162, RAL 153 cells/ mm3 
Safety: 
Similar AE rates in both arms, (up to 9%); diarrhoea, URTI & 
headache commonest in both arms 
DTG: headache 9% 
Fewer virological failure 
with treatment-emergent 
InSTI resistance in DTG 
arm (4 vs 17, p=0.003). 
DRMs in DTG arm FC <2 
 
Those with DTG Ctrough in 
the lowest quartile had the 
lowest virological response 
rates 







BID DTG 50mg added 
to failing regimen 
 
Day 8, background 
regimen optimised with 
≥1 fully active drug and 
DTG continued 
 
ARV experienced with at least triple-class 
resistance (including INI resistance). 
VL > 500copies/mL 
 
Female: 33% 
VL >100,000 cpm: 22% 
Median VL: 4.38 (IQR), log10 cpm 
Median CD4 count: 140 cells/mL 
Median duration of prior ART: 14 years 
Median No of prior ARTs: 14 
Efficacy (FDA snapshot):  
• Week 8: mean change in VL −1.43 log10 cpm 
• Wk 24 HIV-1 RNA <50 cpm: 69% 
Response was most reduced in subjects with Q148 + ≥2 
resistance-associated mutation 
Discontinuations due to AE: 3% 
Safety: 
Drug related AEs rate: 15%, most common diarrhoea, nausea, 
and headache (similar to DTG 500mg OD) 
Strong association between 
baseline DTG susceptibility 
and response n multivariate 
analyses 
 
Formed the basis of the 
FDA approval of DTG for 
INI-resistant patients, at 
BID 50mg 
Table 1.4: Summary of the 5 pivotal licencing clinical trials for dolutegravir. Abbrieviations: DTG: Dolutegravir; TDF: Tenofovir Disoproxil Fumarate; FTC: Emtracitabine; 
EFV: Efavirenz; ABC: Abacavir; 3TC: Lamivudine; RAL: Rlategravir; DRV: Darunavir; OD: Once Daily; BID: Twice Daily; InSTI: Integrase Strand Transfer Inhibitor; PI/r: 
ritonavir boosted Protease Inhibitor; DRMs: Drug Resistance Mutations; ARV: Antiretrovirals; VL: Viral Load; cpm: copies per mL; AEs: Adverse Events; FDA: Food and 
Drug Association; FC: Fold Changes (in drug susceptibility); mITT: modified Intention To Treat analysis; GI symptoms: Gastrointestinal symptoms; IQR: Inter Quartile Range; 
Wk: Week; pts: patients; NRTI: Nucleoside Reverse Transcriptase Inhibitor
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However, like other InSTIs, DTG is at risk of chelation and must not be ingested 
concomitantly with cations-containing agents. If co-prescription is inevitable, it should 
be administered 2 hours before or 6 hours after.82 DTG holds a high genetic barrier.76 
It has an extended linker that allows its difluorophenyl group to enter further than other 
InSTIs into the pocket within the integrase active site, meaning it has a long 
dissociative half-life of 71h (vs 8.8 for RAL and 2.7 for EVG, p <0.0001) and an off-
rate 5 - 40 times slower than RAL and EVG.83 Studies have also shown that it has the 
ability to adjust its structure and conformation in response to structural changes within 
the active sites of RAL- and EVG-resistant integrases, further raising its barrier to 
resistance.84, 85 Finally, it has a high inhibitory quotient (IQ), determined by the 
remarkable distance of DTG minimum concentration within the dosing interval (Cmin) 
from its half maximal inhibitory concentration (IC50) at 50mg OD.57 Importantly, no 
DTG resistance mutation (DRM) had been observed when the drug is used in first-line 
therapy, up until very recently.86, 87 Major resistance pathways to InSTIs are shown in 
table 1.5. DTG distinguishes itself from both RAL and EVG by its very limited cross-
resistance to these compounds.88, 89 It is therefore a strong candidate for patients who 
struggle with adherence and chapter 3 explores DTG PK forgiveness in order to 
inform physicians in prescribing it to poorly adherent patients. Three cases of first-line 
failure with mutations have now been reported worldwide.90 Some potential resistance 
mutations (DRMs) to DTG have been identified at positions F121, S153, G118, E138, 
and R263 in vitro and in vivo.91, 92 R263K was initially reported as the most common 
substitution in cell culture selections but it confers only moderate resistance to DTG 
(2.3-fold).93 Overall, DTG associated DRMs decrease strand transfer activity and viral 
replication capacity, but these case reports highlight that this can be overcome and 





 RAL EVG DTG 
Y143 pathway  Y143C <10 <2 <2 
 Y143R <50 <2 <2 
 T97A, Y143C >100 <2 <2 
 T97A, Y143R >100 <2 <2 
 L74M, T97A, Y143G <50 ND <2 
 L74M, T97A, E138A, Y143C <20 ND <2 
N155 pathway N155N <50 <50 <2 
 E92Q, N155H <100 >100 <10 
 L74M, N155H <50 <50 <2 
Q148 pathway Q148H <20 <10 <2 
 Q148K <100 <100 <2 
 Q148R <50 <100 <2 
 E138K, Q148H <10 <20 <2 
 E138K, Q148K >100 >100 <10 
 E138K, Q148R >100 >100 <10 
 G140S, Q148H >100 >100 <20 
 G140S, Q148K >10 <100 <2 
 G140S, Q148R >100 >100 <10 
 E138A, G140S, Y143H, Q148H >100 ND <50 
R263K pathway R263K <1 3 4 
 R263K, H51Y 3-5 3 4-6 
G118R pathway G118R 10-17 >5 >8 
 G118R, H51Y ND ND ND 
 G118R, E138K 4-20 4-5 8-13 
Table 1.5: Major resistance pathways to raltegravir (RAL), elvitegravir (EVG), and dolutegravir 
(DTG). Abbreviations: ND: Not detetected. Adapted from Wainberg et al., Can. J. Micr, 2017  
Data post-marketing of DTG has focused on treatment simplification strategies, 
special populations infected with HIV, real life tolerability and DDIs, all of which are 
discussed below.  
1.2.3.2. Treatment simplification 
There has been interest, in recent years, in challenging the use of triple therapy, in 
order to lessen toxicity, cost and, potentially, drug interactions.100-103 Well-designed, 
adequately powered long-term randomized controlled trials (RCTs) in diverse 
populations are needed to consider the widespread adoption of simplified regimen into 
clinical practice. At the time of writing, 12 initial studies investigating dual therapy 
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using DTG as the anchor drug had been published: 10 observational studies and 2 
randomized trials.104  Additionally, following supporting bioequivalence data, the first 
dual therapy STR, DTG/RPV (Julucaâ) was approved by the FDA in 2018, for use in 
the US as maintenance therapy in selected patients.54, 105  
1.2.3.2.1. Dual therapy 
DTG + 3TC 
ARV-naïve patients: In the single arm PADDLE study, 20 ARV-naïve patients 
initiating DTG/3TC OD achieved HIV-1 RNA <50 copies/mL at week 48 (bar 1 
suicide, reported as unrelated to study drug).106 This was followed up by another pilot 
study, the ACTG5353, which recruited 120 ARV naïve patients with HIV-1 RNA 
1000-500,000 copies/mL and reported 90% achieving viral load (VL) <50 copies/mL 
at week 24 (FDA Snapshot). There were 3 protocol driven virological failures (VF) all 
of which had DTG levels reflective of suboptimal adherence.107  Finally, a fully 
powered multicenter, parallel-group, double-blind, randomized phase III non-
inferiority trial, GEMINI 1&2, compared DTG/3TC to triple therapy TDF/FTC/DTG 
in treatment naïve subjects with no major resistance associated mutations (n=1433). 
The FDA snapshot 48 weeks analysis reported non-inferiority of the dual therapy 
regimen (viral suppression 90% versus 93% in triple regimen), consistent across 
baseline HIV-1 VL and CD4 counts. There were no treatment-emergent InSTI or 
NRTI mutations observed in patients with confirmed VF.108 
 
Pre-treated patients: The ASPIRE (randomized, phase III) and the ANRS 167 
LAMIDOL (single-arm phase II) studies investigated safety and efficacy of 
DTG/3TC in pre-treated patients, reporting non-inferiority to triple therapy (91% vs 
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89%) in the ASPIRE study and 97% viral suppression in the LAMIDOL study, both 
at 48 weeks. There was no emergence of resistance in either study and no signal for 
lipid and renal toxicity.109, 110 Since 3TC is already available in the generic form, this 
combination would be advantageous in LMIC, with caution applied to hepatitis B 
screening, as Hep B co-infection would require TDF, TAF or an alternative strategy.  
DTG + RPV 
RPV is the one NNRTI with no interaction with DTG.111 This combination has mainly 
been studied as maintenance therapy, with the most compelling evidence coming from 
2 large open-label randomized trials, SWORD 1 and 2, which are discussed in details 
in chapter 4. In summary, the pooled analysis showed non-inferiority to 3- or 4-drug 
regimen with improvements in bone, renal and lipid parameters, also confirmed in 
other studies.112-116 There have also been similar findings in subjects with multiple 
previous treatment failures.117 
DTG + DRV/RTV 
Data for DTG/DRV/RTV dual therapy is discussed in detail in chapter 4. The 
DUALIS RCT demonstrated that OD DTG/DRV/RTV maintenance therapy, in 
suppressed patient, was non-inferior to continuing DRV-based triple therapy.118 
Additionally, cohort studies have investigated the use of DTG/DRV/RTV in multi-
treatment experienced patients with resistance and all demonstrate viral suppression 
in >90% of subjects at 48 weeks and beyond, in this difficult to treat population.119-121 
Whilst an intensive 12-hour PK sub-study of the DUALIS trial was published, there 
is very limited PK data on DTG combined with co-formulated DRV/COBI and, to 
address this, chapter 4 reports the intensive PK of DTG with and without DRV/COBI 
in healthy volunteers.  
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1.2.3.2.2. Monotherapy 
Various small non-randomized studies have investigated the use of DTG monotherapy 
in selected ARV-naïve and experienced patients with conflicting results but with a 
positive response in some individuals.101, 122, 123 This strategy is currently not 
recommended and requires further investigation before use. 
1.2.3.3. Real life tolerability 
DTG demonstrated excellent safety and tolerability in licensing trials.61, 69-72, 124 
However, real life data has emerged reporting higher than expected rates of adverse 
events (AE) and discontinuations secondary to AEs, particularly neuropsychiatric 
(NP) AEs and weight gain.125-151 These data are discussed extensively in chapters 1 
and 6. Consequently, there has been a call for DTG pharmacovigilance and for studies 
in diverse populations to further characterise those at risk of toxicity.127 To this effect, 
the intensive pharmacokinetics of DTG in subjects over the age of 60 are described in 
chapter 1 and DTG impact on sleep architecture and cognition is investigated in this 
population.  
1.2.3.4. Special populations 
Women 
Women represent just over half of the worldwide HIV population and those of 
childbearing age represent a majority in certain LMICs; it is therefore important to 
characterise the use of newer ARVs in women.1, 152 The phase IIIb randomised, open-
label trial, ARIA showed superiority of the fixed drug combination (FDC) 
DTG/ABC/3TC over ATV/RTV plus TDF/FTC in 495 treatment-naïve adult women 
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over 48 weeks. Resistance mutations were low in those with VF and predictably, there 
was a higher rate of discontinuations in the ATV/RTV arm due to AEs (7% vs 4%).153  
Pregnancy 
The first PK evaluation of standard dose DTG in pregnant women, IMPAACT P1026, 
showed that the median DTG AUC0-24, maximum concentration (Cmax), and C24 were 
25% to 51% lower in the second and third trimesters as compared with postpartum 
(n=29). These differences were deemed clinically non-significant since C24 remained 
above the DTG protein adjusted (PA)-EC90, maternal viral loads remained 
undetectable, high placental transfer was demonstrated and all infants were HIV 
negative. For pregnant women initiating third trimester ART, the DolPHIN-2 study 
confirmed that DTG-based therapy conferred quicker virologic response and increased 
likelihood of suppression at delivery than EFV-based therapy, with similar safety 
outcomes.154 Of interest also, DTG transfers into breast milk, resulting in significant 
plasma concentrations in the infant.155 
 
Safety data is available from over 10 observational studies and 1200 pregnancies 
including a number of monitoring databases, all of which suggest that there is no 
increased risk of preterm deliveries, small for gestational age or congenital anomalies 
in women started on DTG during pregnancy, relative to background risk.156-160 But 
there is marked heterogeneity among the databases.65, 161 And this year, some 
concerning results from an unscheduled analysis of the Botswana birth outcomes 
surveillance study revealed a signal for increased neural tube defects (NTD) in patients 
conceiving on DTG compared to other subgroups: 0.3% vs 0.12% in non-DTG ART 
at conception, 0.09% in HIV-negative women and 0% in DTG started after 1st 
trimester.162, 163 As a result, warnings were issued from the WHO, FDA, European 
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Medicines Agency (EMA) and major associations and whilst the final data set from 
the Botswana study is awaited, most recommend avoiding DTG in women at risk of 
conception. 68, 164-167 
Renal Impairment 
DTG is highly protein bound with low water solubility. There is no effect on exposure 
in mild to moderate renal impairment but unexpectedly lower DTG exposures were 
reported in HIV-seronegative subjects with severe renal impairment (AUC0–oo 40% 
lower) and caution should be applied.168 With regards to renal replacement therapy, 
Molto et al., demonstrated minimal DTG removal by haemodialysis (extraction ratio 
7%) suggesting no specific dosage adjustments required in this setting.169-171 Notably 
also, DTG inhibits the renal organic cation transporters 2 (OCT2) on the basolateral 
membrane of renal cells, thereby causing a mild increase in serum creatinine in the 
first 6 weeks of treatment, this is not thought to be clinically significant.57 
1.2.3.5. Drug interactions 
In vitro, DTG was found to be a substrate for the efflux transporters P-glycoprotein 
(P-gp) and human breast cancer resistance protein (BCRP). It is metabolised by 
UGT1A1 and, to a lesser extent by CYP3A4 (10-15%), with minimal contribution 
from UGT1A3 and UGT1A9, without being an inducer or inhibitor of most of the 
usual metabolic systems, thereby limiting DDI perpetration.57, 172 However, in a study 
using healthy volunteers, co-administration of DTG and metformin significantly 
increased metformin plasma exposure in a dose dependent manner; assumed to be 
OCT2 related. Dose adjustment and monitoring for lactic acidosis are therefore recom-
mended in those at risk.173 Studies investigating DTG interactions with the anti-
mycobacterial agents initially showed that co-administration with the potent inducer 
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rifampicin, required twice daily dosing of DTG 50 mg.174 More recent intensive co-
administration PK data showed that DTG dosing could be simplified to 100mg OD.175  
A dose adjustment is not necessary with rifabutin 300 mg.176 There does not appear to 
be a significant interaction between DTG and oral contraceptive pills or proton pump 
inhibitors.50 However, antacids and supplements containing divalent cations, can 
attenuate DTG absorption through chelation and DTG should be taken 2 hours prior 
to or 6 hours after.82 
 
Amongst the ARVs, both EFV and ETV significantly lower DTG levels and should 
be avoided unless ETV is administered with RTV.177, 178 Finally, the PIs currently used 
can be safely administered with DTG, when boosted with RTV. However, interactions 
between DTG and COBI are unclear and require further investigation.179 To address 
this gap in knowledge and as previously mentioned, chapter 4 investigates the 
pharmacokinetics of DTG with and without co-administration of DRV boosted with 
COBI. 
1.2.4. Bictegravir 
Bictegravir, the fourth InSTI was recently licenced, co-formulated with FTC and TAF 
(BIC/F/TAF, Biktarvy®). It was approved in Europe in June 2018, for adults infected 
with HIV-1, without evidence of viral resistance to InSTIs, FTC or TDF.180 Like DTG, 
it has high genetic barrier to HIV-1 resistance.181 In phase 3 trials, it was non-inferior 
to DTG-based therapy in treatment-naïve adults through to 96 weeks and, similarly, 
was noninferior to ongoing DTG/3TC/ABC or boosted EVG- or PI-based therapy in 
preventing virological rebound over 48 weeks in treatment-experienced patients. No 
resistance emerged to any of the antiretrovirals in the STR.182-187 It is generally well 
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tolerated, requires no prior HLA-B*5701 testing (unlike Triumeq®), fulfils the ARV 
regimen requirement for patients with HBV co-infection (TAF) and can be used in 
renally impaired patients with creatinine clearance ≥ 30 mL/min.181, 188  
1.3. COBICISTAT 
For over a decade, low dose RTV has been used as a pharmacological booster for most 
PIs, in order to increase the half-life (t1/2), the time to reach Cmax (tmax), Cmax, and AUC 
through potent CYP3A4 and P-gp (intestinal and hepatic) inhibition. Cobicistat 
(COBI) was released in 2014 as an alternative to RTV, available either as a single 
agent (Tybost®) or co-formulated with the new integrase inhibitor at the time, 
Elvitegravir (EVG/COBI/FTC/TDF, Stribild®).189, 190 It’s approval followed phase III 
studies demonstrating non-inferiority of EVG/COBI/FTC/TDF to EFV, ATV/RTV 
and RAL-based regimen in treatment naïve and virologically suppressed ARV-
experienced participants (GS-102, 103, 145, STRATEGY-NNRTI and 
STRATEGY-PI).191-195 COBI is a structural analogue of RTV. It inhibits CYP3A4 
with a similar potency and, to a lesser degree, P-gp.196-201 Its tolerability profile overall 
is similar to that of RTV.199 At a dosage of 150 mg OD, it provides bioequivalent 
exposures of atazanavir (300 mg OD) and darunavir (800 mg OD) compared with 
those observed with 100 mg of RTV OD and similar virological suppression when 
compared to ATV/RTV.201-211 COBI does not have antiviral activity and good 
solubility lends it to co-formulation. It was approved co-formulated with ATV 
(Evotaz®) and DRV (Rezolsta®) in 2015, potentially reducing pill burden in patients 
requiring a boosted PI. The PK properties of COBI are summarised in table 1.6; there 
are key pharmacological differences between RTV and COBI. Unlike its counterpart, 
COBI does not inhibit CYP1A2, CYP2C8, CYP2C9 or CYP2C19 and is a weaker 
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inhibitor of CYP2D6 and CYP2B6.197-199 The greatest discrepancy between the two, 
however, lies in the fact that COBI does not induce the activity of CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2C19 or UGT1A1 and is not expected to induce that of 
CYP3A4 or P-gp.198-201 Additionally, compared to RTV, COBI has a limited effect on 
the pregnane X receptor (PXR), a nuclear receptor activated by xenobiotics that 
subsequently induces and regulates the expression of various drug-metabolising 
enzymes, including CYP 450 and UGT.197, 198, 212 This is particularly salient to patients 
switching from an RTV-boosted to a COBI-boosted regimen, when the loss of 
CYP/glucuronidation induction may potentially require the dose adjustment of co-
prescribed drugs.198  
PARAMETER COBICISTAT 
Oral bioavailability % ND 
Effect of food on AUC ñ* 
Plasma t1/2, elim, h 3-4 
Plasma protein binding, % 97-98 
Metabolism CYP3A4 >> CYP2D6 
Renal excretion of parent drug, % 8.2 
Cmax (ng/mL) 1200 
AUC (h*ng/mL) 10 900 
Cmin (ng/mL) 70 
Table 1.6: PK properties of cobicistat (reported mean values in adults with normal renal and hepatic 
function). Abbreviations: AUC: Area Under the Curve; t1/2 elim: half-life of elimination; ND: not 
determined. * no formal study conducted 
No COBI dose adjustment is required in patients with renal impairment as data shows 
its PK are not significantly changed following administration of standard daily doses 
in subjects with severe renal impairment (eGFR <30 mL/ min).213 COBI, however, 
like RTV, does inhibit tubular secretion of creatinine leading to an apparent reduction 
in estimated creatinine clearance; yet actual glomerular filtration rate, as measured by 
the clearance of iohexol (a probe excreted solely by glomerular filtration) is not 
altered.214 The effect is reversible and mainly reflects the inhibition of creatinine 
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secretion by the multi-antimicrobial extrusion protein 1 (MATE1) transporter, on 
apical proximal tubular cells.214 Interestingly, COBI leads to greater creatinine 
changes than RTV despite similar IC50 values for MATE1, which may relate to active 
OCT2-mediated COBI transport into tubular cells, increasing its availability to 
MATE1.198, 215 Caution, however, remains when COBI is co-administered with and 
boosts potentially nephrotoxic drugs such ATV and TDF. COBI dosage adjustment is 
not required in patients with mild to moderate hepatic impairment, however is not 
recommended in patients with severe hepatic impairment (lack of data).199 To address 
some gaps in the literature and inform clinicians considering the use of COBI in 
commonly encountered clinical situations, chapter 3 establishes the PK forgiveness 
of EvotazÒ and RezolstaÒ following cessation of drug intake and compares it to that 
of RTV-boosted ATV and DRV. In addition, chapter 5, characterises the PK of one 
of the commonest contraceptive pill, ethinylestradiol/levonorgestrel, when it is co-
administered with ATV/COBI. 
1.4. GENETIC VARIATION AND ARV PK/PD 
The penultimate chapter of this thesis, chapter 6, focuses on the pharmacogenetics of 
dolutegravir PK. Background on pharmacogenetics is provided in the section below.  
The inter- and intra-individual variability observed in both therapeutic and toxic 
effects of a drug is governed by demographic, physiological and genetic factors. 
Pharmacogenomics is the study of the contribution of naturally occurring genetic 
variants to this variability whilst pharmacogenetics refers to single drug–gene 
interactions.216 Precision medicine, then aims to use pharmacogenomic/enetic data, 
amongst other parameters, to predict a patient’s clinical outcome and to tailor therapy 
to genetically-defined sub-populations.217 This is particularly important in areas of 
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medicine, where complex and potentially toxic therapies are prescribed in multiples 
and over prolonged periods of time such as in HIV.216 Genetic sequence variations 
between individuals include single-nucleotide polymorphisms (SNPs), insertions and 
deletions (indels) and short tandem repeats (STRs) amongst others and are described 
as common if they exist in individual genomes at frequencies > 5%. SNPs are the most 
frequent (>90% of all sequence variations).218 They can result from either the deletion, 
insertion or substitution of a single nucleotide in a sequence and occur either within 
the protein coding (exons) or non-coding (regulatory or intron) regions of genes or 
within intergenic regions. SNPs within coding region that result in the same amino 
acid sequence being translated are called synonymous whilst SNPs that result in a 
different amino acid or a premature stop codon are called nonsynonymous. 
Nonsynonymous SNPs can either be classified as missense (leading to change in one 
amino acid in a protein) or as nonsense (leading to a premature stop codon and protein 
truncation), both potentially altering the level of expression and/or intrinsic activity of 
metabolically active proteins.216, 218 Importantly, SNPs in non-protein-coding regions 
may still have a pharmacological effect if they disrupt the regulatory functions of these 
regions, such as transcription regulation.219, 220 SNPs are usually associated via 
haplotype groups, which occur because multiple SNPs are inherited together. This is 
referred to as linkage disequilibrium, which is the non-random association of alleles 
on the same chromosome within a particular population.217, 218, 221  
 
As PK and biodistribution are inherent to both drug safety and efficacy, the most 
commonly studied variants in HIV are SNPs in genes implicated in drug absorption, 
distribution, metabolism and excretion pathways (ADME, figure 1.8), and include 
SNPs in genes that are involved in the production of transporters and enzymes.217 In 
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addition, there is also increasing interest in nuclear receptors that regulate the 
expression of ADME genes (such as PXR), in human leukocyte antigen (HLA) 
subtypes involved in hypersensitivity reactions (HSR) and in genes implicated in the 
development of metabolic toxicity.222  
 
 
Figure 1.8: Enzymes and transporters involved in drug disposition. Blue & Red dots: venous & arterial 
circulation. BBB: Blood Brain Barrier, BCB: Blood Cerebrospinal fluid Barrier. From Calcagno et al. 
2017 
The completion of the Human Genome Project in 2001, heralded the beginning of 
great technological advancements in the era of pharmacogenetics and precision 
medicine. Two main approaches have been used to study pharmacogenetics: 1) the 
analysis of single gene variant’s effect after mechanistic observations and 2) genome-
wide association studies (GWAS). The first relies on preceding observations and 
understanding of drug metabolisms and transports and the latter tests the effect of a 
large number of genes on a selected target, then potentially requires post-hoc 
confirmatory in vitro studies.222 The study described in chapter 6 uses a single gene 
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variant approach following careful selection of common SNPs related to enzymes and 
transporters that are known to be involved in the disposition of DTG.  
 
It is important to note that the effect of genetic variants on drug disposition might vary 
according to the molecule characteristics and metabolism. An accurate selection of the 
compound to be studied might be cost effective. For instance, a practical and relatively 
straightforward method called the relative genetic contribution (rGC) has been 
proposed and recently applied to ARVs. It is quantified comparing the intra- and 
interpatient variation in PK parameters following the repeated administration of a 
drug; compounds with higher rGC have a higher genetic contribution to interpatient 
variability, warranting PK/PG analysis. ARV class-specific differences in rGC may 
exist with NNRTIs seemingly ranking the highest and RAL the lowest.223 
 
The last decade has seen a surge of data in HIV pharmacogenomics, suggesting that 
the choice and dose selection of ARVs might be improved upon knowledge of a 
patients’ pharmacogenetic background;216, 217, 222 however, findings have frequently 
been conflicting and very few confirmatory clinical studies have been published. Only 
three pharmacogenetic markers have been widely replicated and have attained the 
point of potential practical utilisation in the clinical setting: HLA-B*5701 (ABC 
HSR), CYP2B6 516G>T (EFV and NVP PK and toxicity) and UGT1A1*28 (ATV 
hyperbilirubinaemia). In practice, only data on HLA B*5701 genotyping in abacavir 
candidates is clinically decisive and routinely used.224, 225 Limits to the detection and 
strength of any genotype-phenotype relationship include the fact that several enzymes 
and transporters are involved in the ADME of any one drug, often with complex 
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interactions between them. Additionally, huge variability in genetic variants exists 
among different ethnic groups meaning ethnic stratification of data is also key.217, 222 
 
DTG and COBI (in its role as a pharmacological booster for EVG, ATV and DRV) 
are the focus of this thesis; whilst there are pharmacogenetic data for the former, no 
study has been published on the latter. DTG pharmacogenetic studies are discussed in 
details in chapter 6. In summary, studies have primarily investigated the association 
between DTG PK and UGT1A1 and ABCG2 variants. Approximately 40-70% of all 
clinical drugs are metabolised by UGTs within humans and there are three main 
subfamilies (UGT1A, UGT2A and UGT2B).222, 226 UGT1A1-mediated 
glucoronidation is the main metabolic pathway for DTG.57 Several genetic variants in 
the UGTA1 gene have been identified, the most common is a thymidine and adenine 
(TA) repeat polymorphism in the promoter region. Increasing number of TA repeats 
is inversely associated with UGT1A1 transcription, with five and six repeats (alleles 
*36 and *1, respectively) being associated with increased and normal UGT1A1 
activity, and seven and eight repeats (*28 and *37, respectively) with low UGT1A1 
activity.227-229 Individuals are categorised as extensive, intermediate or poor 
metabolisers according to their allele combination.222, 229 UGT1A1*6 211G>A is also 
a common variant associated with reduced enzyme function, it is most prevalent in 
individuals of Asian descent.229 Chen et al. were the first to suggest a moderate 
relationship between UGT1A1*28 and *6 and DTG PK, publishing at the time of DTG 
FDA approval. This was later supported by data from Yagura et al.230,148 As previously 
mentioned, DTG is a known BCRP substrate and the homozygous ABCG2 c.421C>A 
(rs2231142) allele, coding for BCRP, has been associated with a 50% higher DTG 
Cmax.231  
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Since there have been concerns around high rates of insomnia and NP-AEs with DTG 
use, Yagura et al. suggested an association between the UGT1A1 poor metabolising 
status and Cmin-mediated NPAEs as well as all AE-related DTG cessations in a 
Japanese cohort.147, 148 Finally, Borghetti et al. recently reported an association 
between the SLC22A2 808C>A (rs316019) variant, coding for OCT2, and a set of sub-
clinical neuropsychiatric measurements in a European cohort.232 However, findings 
from both groups have yet to be reproduced and collinearity between the respective 
genetic variants and high DTG concentrations needs to be clearly distinguished. 
 
Chapter 6 therefore aims to address some existing gaps in currently published data 
and confirm some already published findings, through exploring the role of UGT1A1, 
ABCG2, CYP3A and NR1I2 SNPs on plasma DTG concentrations, in isolation or in 
combination, in pooled subject data from four clinical trials investigating the PK of 
50mg DTG taken OD. 
1.5. THESIS OBJECTIVES 
As discussed above, 2013-14 saw the approval of two significant new agents for the 
treatment of HIV, DTG and COBI. Both addressed unmet clinical needs at the time 
and are now widely used. DTG’s properties have secured its place as a preferred agent 
in major guidelines, including the WHO Guidelines, meaning that by 2025, an 
estimated 15 million PLWH could be taking it.7, 63, 65 This raises a number of clinical 
questions about the pharmacological behaviour of newly approved drugs in real-world 
settings. Often, these questions are not addressed in licencing trials, because they are 
not FDA and EMA requirements for approval and RCT participants often differ 
substantially from broader patient populations.127 Therefore, in this thesis, we aimed 
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to investigate common and important clinical pharmacological scenarios reflective of 
HIV treatment in real life, focusing particularly on PK in older populations, PK 
forgiveness for the management of late and missed doses, co-administration with 
common drugs and genetic determinants of PK.  
 
More specifically, Chapter 2 characterises the intensive PK of DTG in HIV infected 
participants over the age of 60 and its pharmacodynamic effect on sleep over 6 months. 
The PK tails of DTG and COBI-boosted EVG, ATV and DRV are then reported in 
chapter 3. Chapter 4 and 5 investigate the effect of co-administration of common 
drugs, with DTG and COBI-boosted DRV in chapter 4 and the oral contraceptive pill 
(OCP) and COBI-boosted ATV in chapter 5. Finally, chapter 6 explores the impact 
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By 2015, one in three people accessing HIV care in the UK233 and almost half in the 
US were aged 50 and over.234-238 With advancing age, several physiological changes 
are known to occur and affect drug pharmacokinetics and pharmacodynamics.239 
 
DTG is now the drug of choice for many HIV providers, thanks to high efficacy firmly 
demonstrated in trials, retained activity against some InSTI-resistant HIV-1 
phenotypes and low potential for drug-interactions.72 Overall, these properties make it 
a strong candidate for therapy in older PLWH.236 As discussed in chapter 1, DTG 
demonstrated favorable safety and tolerability profiles in pre-marketing trials with a 
<2% discontinuation rate secondary to any adverse events (AEs), which was 
comparable to RAL and superior to EFV.69, 240 However, contrasting real-life data 
from cohort studies, involving >6400 patients overall,  have  revealed unexpectedly 
higher discontinuation rates secondary to any AEs  (2.3-13.7%, median time 72 days), 
most commonly due to gastrointestinal AEs and insomnia/sleep disturbances and other  
NP-AEs (mean incidence 3.5%, range, 1.4-7.2%), regardless of prior neuropsychiatric 
history, thereby implicating a potentially neurotoxic effect of DTG. Some attempts at 
defining risk factors for NP-AEs, including PK and pharmacogenetics have been made 
but data remain conflicting.127-139, 146-149 Comparison studies suggest that NP-AEs are 
more common with DTG than other InSTIs.135-138 Interestingly, in several reports, NP-
AEs and DTG discontinuation were significantly higher in women and in PLWH >60 
years old, two groups which are often under-represented in licensing trials due to 
highly selective inclusion criteria.133-135 This has prompted a call in the literature for 
prospective studies to evaluate DTG-associated NP-AEs, using detailed, longitudinal, 
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validated sleep architecture and neuropsychological analyses, in conjunction with PK 
determinations, particularly in special populations.241 
 
Importantly, also, a high prevalence of sleep disturbances is already described in the 
HIV population, even in the cART era, (30-73% vs 10-20% in the general 
population)242, 243 and it is strongly associated with poorer disease outcomes, cognitive 
impairment and HIV-associated dementia.242, 244 It is, therefore, important to 
characterise the role of aging on DTG PK/PD, especially with regards to central 
nervous system (CNS) toxicity and sleep disturbances. The primary objectives of this 
study were to describe the steady state PK of DTG 50 mg OD in PLWH ≥60 years and 
compare them to a published younger population (from the SINGLE trial).69 The 
secondary objectives were to evaluate, in detail, changes in sleep and cognition over 
six months following a switch from non-DTG-based ARV regimen to ABC, 3TC and 
DTG, as a fixed dose combination tablet.  
 
We hypothesised that age-related changes in drug PK might impact DTG, except its 
metabolism since it is mainly by UGT1A1 and no evidence supports age-related 
glucuronidation changes.245 We also expected a reverse-association between 
sleep/cognition changes and PK parameters, particularly at the high end of the 
therapeutic range (or higher). 
2.2. METHODS 
2.2.1. Participants 
Written informed consent was obtained from male and female PLWH, stable on cART, 
aged ≥60 years with a body mass index (BMI) 18-35 kg/m2. The protocol required that 
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approximately 70% of subjects be ≥65 years (to ensure a variable age range). 
Eligibility criteria included plasma HIV-RNA <50 copies/mL at screening and no 
history of treatment failure or documented significant drug resistance on viral 
genotyping. With ABC use, a negative HLA-B*5701 allele result was required and 
participants were screened for cardiovascular (CV) risk using the QRISK2 calculator56, 
246 (eligible if 10-year risk of CV event was <20% or if risk factors were well controlled 
with medication/lifestyle measures). Participants were excluded if they had: 
significant acute/chronic illnesses; abnormal physical examination, ECG or laboratory 
determinations or use of known interacting drugs/remedies. No patients had preceding 
Primary Sleep Disorder diagnoses. The study was approved by the London Central 
Research Ethics Committee and the Medicines and Healthcare products Regulatory 
Agency (MHRA) and ran in accordance with Good Clinical Practice and the 
Declaration of Helsinki (NCT02509195). 
2.2.2. Study design 
This was a four-centre, 180-day (excluding screening and follow-up), open-label, 
prospective PK/PD study. After screening, eligible subjects were switched to 
ABC/3TC/DTG 600/300/50 mg FDC (Triumeq®)75 on day 1, one pill OD, orally, in 
the morning with or without breakfast for the study period, except on day 28 (D28). 
On D28, subjects underwent intensive DTG PK determinations, having fasted for six 
hours pre-dose and four hours post-dose to match the SINGLE PK sub-study 
circumstances.69 Blood samples were collected pre-dose, 1, 2, 3, 4, 8, 12- and 24-hours 
post-dose. Study medications safety was evaluated using the National Institute of 
Allergy and Infectious Diseases (NIAID) Division of AIDS table for grading the 
severity of adult and paediatric adverse events (2004), that characterises abnormal 
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findings, vital signs, physical examinations and clinical laboratory investigations. HIV 
viral load was checked on all safety and PK visits. Medication compliance was 
assessed through direct questioning and pill count. 
2.2.3. Collection and quantification of plasma dolutegravir 
Whole blood samples were collected at each time-point on D28, from an indwelling 
venous catheter, into 6 mL spray-coated EDTA tubes. Following centrifugation, 
plasma was aliquoted equally into three 2.0mL tubes (Sarstedt, Germany) and stored 
at -80oC.  Samples were then shipped on dry ice to the Jefferiss Trust Laboratory 
(Imperial College London). DTG plasma concentrations were determined using ultra-
performance liquid chromatography (UPLC) coupled with UV detection.247 The assay 
calibration range was 0.25-10 mcg/ml, intra-assay variability 3.3%-6.1% and inter-
assay variability 4.5%-5.7%. Overall accuracy was between 90.7% and 97.7% for 
three different quality control sample concentrations. The laboratory adheres to the 
ARV International Inter-laboratory Quality Control Program.248 
2.2.4. Pharmacokinetic and statistical analysis 
A sample size of 40 subjects was calculated to provide at least 80% power to detect 
DTG PK parameter changes in older people against 16 controls. The calculated 
parameters were plasma concentration measured 24 hours after the observed dose 
(C24), maximum observed plasma concentration (Cmax), area-under-the-plasma-
concentration-curve from 0 to 24 hours (AUC0–24) and half-life (t1/2). All PK 
parameters were calculated using actual blood sampling time and non-compartmental 
modelling techniques (WinNonlin-Phoenix, version 7.0). Descriptive statistics, 
including geometric mean (GM), 95% confidence interval (CI) and percentage 
coefficient of variation (CV% = 100*standard deviation/mean) were calculated for 
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DTG PK parameters at all time-points on D28, and compared to those obtained from 
the SINGLE PK sub-study control HIV population (≤50 years, n =16)69 using the non-
parametric Mann-Whitney U test. 
2.2.5. Sleep and cognitive data collection  
Six published and validated self-reported paper questionnaires (table 2.1),249-254 
recording different aspects of sleep, were administered to participants at baseline and 
on days 28, 90 and 180 in order to provide a comprehensive description of sleep 
quantity, quality, impact on daytime function, wakefulness, mental status and general 
wellbeing before and after the medication switch. Answers to each question were 
coded as per questionnaire protocols (appendix 2) and entered into Excel for scoring. 
Neurocognitive testing was carried out on D1 and D180 using the validated, widely 
used Cogstate® computerised assessment software,255 which evaluates a range of 
cognitive functions through eight domains: detection (DET)/identification (IDN) 
(speed of performance); one card learning (OCL), one back memory (OBM)/two back 
memory (TWOB) (accuracy of performance); Groton Maze learning (GML), Groton 
Maze recall (GMR), and set-shifting (SETS) (number of errors made on testing). 
Participants completed a mock practice at screening to minimise learning effect. 
2.2.6. Sleep and cognitive data analysis  
Sleep baseline characteristics and outcome measures at each time-point were 
descriptively summarised using medians, interquartile ranges (IQR), and proportions. 
Composite scores for sleep questionnaires were calculated and interpreted as per 
questionnaire protocols and cut-offs (table 2.1). Neurocognitive scores were analysed 
using Cogstate® recommendations.256 Changes in cognitive scores were calculated for 
each subject for each domain (baseline-D180), and were standardised according to the 
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within-subject standard deviation (WSD). The score sign was reversed where 
appropriate so positive values represent improvement for all domains. A composite 
score for the change from baseline was calculated by averaging the standardised 
change scores across all Cogstate® tasks for each individual. As data was not normally 
distributed, non-parametric tests were used for analysis. Changes in sleep and 
cognitive scores from baseline to each time-point were tested for significance using 
the Wilcoxon sign-rank test. Spearman’s correlation examined correlations between 
outcomes and DTG PK parameters. 
 
As EFV use is associated with NP-AEs, especially sleep disturbances, a sub-analysis 
was conducted using the Mann-Whitney test to compare individuals who switched 
from an EFV-based regimen to those who didn’t, thereby preventing EFV removal 
from potentially masking DTG effects.56  
 
Internal consistency was evaluated for outcomes with multiple domains using 
Cronbach’s α and corrected component-total Spearman’s rho (rs) correlations (α ≥.70 
and rs ≥.30 indicated adequate internal consistency). Correlation between different 
sleep questionnaires was evaluated at baseline to determine the level of agreement.  
Statistical analyses were performed using Stata (version 14.1) and GraphPad Prism 
(version 7.03). In the analyses, p-values, uncorrected and corrected for multiple 
comparisons, were calculated; p <0.05 was deemed significant. 
 
The Bonferroni correction was used to account for multiple comparisons.   
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Table 2.1: Summary of content, process and scoring of sleep questionnaires and cognitive testing. 




2.3.1. Study population 
Fifty-three subjects were screened; 43 enrolled and received at least one study drug 
dose. Three/43 participants withdrew before D28 and could not be included in the PK 
analysis (two moved abroad and one experienced fatigue and photosensitivity 
attributed to the study drugs). Forty participants completed the PK phase and 38 
attended the final study visit (D180). One participant withdrew secondary to 
insomnia/vivid dreams (resolved by switching to TDF/FTC/RAL) and the other 
withdrew for job relocation; both were included in D28 PK and PD analyses. Subject 
and control characteristics are summarised in table 2.2.  
2.3.2. Dolutegravir plasma pharmacokinetics 
Steady-state PK parameters are summarised in table 2.3; figure 2.1 demonstrates GM 
DTG concentration vs time curves for the observed and control populations. There 
were no differences in DTG AUC0-24, C24 or t1/2 between the two populations. However, 
Cmax (approximately two hours post-dose in both groups) was significantly higher in 
subjects ≥60 years old (GM 4246 vs 3402 ng/mL, p=0.005).  The PK parameters for 
the participant who withdrew secondary to NP-AEs after day 28 were: Cmax 5300 
ng/mL, C24 2013 ng/mL, AUC0-24 77942 hr*ng/mL and t1/2 19.8 hrs; all were above the 
95th percentile for the study group.  
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Age  Median (range) in years 66 (60-79) 36 (22-50) 
Ethnicity (n) White British/Irish/Other 33 11 
African Heritage 3 3 
Hispanic 2 0 
Asiatic 2 0 
American Indian/Alaskan Native 0 1 
Gender (n) Male 39 15 
Female 1 1 
Pre-switch regimen 
Backbone (n) ABC/3TC 16 N/A 
TDF/FTC 20 N/A 
3rd Agent (n) Boosted Protease PI (of which 
mono & dual therapy with RAL) 
9 
(2 & 1) 
N/A 
NNRTI (of which EFV) 24 (17) N/A 
RAL (of which dual tx with PI/b) 6 (1) N/A 
AZT 1 N/A 
Salvage tx (n) FTC, MVC, DRV, RTV 1 N/A 
Table 2.2: Demographic and clinical characteristics of study participants and controls. Tx: therapy 
Table 2.3: DTG steady-state PK parameters for the observed and control groups over 24 hours. In bold: 
significant difference in Cmax  
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Figure 2.1: GM DTG concentration vs time curves for the observed and control populations 
2.3.3. Sleep questionnaire results at baseline and follow up 
Detailed response rates and median (IQR) scores per questionnaire, domain and time-
point are in appendix 2: table A and figure B.  
2.3.3.1. Overall sleep impairment: Pittsburgh Sleep Quality Index (PSQI)249 
Median global PSQI score was higher at D28 vs baseline (5.0 vs 6.0, p=0.02 adjusted 
for multiple testing) but at no other time-points. No domain achieved statistical 
significance individually. Internal consistency was acceptable for the global score 
(α=0.72). Corrected component-total correlations ranged from 0.19 (daytime 




2.3.3.2. Insomnia: Insomnia Severity Index (ISI)250  
Median (IQR) global ISI scores remained stable (range 5-6.5); four individuals 
developed moderate insomnia over time (ISI 14-21; not significant) and one subject’s 
severe insomnia (ISI >21) improved whilst another’s developed by D28 leading to 
discontinuation (participant described above).  
2.3.3.3. Daytime sleepiness: Epworth Sleepiness Scale (ESS)251 
At baseline, 29% individuals were considered ‘sleepy’ (ESS >10) compared with 24% 
at D180 (not significant). 
2.3.3.4. Daytime function: Functional Outcomes of Sleep Questionnaire (FOSQ)252 
Median (IQR) global FOSQ remained stable from baseline to day D180 (range 18.01-
18.81/20) with a generally good level of daytime function across the cohort. 
2.3.3.5. Fatigue severity: Fatigue Severity Scale (FSS)253 
At baseline, 4/39 (10%) individuals reported having fatigue; this was 20% on D180 
(not significant). 
2.3.3.6. Risks of possessing sleep disorder: Sleep Disorder Questionnaire (SDQ)254 
No participants met the diagnostic criteria at baseline for any of the four sleep disorders 
tested and no significant change in scores was observed over time. 
2.3.3.7. Correlation between sleep measures 
There was a significant correlation between all sleep measures evaluated by more than 
one questionnaire across all scores at baseline (0.37<r<0.83; p <0.05).  
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2.3.3.8. Sleep scores by EFV status 
17/40 (43%) subjects switched from an EFV-based combination. At baseline, some 
measurements appeared worse in individuals who did not switch from EFV. No 
significant difference was observed between groups in overall score changes at each 
time-point compared to baseline for all questionnaires except ISI, which, counter-
intuitively, improved over 180 days in participants without efavirenz in their previous 
regimen and worsened in those with (p=0.02); this did not however remain after 
adjustment for multiple comparisons (p >0.05) (appendix 1; table C). 
2.3.3.9. Relationship between sleep scores and PK parameters 
There was no correlation between DTG PK parameters and D180 sleep scores or intra-
subject change in global scores over 180 days (delta test scores) (figure 2.2; appendix 
2: tables D and E). To rule out an effect dependent on a drug level threshold, the 
Mann-Whitney test was used to compare delta test scores in subjects with Cmax above 
the upper quartile (Q4) to those below (Q1-3). There were no differences (0.62<p-
value<1.0); nor with 95th centile Cmax used as threshold (0.13<p-value<0.73).  
Similarly, there was no difference in Cmax between D180 test score or delta test score 
low and high quartile groups for all sleep questionnaires (0.31≤p-value≤0.66 and 
0.63<p-value<1.0). 
2.3.4. Changes in cognitive scores 
Between baseline and D180, no change in global cognitive composite scores and 
individual domain scores was observed over time except GML (executive function) 
where a significant improvement from baseline to D180 was seen (median change 
(IQR) 0.32 (0-0.74), unadjusted p=0.002). 
 
 65 
There was no correlation between C24 and AUC0-24 and D180 cognitive function or 
delta cognitive scores (individual domains and global composite scores; p=0.07). 
Unexpectedly, higher Cmax was associated with improvements in global cognitive 
function (r=0.39, p=0.02 figure 2). The improvement in median (IQR) delta score was 
higher in those with a Cmax >upper 95% CI than in those below (p=0.0195) (table 2.4). 
Note: for difference scores, score sign reversed for all outcome measures where increasing values 
indicate performance decline. Thus, for all measures, negative values indicate performance decline and 
positive values indicate performance improvement. Difference scores standardised according to within-
subject standard deviation (WSD). Composite score for each subject calculated by averaging 
standardised change scores across all domains. P-values are exact derived from Wilcoxon matched-
pairs sign-rank test (not adjusted for multiple comparisons). *p <0.05, **p <0.01 
Table 2.4: Change in neurocognitive scores (effect size)  
2.3.5. Clinical safety and efficacy 
2/43 (4.6%) participants discontinued the study secondary to AEs (described above). 
In the remaining subjects, there were no virological failures or grade 3 or 4 toxicity 
following treatment initiation. The studied FDC was well tolerated. 
Cogstate domain Cognitive function 
Standardised change score  
(Day 180-baseline) 
n Median (IQR) p-value 
Detection task Psychomotor function 37 0.02 (-0.16,0.13) 0.743 
Identification task Attention 37 -0.04 (-0.47,0.58) 0.602 
Set Shifting Executive function 37 0.05 (-0.32,0.75) 0.471 
Groton Maze 
Learning Executive function 34 0.32 (0.00,0.74) 0.002** 
Groton Maze Recall Delayed recall 35 0.27 (-0.82,1.37) 0.176 
One Card Learning Learning 36 0.06 (-0.69,1.00) 0.592 
One Back Memory Working memory - simple 37 0.24 (-0.90,0.77) 0.908 
Two Back Memory Working memory - complex 37 0.00 (-0.97,0.84) 0.982 
Composite score   37 0.16 (-0.23,0.37) 0.187 
    
 Cmax <95
th centile 
(n = 25) Cmax >95
th centile (n=12) p-value 
Median Cogstate 
Delta score (IQR) 0.08 (0.30-0.20) 0.41 (0.12-0.64) 0.0195* 
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The steady-state PK of DTG 50 mg OD was characterised in an aging HIV population, 
mostly over 65 years, the age associated with potential changes in drug PK.245 
Compared to the younger control group, Cmax was significantly higher (25%) in those 
≥60, indicating increased DTG absorption. Whilst the net effect of age-related 
physiological intestinal changes (e.g. reduction in pH, gastrointestinal motility etc.) on 
the absorption of most drugs is thought to be minimal,239, 257 our findings could 
potentially be explained by age-related alterations in expression of active DTG efflux 
transporters, such P-gp and BCRP, across epithelial cells in the gastrointestinal 
tract;239, 245, 258 however further research is required. There were no differences in DTG 
C24, AUC0-24 or t1/2 between the two groups, supporting a lack of age-associated effect 
on the main DTG metabolic pathway (UGT1A1).  
 
To address the call for prospective PD data, this report describes the first post-
marketing analysis of sleep and cognition-related PD changes following a switch to 
ABC/3TC/DTG, over 180 days.125, 241 DTG-related NP-AEs (including insomnia) are 
an emerging concern and older age has been described as an independent risk factor. 
125-151 In this study, two participants discontinued DTG because of NP-AEs (4.6%), 
which is consistent with published cohorts (1.4-7.2%). However, when investigating 
sleep quality and Cogstate status in those who continued the drug, we only observed a 
small increase in PSQI scores at D28, which resolved by D90, and a non-significant 
trend towards an increase in FSS score. Other scores remained stable or improved 
following the introduction of DTG. Whilst the one subject with PK measurements who 
withdrew secondary to NP-AEs had elevated levels of DTG, we did not find any 
association between DTG PK parameters and changes in sleep scores in the remaining 
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subjects over time, which is in keeping with observations from Riva and Hoffman.259, 
151 There were also no changes in sleep scores in subjects with very high drug 
concentrations in whom, surprisingly, cognition improved significantly. These 
interesting findings suggest that the mechanisms of DTG-related neurotoxicity are 
likely to be more complex than a simple linear or threshold-defined PK relationship 
and may relate to a combination of factors that include pharmacogenetic, immune 
and/or functional predispositions. Of interest and mentioned in the introduction, 
Yagura et al. and reported that DTG C24 (≥1.06 µg/mL) correlated with CNS side 
effects in younger Japanese PLWH. No significant difference in DTG concentration 
was, however, observed with individual symptoms or insomnia. The researchers 
subsequently reported a weak association with UGT1A1*6 and UGT1A1*28 alleles.148 
 
Capetti et al. found DTG-related sleep disorders resolved in some patients switching 
to morning dosing (0.9% vs 3.5%).134 In the study reported here, subjects were dosed 
in the morning to allow for steady state PK measurements; this could partially explain 
the absence of new sleep disturbances, although other researchers report unchanged 
rates of NP-AEs with morning dosing.148, 241 The present subject population was a 
group of only mildly sleep-disturbed individuals from baseline, which may also 
partially explain the lack of positive findings in those who completed the study. 
Overall, whilst sleep impairment rates (PSQI >5) at baseline, matched that historically 
reported in the HIV literature (44-51%), scores were only just in the lower range of 
abnormal (≤7). Additionally, the prevalence of subjects with moderate insomnia (ISI) 




Controlling for a switch from EFV did not change the lack of positive results; this 
likely to be due to the fact that the EFV subjects in this study were stable on it and are 
therefore a self-selected group of patients who do not experience major sleep 
disturbances on EFV. 
 
There are limitations to this study. Subjects were predominantly male, thereby not 
fully representative of real-life cohorts. DTG NP-AEs are thought to be higher in 
women, although it is an independent risk factor.  Importantly, the study was not 
powered to detect changes in sleep quality but for the ability to detect PK differences 
between younger and older PLWH, PD results should therefore be interpreted with 
caution (although the numbers mirrored previous HIV sleep studies242 and consistency 
across sleep tools (measuring the same effect) suggest that results are accurate). 
Furthermore, the use of self-reported questionnaires may compromise intra- and inter-
subject consistency and lead to recall bias. The effect of suggestion may also introduce 
bias as was proposed by the authors of the SINGLE trial (EFV vs DTG)69 to explain 
higher rates of DTG-related sleep disturbances. Although validated in the general 
population, the sleep questionnaires used in this study are not validated in aging 
PLWH. Nevertheless, a good correlation between direction changes reflects good 
inter-questionnaire reliability. Finally, the use of historical controls is a limitation, 
which should be addressed in future studies with a larger and active control arm. 
 
The strengths of this study lie in its prospective and controlled design, investigating a 
special population in need of data, which is growing in size and requires appropriate 
HIV treatment tailoring. Additionally, it is the first to characterise detailed sleep and 
cognitive data in PLWH following the introduction of Triumeq® and to explore the 
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DTG PK/PD relationship in aging PLWH. The use of multiple questionnaires also 
allowed a more comprehensive evaluation of sleep and its effects than previously 
reported. 
 
In conclusion, a significantly higher DTG Cmax was seen in PLWH ≥60 vs younger 
subjects. The discontinuation rate was similar to previous real-life reports but the Cmax 
increase was not associated with sleep or cognitive decline over six months. This data 
informs physicians and patients on the safety and tolerability of DTG in older patients, 
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Despite advances in antiretroviral therapy (ART) facilitating better adherence to HIV 
treatment, delay or omitted doses still occur, potentially leading to drug 
underexposure, virological failure and selection of drug-resistance mutations, 
conditioning future choice of ART. Therefore, plasma PK data after cessation of ARV 
drugs are important to understand and guide the management of late and missed doses, 
particularly in drugs, such as the protease inhibitors and the integrase inhibitors, that 
are used in complex cases of viral resistance, poor adherence and extensive 
antiretroviral treatment experience.56, 260, 261 Drug persistence in plasma is dependent 
on its half-life (which itself depends on clearance, CL, and volume of distribution, 
V).262 ARV agents with longer half-life may be more forgiving and allow for forgotten 
doses, especially if drug concentrations remain above therapeutic concentrations until 
the patient reinitiates drug intake. 
 
In addition to information on ‘forgiveness’, PK data after cessation of intake may also 
inform the appropriateness of specific compounds for HIV pre-exposure prophylaxis 
(PrEP) and for alternative treatment strategies tailored to facilitate adherence, such as 
described in the FOTO and  BREATHER studies.263 The former demonstrated that an 
ARV strategy that includes structured, short-cycle, treatment interruptions (dosing for 
5 days consecutively followed by a 2-day break) with ART containing TDF/FTC/EFV, 
all long t1/2 agents, was non-inferior in HIV-infected adults to continued daily therapy 
and resulted in no virological failures, whilst being preferred by patients.263 The 
BREATHER study, carried out in both, LMIC and high-income countries (HIC), 
demonstrated similar efficacy of the same strategy in adolescents264 
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In vivo data for the InSTIs, DTG and EVG/COBI, concentration decay after intake 
cessation have not been previously described. Neither have they been investigated in 
the PIs, DRV and ATV, when they are boosted by COBI rather than RTV.  This 
chapter describes two pharmacokinetic tail studies in HIV-negative healthy volunteers 
that aim to address these gaps in pharmacokinetic knowledge.  
 
InSTIs are the newest ARV class approved and as described earlier, they are 
increasingly favoured over older drug classes thanks to their high efficacy and 
tolerability.265 EVG, is prescribed in combination with the CYP3A4 inhibitor, COBI, 
which enhances EVG exposure and enables its once-daily dosing, whilst DTG does 
not require pharmacological boosting. Both are available in a FDC taken once-daily, 
thereby facilitating potential for adherence.266-268 
 
Conversely, most PIs do require pharmacological boosting.260 RTV-boosted PIs such 
as ATV and DRV have been used for many years and remain an instrumental option 
as third agents in the management of HIV. As discussed in chapter 1, advantages of 
pharmacological boosting include increased drug exposure and a prolonged half-life 
allowing OD dosing, and in the case of PIs, achieving a high genetic barrier to 
resistance.260 COBI, the newer pharmacokinetic enhancer lends itself to co-
formulation and lacks enzyme-inducing activity, thereby reducing pill burden and 
potentially offering a better drug interaction profile than RTV.198, 199 At 150 mg OD, 
it provides bioequivalent exposures of ATV (300 mg OD) and DRV (800 mg OD) 
compared with those observed with 100 mg of RTV OD.198, 199, 204, 211  
 
Previously published data on the pharmacokinetic forgiveness of OD RTV-boosted 
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DRV and ATV, showed a favorable ATV PK tail and a slight increase in decline rate 
for both protease inhibitors as RTV concentrations decrease.269 
 
The objectives of the two studies described below were to independently evaluate the 
plasma PK of once-daily InSTIs, DTG and EVG/COBI, up to 9 days (216 hours) 
following cessation of drug intake and the plasma PK of once daily PIs, ATV and 




Written informed consent was obtained from male and non-pregnant, non-lactating 
female healthy volunteers aged between 18 and 65 years old and with a BMI between 
18-35 kg/m2. Participants were excluded if they had any significant acute or chronic 
medical illness, abnormal physical examination, ECG or clinical laboratory 
determinations; positive screens for HIV, hepatitis B or C; current or recent (within 
three months) gastrointestinal disease; clinically relevant alcohol or drug use that the 
investigator felt would adversely affect compliance with trial procedures; exposure to 
any investigational drug or placebo within three months of the first dose of the study 
drug; use of any other drugs, including over the counter medications and herbal 
preparations, within two weeks before the first dose of the study drug; and previous 
allergy to any of the constituents of the pharmaceuticals administered  during the trial.  
3.2.2. Study design 
Both studies were open-label, two-phase PK trials carried out at the Clinical Trial Unit 
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of the St. Stephen’s Centre, Chelsea, and Westminster Hospital, London, United 
Kingdom. Participant involvement was 38 days in Study 1 (DTG and EVG/COBI) and 
33 days in study 2 (ATV/COBI and DRV/COBI), excluding screening and follow up 
visits.  
At screening, participants had a clinical assessment and routine laboratory 
investigations performed. The safety and tolerability of study medications were 
evaluated throughout the trial (on safety visit days, PK days and at follow-up) using 
the 2004 NIAID Division of AIDS table for charaterising and grading the severity of 
adult and paediatric AEs described previously. 
3.2.2.1. Study 1 (InSTIs):  
After successful screening, participants were administered DTG 50 mg (Tivicay®) 
OD for 10 days for the first phase of the study. They were admitted to the unit on D10. 
Blood samples for DTG PK assessment were taken before the final dose in the morning 
of D10 and at 2, 4, 8, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192- and 216-hours 
post-dose. After a washout period of nine days, on day 20, all subjects were 
administered fixed-dose combination TDF/FTC/EVG/COBI 245/200/150/150 mg 
(Stribild®) OD for 10 days for the second phase of the trial and blood samples were 
taken at the same intervals as above, prior to and over 216 hours following the final 
dose. On the PK days, study medication intake was witnessed and taken with a 
standardised breakfast (626 kcal) and 240 mL of water and subjects were admitted for 
12 hours, after which they could leave the unit and return at specified intervals to 
complete sampling over nine days. 
3.2.2.2. Study 2 (PI/COBI): 
After successful screening, volunteers were administered fixed-dose combination 
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ATV/COBI 300/150 mg (Evotaz®) OD in the morning for 10 days. On D10, 
participants were admitted and blood samples for ATV and COBI PK assessment were 
taken pre-dose and at 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48, 60, and 72 hours 
post-dose. After a washout period of seven days, all subjects were administered fixed-
dose combination DRV/COBI 800/150 mg (Rezolsta®) OD for 10 days. On study 
D30, sampling for DRV and COBI plasma PK was taken pre-dose and at 1, 2, 3, 4, 6, 
8, 10, 12, 16, 20, 24, 30, 36, 48, 60, and 72 hours post-dose. On the PK days, study 
medication intake was witnessed and taken with a standardized breakfast (626 kcal) 
and 240 mL of water. Study staff assessed compliance with study drug administration 
using direct questioning and pill count, throughout both studies.  
3.2.3. Ethics 
The study protocol for study 1 was approved by the London Westminster Research 
Ethics Committee, London, United Kingdom whilst the study protocol for study 2 was 
approved by the Bloomsbury Research Ethics Committee, London, United Kingdom. 
Both studies were also approved by MHRA UK and were conducted according to 
Good Clinical Practice and the Declaration of Helsinki (Study 1: NCT02219217; 
Study 2: NCT02589158).  
3.2.4. Plasma collections for DTG, EVG, COBI, ATV and DRV 
Blood samples were collected into lithium heparin containing-blood tubes (6 mL) at 
each time-point, immediately inverted several times and then kept on ice or 
refrigerated until centrifugation. Within 30 minutes of blood collection, each blood 
sample was centrifuged for 10 minutes at 2000 g at 4°C. Plasma was then aliquoted 
equally into three 2.0 mL tubes (Sarstedt Germany) and stored at -20°C. Samples were 
shipped on dry ice to the Liverpool Bioanalytical Facility for analysis. The laboratory 
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is Good Clinical Laboratory Practice-accredited and participates in an external quality 
assurance scheme (KKGT, the Netherlands).270, 271 
3.2.5. Quantification of plasma DTG, EVG, COBI, ATV and DRV 
Quantifications of DTG, EVG, COBI, ATV and DRV in plasma were determined 
using liquid-liquid extraction (with methyl tertiary-butyl ether) of analyte and internal 
standard (d5-DTG, d6-EVG, quinoxaline, ATV-d5 and DRV-d9) using validated high-
pressure liquid chromatography tandem mass spectrometry and analytical conditions 
described by the Liverpool University group in the literature.272, 273  
 
The lower limit of quantification (LLQC) was 0.75 ng/mL for all plasma analyses in 
study 1, 10 ng/mL for ATV and 15 ng/mL for DRV in study 2. For concentrations 
below the assay limit of quantification, a value of one-half of the quantification limit 
was used in both studies. 
 
In study 1, the assay was validated over a calibration range of 10-4000 ng/mL and 
0.75-20 ng/ml (for concentrations below the LLQC of the initial assay). Accuracy 
(percentage bias) was between 98.0% and 104.6% (DTG), 101.8% and 106.7% (EVG), 
99.8% and 106.2% (COBI) and precision was between 4.6% and 6.2% (DTG), 4.3% 
and 5.6% (EVG) and 5.0% and 6.0% (COBI).   
 
In study 2, the assay was validated over a calibration range of 3.7-500 ng/mL for all 
three analytes. Accuracy (percentage bias) was between 99.5% and 108.2% (ATV), 
94.2% and 101.2% (DRV) and 92.3% and 104.0% (COBI), and precision was between 
2.8% and 5.4% (ATV), 4.4% and 6.0% (DRV) and 3.1% and 6.5% (COBI). 
 
 79 
3.2.6. Pharmacokinetic and statistical analysis  
The calculated PK parameters for DTG, EVG, COBI, ATV and DRV were the plasma 
Cmax, AUC0-24 and C24. The half-life was determined from the elimination phase within 
the normal dosing interval of 0 to 24 hours and as a terminal elimination half-life to 
the last measurable concentration within 216 hours for DTG and EVG/COBI and 
within 72hrs for ATV/COBI and DRV/COBI. All PK parameters were calculated 
using actual blood sampling time and non-compartmental modelling techniques 
(WinNonlin Phoenix, version 6.1; Pharsight Corp., Mountain View, CA). 
 
Descriptive statistics, including GM and 90% or 95% CI were calculated for all 5-drug 
PK parameters. GMs were compared to the suggested therapeutic targets established 
in vitro (DTG, EVG and DRV) or in vivo (ATV), currently available in the literature. 
For the integrase inhibitors, this is the population protein binding-adjusted (PA) 
inhibitory concentration at 90% (IC90) for wild type (WT) virus for DTG (64 ng/mL) 
and the PA-IC95 for EVG (45 ng/mL). For the PIs, the suggested therapeutic target is 
the consensus minimum trough concentration (equivalent to 10 times the protein-
binding-corrected IC50 for WT virus), which is 150 ng/mL for ATV for wild type virus 
and 550 ng/mL for DRV for resistant virus, as defined at the 7th International 
Workshop on Clinical Pharmacology of HIV.76, 274-276 Inter-individual variability in 
drug PK parameters was expressed as a percentage coefficient of variation [CV%]. 
3.3. RESULTS 
3.3.1. Study populations 
3.3.1.1. Study 1 
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Seventeen participants completed all phases of study 1. The median (range) age was 
39 (26-52) years, and the median BMI (range) was 26 (19-34) kg/m2. Twelve 
participants were female; nine described themselves as Caucasians and eight as Black.  
3.3.1.2. Study 2  
Sixteen volunteers completed all phases of study 2. Median (range) age and BMI were 
38 (24-54) years and 25 (22-31) kg/m2, respectively. Nine were female. Nine described 
themselves as Caucasian, six as Black and two as Asian.  
3.3.2. Drug plasma pharmacokinetics 
3.3.2.1. Study 1: DTG and EVG/COBI  
PK parameters for DTG, EVG and COBI are summarised in tables 3.1 and 3.2. GM 
plasma concentration vs time curves are shown in figure 3.1. 
Dolutegravir plasma pharmacokinetics 
The GM terminal elimination half-life (90% CI) for DTG was 23.1 hours (19.7-26.6). 
This value was higher than the half-life measured over the dosing interval of 24 hours 
(14.3 hours; 12.9-15.7).  
 
The PA-IC90 for DTG is 64 ng/mL.76 GM plasma DTG concentrations were measured 
above this value in all participants, at 24, 36, and 48 hours post-cessation of drug 
intake. At 60- and 72-hours post-drug intake cessation, 16 out of 17 subjects had DTG 
concentrations above the PA-IC90. At 96 hours post-dose, DTG GM concentration fell 
below the PA-IC90 (52.2ng/ml, range 6.9-153.0), with four subjects remaining above 
the PA-IC90 (table 3.1; figure 3.2). 
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Elvitegravir plasma pharmacokinetics 
EVG GM terminal elimination half-life (90% CI) to the last measurable concentration 
was 5.2 hours (4.7-6.1), which was lesser than the half-life measured over the dosing 
interval of 24 hours (10.8 hours, 9.7-13.0).  
 
The suggested PA-IC95 for EVG is 45 ng/mL.9 All subjects had EVG concentrations 
above the PA-IC95 at 24 hours post-dose. EVG GM plasma concentration was above 
the PA-IC95 36 hours post-drug cessation (GM 57 ng/mL, range from 11 to 296 
ng/mL), however only 11/17 subjects had EVG concentrations above it. The EVG GM 
concentration fell below the PA-IC95 at 48, 60- and 72-hours post-drug intake cessation 
and EVG concentrations were below the lower limit of quantification in all study 
participants at 96 hours post-dose (table 3.1; figure 3.3). 
Cobicistat plasma pharmacokinetics when combined with EVG 
The GM terminal elimination half-life (90% CI) to the last measurable concentration 
for COBI was 18.2 hours (16.2-26.0). This was higher than the half-life measured over 
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Table 3.1: Summary of dolutegravir and elvitegravir concentrations (expressed as GM) and detectability at significant time points 
Hour post-dose Variable Dolutegravir (PA-IC90 64 ng/mL) Elvitegravir (PA-IC95 45 ng/mL) 
24hrs 
GM concentration (ng/mL) 1324 419 
Proportion detectable in plasma 100% (17/17) 100% (17/17) 
Proportion above IC90 or IC95 100% (17/17) 100% (17/17) 
36hrs 
GM concentration (ng/mL) 711 57 
Proportion detectable in plasma 100% (17/17) 100% (17/17) 
Proportion above IC90 or IC95 100% (17/17) 65% (11/17) 
48hrs 
GM concentration (ng/mL) 427 8.3 
Proportion detectable in plasma 100% (17/17) 94% (16/17) 
Proportion above IC90 or IC95 100% (17/17) 0% 
60hrs 
GM concentration (ng/mL) 240 2.5 
Proportion detectable in plasma 100% (17/17) 76% (13/17) 
Proportion above IC90 or IC95 94% (16/17) 0% 
72hrs 
GM concentration (ng/mL) 131 1.7 
Proportion detectable in plasma 100% (17/17) 53% (9/17) 
Proportion above IC90 or IC95 94% (16/17) 0% 
96hrs 
GM concentration (ng/mL) 52.2 — 
Proportion detectable in plasma 100% (17/17) 0% 

















Figure 3.2: DTG Plasma concentrations over time and proportion of subjects with DTG concentration above PA-IC90 at key time points. Top right corner: concentration-time 
curve for each individual subject showing spread of the concentration decay data
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Figure 3.3: EVG Plasma concentrations over time and proportion of subjects with DTG concentration above PA-IC90 at key time points 
Time (h) 
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48 h: GM 8.3 ng/ml (range from <LLQ-21.7, 16/17 detectable but all below PA-IC95)
36 h: GM 57 ng/ml  (range from 11 to 296, above PA-IC95 in 11/17)
45ng/mL












DTG EVG COBI 
PK parameters 







































































C48: concentration 48 hours post-dose 
Table 3.2: Plasma dolutegravir and elvitegravir/cobicistat PK parameters 
3.3.2.2. Study 2: ATV/COBI and DRV/COBI 
ATV and DRV PK parameters are summarised in table 3.3. 
Atazanavir plasma pharmacokinetics 
ATV GM plasma concentration vs time curves when combined with COBI are shown 
in figure 3.4. The GM terminal elimination half-life to 72 hours of ATV was 6.77 
hours (95% CI 6.2-7.5). This value was lower than the half-life measured over the 
dosing interval of 24 hours (GM 9.69 hours; 95% CI 9.2-12.8).  
 
All subjects had ATV concentrations above the suggested target 24 hours post-dose 
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(GM [range] 759.2 [249-2667] ng/mL). Out of 16 subjects, 2 and 13 had 
concentrations below the target at 30 and 48 h post-dose, respectively (GM 407.0 and 
65.9 ng/mL, table 3.4). The inter-individual variability in ATV C24 was 73%. 
Darunavir plasma pharmacokinetics 
Darunavir GM plasma concentration vs time curves when combined with COBI are 
shown in figure 3.4. DRV GM terminal elimination half-life was 6.4 hours (95% CI 
5.9-7.0). This value was lower than the half-life measured over the dosing interval of 
24 hours (GM 10.4h; 95% CI 9.2-12.9).  
 
Out of 16 subjects, 3 had DRV concentrations below the suggested target 24 hours 
post-dose and 11 had concentrations lower than the target at 30 hours (GM [range] 
1032.6 [373-3359] and 381.7 [97-2057] ng/mL respectively; table 3.4). Of note, the 
GM DRV concentration was 1202 ng/mL, at 20 hours, the last sampling time before 
24 hours. The inter-individual variability in DRV C24 values was 65%. 
Cobicistat plasma pharmacokinetics 
Steady-state COBI PK parameters when combined with ATV and DRV are reported 
in table 3.5. When combined with ATV, the GM terminal elimination half-life to the 
last measurable concentration for COBI was 4.2 hours (95% CI 3.9-4.7) and over the 
dosing interval of 24 hours was 4.4 hours, 95% CI 4.0–5.2).These were higher than 
when COBI was combined with EVG and with DRV.  
When combined with the latter, GM terminal elimination half-life to the last 
measurable concentration of COBI was 3.6 hours (95% CI 3.3-4.0) and was 3.8 (95% 





















GM 9.69 6.77 3718.85 759.20 6.36 37713 46129 
low 
95% 9.24 6.22 3308.00 612.57 1.29 32661 38592 
up 
95% 12.83 7.54 4940.55 1290.07 19.00 51556 67844 
Min 6.32 5.42 844.97 256.10 5.00 11414 14058 
Max 19.26 9.96 7282.82 2666.54 77.28 83763 128323 
CV 





















GM 10.41 6.35 5515.02 1032.56 8.80 58100 66710 
low 
95% 9.18 5.88 4949.07 837.92 6.01 51464 58145 
up 
95% 12.94 7.03 6566.03 1625.74 14.44 70391 83214 
Min 5.23 4.25 2855.55 372.96 7.50 26404 29317 
Max 19.15 8.48 8365.97 3359.34 41.13 111312 141982 
CV 
(%) 35 18 29 65 84 32 36 
Table 3.3: Plasma atazanavir (ATV) and darunavir (DRV) steady state pharmacokinetic (PK) 
parameters, expressed as geometric mean (GM) and 95% confidence intervals (CI), range (minimum, 





































 Hours post-dose 











No of subjects 











No of subjects 
below target 3/16 11/16 15/16 16/16 
Table 3.4: Plasma concentrations of atazanavir (ATV) and darunavir (DRV) measured at 24, 30, 36, 48 
hours post-dose, expressed as geometric mean (GM) and range, and number (No) of subjects below 
target per time-point. 
3.3.3. Safety and tolerability 
No serious breaches to the protocols were recorded in either study. Study drugs in 
study 1 were well tolerated and no grade 3 or 4 adverse events were reported.  
 
During study 2, treatment was generally well tolerated, and no serious adverse events 
occurred during the study. As expected because extensively described in the 
literature,277 the most common adverse events observed throughout the study were 
scleral icterus and hyperbilibirubinaemia (during the ATV/COBI phase). No other 




Table 3.5: Plasma cobicistat (COBI) steady state pharmacokinetic (PK) when combined with atazanavir 
and with darunavir, expressed as geometric mean (GM) and 95% confidence intervals (CI), range 
(minimum, Min and maximum, Max) and coefficient of variation (CV), measured over 24 and 72 hours.















GM 4.43 4.21 1408.02 49.59 5.00 10554 10924 
low 
95% 3.95 3.87 1293.37 42.07 5.00 9589 9905 
up 
95% 5.19 4.69 1577.76 79.63 5.00 12059 12535 
Min 3.14 3.21 929.72 14.15 5.00 7826 8145 
Max 8.39 6.13 1986.37 156.24 5.00 14681 15068 
CV 
(%) 28 19 20 63 0 23 24 
  















GM 3.81 3.62 1250.25 27.56 5.00 9532 9681 
low 
95% 3.49 3.34 1149.77 22.29 5.00 8678 8791 
up 
95% 4.29 3.98 1392.73 51.37 5.00 10857 11079 
Min 2.59 2.59 932.46 5.00 5.00 6167 6254 
Max 5.60 5.55 1867.32 120.90 5.00 14426 14933 
CV 






























DRV (with RTV) 
ATV (with RTV) 
DRV (with COBI) 

















































In the first study, the steady-state plasma pharmacokinetics of DTG 50 mg OD and 
EVG 150 mg OD boosted by COBI (150 mg) over 10 days following drug intake 
cessation was reported, in 17 male and female healthy volunteers. This data fully 
characterised, for the first time, the PK forgiveness of the two newest InSTIs (at the 
time of publishing). Following achievement of steady-state, GM DTG concentrations 
remained above the suggested plasma PA-IC90 of 64 ng/mL for up to 72 hours post-
drug intake cessation, with most subjects (94%) showing concentrations above the PA-
IC90 at this time. The GM concentration for EVG was above the suggested PA-IC95 of 
45 ng/mL at 24- and 36-hours post-drug cessation, with 65% of participants above this 
cut-off at the latter time point, but it had fallen below the PA-IC95 by 48 hours post-
dose (with no participant above this cut-off then). At the time of the study, there were 
no established minimum effective therapeutic concentrations for either agents. Being 
above the (partially PA) in-vitro IC90 or IC95 does not imply that exposure is sufficient 
for a fully effective in vivo drug exposure, especially when optimal drug exposures 
are needed during induction of virological control. More recently, an in-vivo minimum 
effective concentration (MEC) of 324 ng/mL has been suggested for DTG, based on 
data from the initial 10-day monotherapy study, which showed that, with a Hill Factor 
of 1, it was associated with 90% of Emax.57, 59 If this MEC is used, GM DTG Cmin 
remained therapeutic for over 48 hours in our study, falling below target at 60 hours. 
Plasma inter-individual variability (CV) was 27% in DTG C24 and 32% in EVG C24, 
which is consistent with previously published data.57 These values are considerably 




Interestingly, whilst DTG is not dependent on a booster and concentrations are 
persistent in the systemic circulation for a prolonged period; concentrations of EVG 
were observed to drop when the concentrations of its booster, COBI, fell below a 
certain level. The terminal t1/2 (0 to 216 h) was longer than the t1/2 within the dosing 
interval (0–24 h) for DTG, whilst the opposite was true for EVG (23.1 vs 14.3 hours 
and 5.2 vs 10.8 hours, respectively). One explanation for this phenomenon could be 
saturation of metabolic processes at higher concentrations, meaning a change in rate 
of CL as COBI concentrations fall to non-saturating levels.  
 
Of note, the single-tablet formulations of DTG and EVG contain partner NRTIs of 
varying t1/2 values. It has been previously shown that the plasma t1/2 of ABC and 3TC 
are 3–4 hours and 5.7 hours, respectively, with intracellular half-lives of the active 
triphosphorylated metabolite of ABC (carbovir) and the active triphosphorylated 
metabolite of 3TC being 14.1 hours and 19 hours, respectively.279 Exposures do differ 
between male and female subjects. The longer t1/2 of FTC and TDF, both in plasma 
and peripheral blood mononuclear cell (PBMC; 31 hours and 37 hours and 164 hours 
and 39 hours, respectively)280-283 may also be important to the clinical forgiveness of 
these regimens and the specific resistance mutations that are observed at failure. DTG 
is currently available in co-formulation with ABC and 3TC; it is interesting to note 
that the t1/2 of carbovir and the active triphosphorylated metabolite of 3TC match 
DTG’s t1/2 both within the dosing interval (14 hours) and to the last measurable 
concentration (23 hours). 
 
One of the limitations of study 1 is that DTG was administered alone, whilst 
EVG/COBI were co-administered as part of a single tablet combination therapy with 
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TDF/FTC. DTG administered within an ABC/3TC FDC was not considered justified, 
based on the risk of ABC hypersensitivity in HIV-negative subjects 284 and the known 
lack of effect of backbone NRTIs on the pharmacokinetics of either EVG or DTG. 
Additionally, it is not impossible that a minority of patients had residual exposure to 
low-dose DTG at the start of the EVG phase of the study, but this exposure is likely to 
be minimal, as PK sampling for EVG was carried out 19 days after the last dose of 
DTG and, importantly, DTG has no known impact on EVG/COBI metabolic 
pathways. 
 
The second study reports the steady-state PK of COBI-boosted ATV 300 mg and DRV 
800 mg in plasma over 72h following drug intake cessation in HIV-negative healthy 
volunteers, to describe the PK forgiveness of these two commonly used PIs when 
boosted by COBI (150mg). Concentrations of ATV were measurable in all subjects 48 
hours post-dose and in 11 and 2 subjects 60- and 72-hours post-dose. Importantly 
14/16 subjects had concentrations above the suggested minimum effective 
concentration (MEC) of 150 ng/mL and the remaining two had concentrations close 
to the MEC (148 ng/mL) 30 hours post-dose, suggesting that a 6-hour drug intake 
delay would not compromise optimal drug exposure and efficacy. Similarly, DRV 
concentrations were measurable in 13/16, 6/16 and 2/16 subjects 48, 60- and 72-hours 
post-dose, respectively. However, 3/16 study individuals had concentrations below the 
suggested 550 ng/mL cut-off 24 hours post-dose and only 5 had concentrations above 
550 ng/mL 30 hours post-dose. Whether this is clinically significant is unclear and 
more data in patients who are poorly adherent to DRV/COBI are needed in the near 
future to help clinicians with prescribing the optimal booster in certain complex 




Notably, measurements of ATV PK forgiveness in the presence of COBI were similar 
to those in the presence of RTV where ATV terminal elimination half-life was 6.77 
hours with COBI vs 6.74 hours with RTV (figure 3.5).269  DRV terminal elimination 
half-life was measured at 6.35 hours with COBI vs 6.48 hours with RTV (figure 3.5). 
While there is no doubt of PI robustness in ARV-naïve PLWH, in patients who are 
inclined to poor compliance or harbour viral resistance, PK forgiveness knowledge 
may be particularly important. 
 
In addition, we did not see the small increase in DRV plasma concentration at the end 
of the dosing period (C24) relative to previous time points (i.e.C20) described with both 
RTV and, to a lesser extent, COBI in bioequivalence studies.204, 285 This effect remains 
unexplained; it has been tentatively attributed to either enterohepatic recycling or 
redistribution of cellular DRV into plasma as the effect of RTV or COBI on cellular 
influx or efflux transporters diminishes with dropping concentrations.204 This effect is, 
however, unconfirmed and would require further investigation.  
 
Both COBI and RTV inhibit CYP3A4, thereby reducing the metabolism of 
concomitantly administered PIs and leading to enhanced drug exposure.198 Although 
very similar, the two drugs are not identical and their relationship with the therapeutic 
agent they enhance may explain concentration decay patterns. Importantly, the rates 
of decline of both ATV and DRV slightly increased as COBI concentrations declined. 
COBI itself is metabolised by CYP3A4 and when given with ATV, a moderate 
CYP3A4 inhibitor,189 it achieves slightly higher concentrations than when co-
administered with DRV, which, although also a CYP3A4 inhibitor, may have a lesser 
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effect.189 COBI terminal half-life was 4.21 hours with ATV and 3.62 hours with DRV, 
therefore shorter than RTV terminal half-life with ATV (5.03 hours) and DRV (6.30 
hours), respectively. The inter-individual variability (CV) in ATV and DRV C24 was 
73% and 65% with COBI, therefore similar to those previously measured with RTV 
(81% and 62%, respectively).269 
The cut-off values used in study 2 were those used in the published PK tail study for 
ATV and DRV when boosted with RTV, to allow for direct comparison between the 
studies.269 They were the ATV MEC (150 ng/ml, 10-fold the in-vitro PA-IC50 
calculated during drug development) and the DRV PA-EC50 for protease inhibitor-
resistant strains (550 ng/ml) used as a reference by TDM services.276 Of note, for 
treatment-naïve patients with wild-type virus, the DRV target is a lower 200 ng/ml.286, 
287 
 
There are limitations common to both studies. They were carried out in healthy 
volunteers so as not to impose ARV dose delays in patients infected with HIV. As 
such, PK/PD deductions or predictions on the in-vivo concentrations needed to 
maintain efficacy cannot be robustly drawn. Ideally, pharmacodynamics data in HIV 
infected participants are required to draw definite conclusions on how late a drug dose 
can be or how many drug doses can be missed before efficacy is lost. 
Additionally, discrepancies in ARV drug pharmacokinetics between healthy 
volunteers and people living with HIV have been previously described, particularly 
for the PIs.288 Such differences are thought to be related to physiological variability in 
several parameters between the two populations, including CYP450 activity and α-1-
acid glycoprotein expression, and must be kept into consideration when interpreting 
data from healthy volunteers.288 With regards to the InSTIs, intensive PK data from 
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licensing studies suggest that DTG and EVG concentrations may be moderately lower 
in healthy compared to HIV-infected subjects, but this is not thought to be 
significant.57 Drugs in both studies were well tolerated, with adverse events limited to 
expected increases in indirect bilirubin levels during the ATV/COBI study phase. 
 
PK forgiveness data is important, particularly in diseases that are chronic, where sub-
optimal compliance to medications is common.289 In the context of HIV infection, this 
is especially salient since therapy is life-long and insufficient drug exposure from 
missed doses can lead to the emergence of drug-resistant HIV strains and limit future 
therapeutic options. Great efforts are made to support and encourage patients with 
respect to the importance of adherence, but it is often unclear how delayed a dose can 
be or how many doses can be omitted before efficacy is lost. Additionally, and as 
previously mentioned, understanding the PK attributes of a drug and, more 
specifically, its PK forgiveness can also allow identification of potential candidates for 
PreP and alternative treatment strategies where optimal dosing frequency needs to be 
characterised. These studies on PK forgiveness address some of these issues and gaps 
in knowledge for commonly used InSTIs and PIs. 
 
In conclusion, these data contribute to understanding whether doses, for the specific 
drugs investigated, can be delayed or missed and, if so, to what extent. In particular, 
marked differences were found in the elimination rates of DTG and EVG following 
treatment interruption. This suggests that clinical differences may emerge in patients 
who have suboptimal adherence. Although, the net risk or benefit of these elimination 
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As discussed in the introduction, triple-drug therapy has been the cornerstone of HIV 
treatment since 1996, leading to unprecedented success in disease control in PLWH. 
With increasingly potent agents, there has, in recent years, been a drive to investigate 
treatment simplification strategies that aim to lessen toxicity, drug interactions and 
cost through reducing the number of drugs taken.100 This is particularly salient since 
the HIV-infected population is aging and, with increasing comorbidities, 
polypharmacy is rising.290 Current available evidence favours dual therapy over 
monotherapy and is most reassuring in suppressed patients who have maintained 
virological control for at least six months on triple therapy.103 
 
DTG and boosted DRV (DRV/b) are both strong players in this paradigm shift and 
both have featured independently in most of the recent dual combinations 
investigated.103 They are the agents with the highest potency and resistance barrier 
within their respective classes and overall,291, 292 meaning that they are also important 
in salvage therapy in patients experiencing treatment failure and harbouring multi-
class drug resistances (BD dosing recommended).72, 293 They have both been paired 
individually with 3TC in dual therapy studies, with promising data in treatment naïve 
and in virologically suppressed patients; this is outlined in chapter 1.106-109, 294-296 DTG 
combined with RPV has also been studied as maintenance therapy in two large RCTs 
(SWORD 1&2) and in smaller cohort studies, showing high efficacy, improved safety 
and cost savings, when used as maintenance therapy (albeit with slightly higher 
discontinuation rates secondary to AEs, 3% vs <1%).112-116, 297 Of note, Diaz et al. 
reported that switching suppressed HIV-infected patients with multiple previous 
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treatment failures to standard dose DTG/RPV OD was effective through to 48 weeks, 
with improved safety profiles.117 
However, the aforementioned options are not appropriate in the context of NRTI-
related long-term toxicities and NRTI/NNRTI-associated resistance mutations.102 In 
this setting, combining a PI and an InSTI offers an appealing NRTI-sparing 
alternative.101, 102 The NEAT001/ANRS143 study found DRV/RTV combined with 
RAL non-inferior to DRV/RTV/TDF/FTC based on clinical and/or virological failure 
at 96 weeks in 800 ART naïve individuals. However, the genetic barrier of the two-
drug regimen in this context was lower than the three-drug regimen, with more 
frequent emergence of resistance in cases of VF, particularly in those with high 
baseline VL.298, 299 Additionally, the SPARE pilot study in already virologically 
suppressed patients, suggested that RAL/DRV/RTV was effective in maintaining viral 
suppression.300 This combination requires twice daily drug intake, whereas combining 
boosted DRV with DTG offers the benefits OD dosing and a high genetic barrier to 
resistance, since both agents have a high affinity for their target enzymes.83, 301, 302 
 
A small number of cohort studies have been published on the use of DTG/DRV/RTV 
in multi-treatment experienced patients.119-121In Canada, Wheeler et al demonstrated 
high tolerability and maintenance of viral suppression after a mean of 12.8 (range 1-
22) months in all of 13 HIV patients with primary transmitted thymidine analogue 
mutation (TAM) resistance, who switched from a complex salvage multi-drug regimen 
to DTG/DRV/RTV.119 Similarly, in Italy, Capetti et al. followed 130 patients, with a 
current or past history of VF and documented viral resistance to one to five ARVs, 
who switched to DTG/DRV/RTV for simplification or rescue therapy. At 48 weeks, 
subjects with viral suppression increased from 60% to 94% and the metabolic impact 
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was favorable.120 A single-point pharmacokinetic (PK) analysis in a subgroup of this 
study (32 subjects) confirmed adequate median C24 for both drugs (DTG 579 ng/mL; 
DRV 3007 ng/mL); the thresholds used were the in vitro PA-IC90 for wild type HIV 
for DTG (64 ng/mL) and the PA-IC50 for PI-resistant viruses, for DRV (550ng/mL).274, 
286 Five subjects were taking darunavir 600 mg BD and three were taking DTG BD 
(the majority of InSTI single mutations cause <10 fold changes in DTG sensitivity, 
BD dosing is recommended, however, in the presence of any InSTI resistance 
associated mutation patterns).60, 76, 303 The DUALIS study, a recent large, prospective, 
interventional RCT (n=320) showed that OD DTG/DRV/RTV maintenance therapy in 
suppressed patient, was non-inferior to continuing DRV-based triple therapy, with 
high rates of maintained VLs and comparable rates of AEs demonstrated.118 An 
intensive PK sub-study over 12 hours was published and described steady-state PK 
parameters for both drugs during co-administration (median Cmax was 3427 ng/mL for 
DTG and 6170 ng/mL for DRV, C12 was 637 ng/mL for DTG and 1245 ng/mL for 
DRV and AUC0-12 was 26809 ng*h/mL for DTG and 49920 ng*h/mL for DRV), C24 
was not measured.304 
 
COBI may be preferable to RTV in some patients, in view of its lower potential for 
drug interactions than RTV and lower pill burden when co-administered.198-200 
However, PK data for DTG co-administration with DRV/COBI are very limited. DTG 
C24 doubled, when measured at least 10 days after switching DRV/RTV to DRV/COBI 
in a therapeutic drug monitoring (TDM) survey of HIV infected subjects taking DTG 
and DRV (n=12),305 in contrast to a 38% decrease seen in DTG C24 when co-prescribed 




No intensive PK data have been published to date on DTG/DRV/COBI co-
administration. We, therefore, aimed to describe the steady-state PK of DTG 50 mg 
(Tivicay®) OD and of fixed dose DRV/COBI 800/150 mg (Rezolsta®) OD, over 24 
hours when co-administered in healthy volunteers. 
4.2. METHODS 
4.2.1. Participants 
Eligible participants were male and non-pregnant and non-lactating female healthy 
volunteers aged between 18 and 65 years with a BMI between 18 and 35 kg/m2. 
Participants were excluded if they had any significant acute or chronic medical illness; 
abnormal physical examination, ECG or clinical laboratory determinations; positive 
screens for HIV, hepatitis B or C; current or recent (within three months) 
gastrointestinal disease; clinically relevant alcohol or drug use which the investigator 
felt would adversely affect compliance with trial procedures; exposure to any 
investigational drug or placebo within three months of the first dose of the study drug; 
use of any other drugs, including over the counter medications and herbal preparations, 
within two weeks of the first dose of the study drug; and previous allergy to any of the 
constituents of the pharmaceuticals administered during the trial. 
4.2.2. Study design 
The study design is illustrated in figure 4.1. This was a randomised phase 1, open 
label, 57-day, crossover PK study carried out at the Clinical Trial Unit of the St. 
Stephen’s Centre, Chelsea, and Westminster Hospital, London, United Kingdom. At 
screening, participants had a clinical assessment and routine laboratory investigations 
were performed. After successful screening, eligible participants were randomised to 
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one of two groups. Group one received DTG 50 mg OD for 14 days followed by a 7 
day wash out (days 15 – 21). From day 22 to 35, the co-administration period, they 
received DTG 50 mg OD plus DRV/COBI 800/150 mg OD for 14 days, which was 
followed by a 7 day wash out (day 36 – 42) and finally a 14-day period of DRV/COBI 
800/150 mg OD ensued. Group 2 followed the same structured sequence but started 
with DRV/COBI 800/150 mg OD and concluded with DTG 50 mg OD. Subjects were 
asked to take both DTG and DRV/COBI in the morning within 15 minutes of a 
standard breakfast. The safety and tolerability of study medications were evaluated 
throughout the trial (on days 7, 28, 49, PK days and at follow-up) using the NIAID 
Division of AIDS table for grading the severity of adult and paediatric adverse events 
(published in 2004). Each group underwent intensive PK sampling on study days 14, 
35 and 56 to measure plasma concentrations of DTG and/or DRV/COBI at 0 (pre-
dose), 2, 4, 8, 12- and 24-hours post-dose. On the PK days, study staff witnessed study 
medication intake with a standardized breakfast (626 kcal) and 240 mL of water. 
Figure 4.1: study design. PK = pharmacokinetics, DTG = dolutegravir, DRV = darunavir, COBI = 
cobicistat 
4.2.3. PK sample collection 
Blood samples were collected into lithium heparin-containing blood tubes (12 mL) at 
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each time-point, immediately inverted several times and then kept on ice or 
refrigerated until centrifugation. Within 30 minutes of blood collection, each blood 
sample was centrifuged for 10 min at 2000 g at 4°C. Plasma was then aliquoted equally 
into three 2.0 mL tubes (Sarstedt, Germany) and stored at -20°C. Samples were 
shipped on dry ice to the Liverpool Bioanalytical Facility for analysis. The laboratory 
is Good Clinical Laboratory Practice-accredited and participates in an external quality 
assurance scheme (KKGT, the Netherlands).270, 271  
4.2.4. Quantification of plasma DTG, DRV and COBI 
Concentrations of dolutegravir, darunavir and cobicistat in plasma were measured 
using validated high-pressure liquid chromatography–tandem mass spectrometry 
methods as previously described (HPLC MS/MS).272, 273 The lower limits of 
quantification (LLOQ) for plasma DTG was 10 ng/mL, 15 ng/mL for DRV and 10 
ng/mL for COBI. For concentrations below the assay limit of quantification, a value 
of one-half of the quantification limit was used. Accuracy (percentage bias) was 
between 92.5% and 96.2% (DTG), 104.1% and 104.9% (DRV) and 95.0% and 105.1% 
(COBI), and precision was between 2.6% and 4.1% (DTG), 4.4% and 9.4% (DRV) 
and 5.7% and 7.3% (COBI). 
4.2.5. Data analysis 
The calculated PK parameters for plasma DTG, DRV and COBI were C24, Cmax and 
AUC0–24. All PK parameters were calculated using actual blood sampling time and 
non-compartmental modeling techniques (WinNonlin Phoenix, version 6.1; Pharsight, 
Mountain View, CA). Descriptive statistics, including GM 95% CI were calculated for 
DTG, DRV and COBI plasma PK parameters. Each drug PK parameter during the co-
administration period was compared to the unaccompanied drug PK parameter by 
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calculating GM ratios (GMR) and 90% CI (co-administered/alone). Inter-individual 
variability in drug PK parameters was expressed as CV%. 
Since both COBI and DTG are associated with a small rise in creatinine through renal 
MATE1 and OCT2 transporter inhibition respectively, the statistical significance of 
the changes in creatinine from baseline was calculated using the two-sided Wilcoxon 
signed-rank test for paired samples.307, 308 
 
Additionally, as DTG is a substrate of P-gp and BCRP transporters, both of which are 
present within the endothelium of the blood brain barrier and are inhibited by COBI,198 
a review of neuropsychiatric adverse events (NP AE) was carried out. 
4.2.6. Statistical power  
This is an exploratory study and, as such, no formal sample size calculation was 
performed. Twenty (20) participants completing the study was deemed appropriate to 
allow for relevant conclusions, as is standard for PK studies.309 
4.2.7. Ethics 
The study protocol was approved by the Surrey Borders Research Ethics Committee 
and by MHRA UK. The study was conducted according to Good Clinical Practice and 
the Declaration of Helsinki (NCT03094507). 
4.3. RESULTS 
4.3.1. Study Population 
Twenty-five healthy volunteers were screened, 21 attended baseline and 20 completed 
all PK phases (eleven in group 1 and 9 in group 2; one subject withdrew for personal 
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reasons). Median age was 33.5 years (range 24-63), 13 participants were female and 
median BMI was 27 (range 20-31) kg/m2. Thirteen subjects described themselves as 
Caucasian, six as Black African/Caribbean and one as White and African.  
4.3.2. DTG, DRV and COBI plasma pharmacokinetics 
4.3.2.1. Dolutegravir plasma pharmacokinetics 
Figure 4.2 illustrates the DTG GM plasma concentration vs time curves with and 
without DRV/COBI, in relation to DTG’s PA-IC90 for wild type virus (64 ng/mL).76 
DTG geometric mean ratios (GMR, DTG+DRV/COBI vs DTG alone) and 90% 
confidence intervals (CI) for Cmax, AUC0-24 and C24 were 1.01 (0.92-1.11), 0.95 (0.87-
1.04) and 0.9 (0.8-1.0). No differences were seen between groups 1 and 2.  The inter-
individual variability in DTG values was between 23 and 40% when administered 
alone and between 28 and 48% during co-administration with DRV/COBI. C24 
remained 7 to 32 fold above the PA-IC90.76 
4.3.2.2. Darunavir plasma pharmacokinetics 
Figure 4.3 shows the DRV GM plasma concentration vs time curves with and without 
DTG in relation to DRV’s suggested PA-EC50 for resistant virus (based on in-vitro 
studies; 550 ng/mL).274 DRV GMR (DRV/COBI+DTG vs DRV/COBI alone) and 90% 
CI for Cmax, AUC0-24 and C24 were 0.90 (0.83-0.98), 0.93 (0.86-1.00) and 0.93 (0.78-
1.11) and for COBI Cmax, AUC0-24 and C24 were 0.96 (0.89-1.04), 0.98 (0.88-1.08) and 
0.98 (0.79-1.22). The inter-individual variability in DRV values was between 31 and 
52% when administered alone and between 20 and 53% during DTG co-
administration. 
C24 remained 1 to 4.5 fold above the suggested PA-EC50 (550 ng/mL)274 for DRV in 
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all subjects (except for one participant with a DRV C12 of 1428 ng/mL but C24 185 
ng/mL).  
Table 4.1 summarises the PK parameters for DTG and DRV/COBI when administered 
alone or together in the co-administration phase, in both groups combined. No 
difference was seen between groups for either drugs.  
4.3.3. Safety and tolerability 
The studied drugs were well tolerated, with no grade 3 or 4 side effects or laboratory 
abnormalities. Median (IQR) creatinine was 67 µmol/L (63-71) at baseline, 70 µmol/L 
(65-74) during DRV/COBI alone, 76 µmol/L (69-81) during DTG alone and 74.5 
µmol/L (70-79.5) during co-administration (equivalent to 0.75,0.79, 0.86 and 0.84 
mg/dL respectively). The difference between baseline and during co-administration 
was significant (T=2.5, p <0.01), which was driven by DTG. However, there was no 
evidence that adding DRV/COBI to DTG changed median creatinine significantly 
(>0.05), whilst adding DTG to DRV/COBI did (T=29.5, p <0.01). 
 
Grade 1-2 drug related NP-AEs were seen in 6 participants (30%) during DTG 
monotherapy and in 3 participants (15%) during DRV/COBI monotherapy. The co-
administration of the two drugs did not change the prevalence of drug related NP-AEs, 
which was 15% during the co-administration period and remained low grade (1-2). 
The commonest drug related NP-AEs were a grade 1 headache and sleep disturbances.
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Figure 4.2: GM dolutegravir concentration vs time curves and standard error bars over 24 hours with 
and without darunavir/cobicistat (DRC/c)  








































































































Table 4.1: Dolutegravir (DTG), darunavir (DRV) and cobicistat (COBI) steady state pharmacokinetic (PK) parameters, expressed as geometric mean (GM), 90% confidence 
intervals (CI), coefficient of variation (CV) and GM Ratios (GMR, alone/co-administered). Cmax: maximum concentrations, AUC0-24: area-under-the-curve, C24: concentration 




The steady state PK of standard dose DTG co-administered with DRV/COBI over 24 
hours was characterised in healthy volunteers. The changes in DTG PK parameters 
during co-administration compared to DTG administered alone were minimal. DTG 
C24 decreased by 10%, whilst AUC0-24 decreased by 5% and Cmax remained unchanged. 
DRV concentrations also decreased by less than 10% in all parameters. DTG and DRV 
concentrations remained manifold above the PA-IC90/PA-EC90 in all participants at all 
time points, suggesting that the combination of DTG and DRV/COBI can be 
prescribed safely in the treatment of HIV-1, including in patients harbouring resistance 
who benefit from optimal ARV exposures and in which BD dosing is recommended. 
In contrast, DTG C24 had decreased by 38% when co-administered with DRV/RTV 
(twice daily) in early DTG drug interaction studies, which was not deemed clinically 
significant (Cmax decreased by 11% and AUC0-24 22%; participants received multi-
dose DTG 30 mg, administered with food).306 
 
Our findings are in agreement with Gervasoni et al., who showed a doubling of DTG 
C24 in HIV patients who switched from DRV/RTV to DRV/COBI.305 DTG is primarily 
metabolised by UGT1A1 and is only a minor substrate for CYP3A4.172 Whilst both 
COBI and RTV are potent CYP3A4 inhibitors, unlike RTV, COBI does not induce 
glucoronidation (or any CYP enzymes),196 which, as previously discussed, is likely to 
explain the difference in effect seen between the two pharmacological boosters. A lack 
of inhibition of UGTA1A1, 1A3, 1A6, 1A9, 2B4 and 2B7, by both RTV and COBI, 
was recently demonstrated in-vitro, meaning that, in agreement with our results, COBI 
has a lack of effect overall on UGT.310 Interestingly, Gervasoni et al. commented on 
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the possibility that their observed surge in DTG concentrations when RTV was 
switched to COBI may be driven, at least in part, by a higher degree of inhibition of 
COBI on intestinal efflux transporters (P-gp and BCRP), leading to increased DTG 
absorption.196, 305 There was no rise in DTG Cmax, in our study, when DRV/COBI was 
added to DTG, which would suggest, conversely, that the inhibitory effect of COBI on 
these transporters in this setting is, at the most, limited.196, 198 DTG does not induce or 
inhibit CYP enzymes,76 therefore effects on DRV and COBI (which are mainly 
metabolised by CYP3A4) were not expected during co-administration with DTG.  
 
Interestingly, the PK parameters of DTG in this study were, overall, lower than seen 
in Min et al.’s early DTG PK study (healthy volunteers, n=8, food intake not specified) 
when administered alone and lower than in the Gervasoni et al. study when co-
administered with COBI, highlighting the importance of describing intra-individual 
effect in drug interaction studies.60, 305  
 
Serum creatinine concentrations significantly increased from baseline during DTG 
administration, but no significant increment was recorded when DRV/COBI was 
added to DTG, which is consistent with previous observations that administration may 
not result in additive renal effect, at least in the short-term.305, 308 The commonest NP-
AEs seen were mild headache and sleep disturbances, particularly with DTG (30%). 
Co-administration of DTG and DRV/COBI did not increase the prevalence of NP-
AEs, however, this study was not powered for a toxicodynamic analysis.  
 
There are limitations to this study. Subjects were healthy volunteers and 
pharmacokinetic conclusions cannot be fully drawn in HIV infected participants. In 
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licencing trials, DTG concentrations appeared generally lower in HIV infected 
participants than in healthy volunteers.57 Indeed, discrepancies in ARV drug PK 
between healthy volunteers and PLWH have been previously described (particularly 
for the protease inhibitors), which was discussed in chapter 3.288 Additionally, 
pharmacodynamics deductions cannot be drawn from healthy volunteers; however, 
previous cohort studies have reported good efficacy of DTG/DRV/COBI in small 
groups of treatment experienced HIV infected individuals.119, 120 Finally, DTG 
intensive PK over 24hrs remain to be determined during co-administration with DRV 
when the latter is boosted with RTV (to date only 12hr data is available); this is 
important in view of RTV’s known induction of UGT1A1 and is particularly relevant 
to patients with a background of InSTI resistance.   
 
The strengths of this study lie in its prospective, controlled and crossover design, 
which allowed an analysis of intra-individual effect. Additionally, the study 
population was appropriately diverse in gender, ethnicity and age. 
 
In conclusion, this study investigated the intra-individual variance in DTG and 
DRV/COBI PK parameters when administered together compared to alone. The 
results suggest that no dose adjustment is required in either agents and that this 
combination can be prescribed safely, at standard recommended doses, in the treatment 
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Women account for just over half of the world’s 36.7 million people living with 
HIV/AIDS and the majority are of childbearing age.311 Early and sustained HIV viral 
load suppression with ARV therapy now enables longer, healthier lives and improved 
fertility in women living with HIV (WLWH).312-314 A significant number do, however, 
report requiring the flexibility to plan or prevent pregnancy,313, 314 meaning that access 
to safe and reliable contraception in the context of ARVs is critical.315, 316 The 
combined oral contraceptive pill (COCP) is a preferred method of contraception for 
many women worldwide.317, 318 Nevertheless, WLWH have often been unable to use 
the COCP due to drug-drug interactions with some ARVs leading to altered drug levels 
and adverse events.319 For instance, a reduction in the progestogen component of the 
COCP potentially runs the risk of contraceptive failure and unwanted pregnancy319 
whilst overexposure can lead to a number of side effects such as increased appetite, 
fluid retention, acne and headaches.320 Meanwhile, changes in oestrogen 
pharmacokinetics impact tolerability (e.g. breakthrough bleeding with underexposure, 
which can impact adherence) and toxicity (e.g. thrombotic events with increased 
concentrations).321-323 There is now good evidence that an undetectable viral load 
equates to HIV being untransmittable4 and, hence, many HIV serodifferent couples 
choose to rely on hormonal contraception alone without condoms.313, 324 It is therefore 
essential to define the pharmacokinetics and pharmacodynamics of hormonal 
contraception co-administered with individual ARVs in order to inform guidelines and 
ensure that the efficacy and safety of both are maintained.321 
 
In addition, exogenous oestrogens are also used by trans-gender women (TGW) as 
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feminising therapy.325 TGW carry a disproportionate burden of HIV infection 
(estimated global prevalence 19.6% and incidence 3.4 to 7.8 per 100 person-years 
worldwide)326, 327 and are less likely to engage into care or being compliant with 
ART.328, 329 Qualitative studies have attributed this, in parts, to a limited understanding 
of the interactions between some ARVs and gender affirming hormones and to fears 
amongst TGW that ARVs will impede on hormonal efficacy, further underscoring the 
importance of having evidence-based data on DDIs.325, 330 Ethinylestrodiol (EE), 
specifically, is not recommended for feminisation therapy in guidelines;331 however, 
it is the most studied oestrogen and the reference agent for drug interaction 
guidance.325 It is also often used by TGW outside of healthcare settings for medical 
transition.332 
 
Despite very recently being removed from some major guidelines,312, 333, 334 boosted 
atazanavir (ATV/b) remains the preferred second-line ARV agent in the World Health 
Organisation guidelines and large numbers of patients, stable on treatment, continue 
therapy with ATV/b worldwide.246 With its long-standing experience history, high 
genetic barrier and once daily dosing, it remains an instrumental option in the 
management of HIV.335 For over a decade, ATV was mainly co-administered with the 
only pharmacological booster available, RTV. Hormonal contraceptives are 
extensively metabolised by CYP enzymes (CYP3A and CYP2C9/19) and drug 
interactions between the COCP and ATV (with or without RTV) have been 
demonstrated.336 The progestogens studied to date, norgestimate (NGM) and 
norethisterone (NET), are both increased in exposure with unboosted and with 
ritonavir-boosted ATV, through the inhibition of CYP3A4-mediated progestogen 
metabolism by both agents, thereby potentially leading to the side effects described 
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above.337, 338 Similarly EE concentrations also increase with unboosted ATV (48% rise 
in area under the curve, AUC)339 but, in contrast, decrease with ATV/RTV (16% 
decrease in EE Cmax, 19% in AUC and 37% in Cmin)338 which is thought to result from 
RTV’s concomitant induction of CYP2C9 and of the glucuronidation responsible for 
EE clearance (via UGT1A1).336 Therefore, according to guidelines and the ATV 
summary of product characteristics (SPC), if a combined oral contraceptive is 
administered with ATV/RTV, it must contain at least 35µg of EE, strict compliance is 
necessary and a second method of contraception is recommended, considering the 
unknown PD effect of the drug interactions.255, 338, 339 
 
Unlike RTV and as previously discussed, COBI is available co-formulated with ATV 
(Evotaz®) and is neither a UGT1A1 nor a CYP2C9 inducer.198-200 The product insert 
for Evotaz® and the University of Liverpool’s HIV drug interactions website58 state 
that no dosing recommendations can be made for COCP co-administration with 
ATV/COBI due to a lack of published data. It is currently suggested that additional or 
alternative (non-hormonal) forms of contraception should be considered. ATV/COBI 
co-administration with the COCP has been investigated in an unpublished, phase I 
drug interaction study (Majeed et al., IWCPAT, Chicago 2017), which only assessed 
a single dose of drospirenone (DRSP)/EE 3mg/20µg administered prior to and at the 
end of a 14-day course of standard dose ATV/COBI in healthy volunteers (n=14). The 
investigators found a 130% increase in DRSP AUC0-∞ and a 12% increase in Cmax. 
There was a non-clinically significant decrease in EE (22% reduction in AUC0-∞ and 
18% in Cmax). C24 was not reported.340 Neither COCP C24 nor ‘steady state’ (real life 
use) PK data are available; the latter are important since progestogen serum levels are 
2 to 3 fold higher in the steady state compared to a single administration (after 
 
 120 
approximately 8-10 days of treatment) and EE steady state concentrations increase by 
a 30-40% rise in plasma level (5-6 days post-initiation).323, 341 
 
EE/levonorgestrel (LNG; Microgynon®) is the leading COCP prescribed in the UK.342 
The aim of this study was therefore to investigate the steady state PK of EE/LGN 
30/150µg and ATV/COBI 300/150mg (Evotaz®) when co-administered in HIV 




Written informed consent was obtained from non-pregnant and non-lactating female 
healthy volunteers aged between 18 and 35 years with a body mass index (BMI) 
between 18 and 35 kg/m2. Participants were excluded if they had any significant acute 
or chronic medical illness; abnormal physical examination, ECG or clinical laboratory 
determinations; positive screens for HIV, hepatitis B or C; current or recent (within 
three months) gastrointestinal disease; clinically relevant alcohol or drug use that the 
investigator felt would adversely affect compliance with trial procedures; exposure to 
any investigational drug or placebo within three months of the first dose of the study 
drug; use of any other drugs, including over the counter medications and herbal 
preparations, within two weeks of the first dose of the study drug; and previous allergy 
to any of the constituents of the pharmaceuticals administered during the trial. Women 
of childbearing potential required a negative pregnancy test at screening and baseline 
and additional contraception if required. 
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5.2.2. Study design 
Figure 5.1: Study design. PK: Pharmacokinetics, W-O: Washout period. *14 or 21 days, patient choice 
The study design is shown in figure 5.1. This was an open-label, crossover, 57-day 
(excluding screening and follow-up) phase 1 PK trial carried out at the Clinical Trial 
Unit of the St. Stephen’s Centre, Chelsea and Westminster Hospital, London, UK.  
 
At screening, clinical assessment and routine laboratory investigations were performed 
in all participants. The safety and tolerability of study medications were evaluated 
throughout the trial (on days 7, 28, 49, on PK days and at follow-up) using the previously 
referred to NIAID Division of AIDS table for grading the severity of adult and pediatric 
adverse events (2004). After successful screening, volunteers were randomized to either 
i) group 1, which received EE/LNG 30/150 µg alone on days 1-21, EE/LNG (21 days) 
+ ATV/COBI 300/150 mg (14 days) in the co-administration period (days 22-42) and 
ATV/COBI alone on days 43-56 (14 days) or ii) group 2, which followed the same 
structured sequence but started with ATV/COBI alone and finished with EE/LNG alone 
(14 or 21 days, patient choice). Each group underwent intensive PK sampling on study 
days 14, 35 and 56 to measure plasma concentrations of EE/LNG and/or ATV/COBI at 
0 (pre-dose), 2, 4, 8, 12- and 24-hours post-dose. On the PK days, study staff witnessed 




Adherence was assessed through direct questioning of dosing schedules, missed and 
late doses at each safety and PK visit. A pill count was carried out at each PK visit.  
5.2.3. Analytical and PK methods 
Blood samples were collected into lithium heparin-containing blood tubes (12 mL) at 
each time-point, immediately inverted several times and then kept on ice or 
refrigerated until centrifugation. Within 30 minutes of blood collection, each blood 
sample was centrifuged for 10 minutes at 2000 g at 4°C. Plasma was then aliquoted 
equally into three 2.0 mL tubes (Sarstedt, Germany) and stored at -20°C. Samples were 
shipped on dry ice to the Liverpool Bioanalytical Facility for analysis. The laboratory 
is Good Clinical Laboratory Practice-accredited and participates in an external quality 
assurance scheme (KKGT, the Netherlands).270, 271  
5.2.4. Quantification of LNG, EE, ATV and COBI 
Concentrations of LNG, EE, ATV and COBI in plasma were measured using validated 
high-pressure liquid chromatography–tandem mass spectrometry methods (LC-
MS/MS).272, 273, 343 The LLOQ for the plasma analyses were 0.240 ng/mL for LNG, 5 
pg/mL for EE, 10 ng/mL for ATV, and 5 ng/mL for COBI. For concentrations below 
the assay limit of quantification, a value of one-half of the quantification limit was 
used. Accuracy (percentage bias) was between -0.42% and 1.5% (LNG), 0.61% and 
3.28% (EE), 4.70% and 6.36% (ATV), and 6.45% and 8.07% (COBI) and precision 
was less than 3.1% (LNG), 8.0% (EE), 6.3% (ATV), and 8.0% (COBI). 
 
5.2.5. Data analysis 
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The calculated PK parameters for plasma LNG, EE, ATV and COBI were plasma C24, 
Cmax and AUC0–24. All PK parameters were calculated using actual blood sampling 
time and non-compartmental modeling techniques (WinNonlin Phoenix, version 6.1; 
Pharsight, Mountain View, CA). Descriptive statistics, including GM 90% CI were 
calculated for LNG, EE, ATV and COBI plasma PK parameters. Each drug PK 
parameter during the co-administration period was compared to the unaccompanied 
drug PK parameter by calculating GMR and 90% CI (co-administered/alone). Inter-
individual variability in drug PK parameters was expressed as CV%. 
5.2.6. Statistical power 
This was an exploratory study and, as such, no formal sample size calculation was 
performed. Sixteen (16) participants completing the study was deemed appropriate to 
allow for relevant conclusions and is standard for PK studies. 
5.2.7. Ethics 
The study protocol was approved by the Westminster Research Ethics Committee, 
London, United Kingdom, as well as by MHRA UK. The study was conducted 
according to Good Clinical Practice and the Declaration of Helsinki (NCT02697851). 
5.3. RESULTS 
5.3.1. Study population 
Fourteen healthy female volunteers were screened, 13 were enrolled and 11 attended 
the baseline visit (2 withdrew prior to baseline for personal reasons). 9 completed the 
intensive PK day 14 (five in group 1, four in group 2), 8 completed day 35 (four in 
each group) and 6 completed day 56 (four in group 1, two in group 2). Overall, seven 
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participants withdrew consent; five because of adverse events and two before starting 
the study medications. Of the six participants who completed all PK phases (up to day 
56), the median (range) age and BMI were 31 (19-35) years, and 24 (19-29) kg/m2, 
respectively. Of the eleven participants who attended the baseline visit, four 
participants described themselves as Caucasian, six as black African, and one as 
Hispanic. Demographics and reasons for withdrawals are summarised in table 5.1. 
 
Table 5.1: Participant demographics, withdrawals and withdrawal reasons. ID = study identification, 
BMI = body mass index, G = group, D = day, n/a = not available, WBC = White and Black Caribbean 
5.3.2. Pharmacokinetic results 
PK data for all four drugs in the two separate groups are detailed in table 5.2. For each 
drug, only paired data from participants who completed the first period (either 
EE/LNG or ATV/COBI alone) and the co-administration period were used, so as to be 
able to assess and summarise intra-individual PK changes between the two periods. 




Ethnicity BMI Group Study stage reached Reason for 
withdrawal 
101 31 Hispanic 21.1 G1 Completed N/A 
102 27 White 23.7 G2 Between D7 and D14 Rash 
103 30 African 29.3 G1 Completed N/A 
104 33 White 22.1 G2 Completed N/A 
105 30 African 26.8 G1 Between D28 and D35 Deranged LFTs 
106 28 Turkish 23.1 G1 Before baseline 1st dose not given 
107 35 White 26.9 G1 Completed N/A 




109 18 White 20.7 G2 Between Baseline and D7 
Side effects, not 
specified 
110 27 White 25.3 G2 Completed N/A 
111 19 White 19.0 G1 Completed N/A 
112 25 WBC 22.4 G2 Between D35 and D43 No cause given 
113 29 White 27.6 G1 Before baseline 1st dose not given 
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5.3.2.1. Levonogestrel plasma pharmacokinetics 
Six participants provided data for LNG intake with and without ATV/COBI (G1 n=4, 
G2 n=2). Geometric mean ratios (with ATV/COBI vs without) and 90% CI for LNG 
Cmax, AUC0-24 and C24 were 0.83 (0.68-1.02), 0.92 (0.71-1.18) and 1.01 (0.73-1.38) 
respectively. 
5.3.2.2. Ethinylestradiol plasma pharmacokinetics 
Six participants provided data for EE intake with and without ATV/COBI (G1 n=4, 
G2 n=2). GMR (90% CI) for EE Cmax, AUC0-24 and C24 were 1.05 (0.92-1.19), 1.01 
(0.88-1.22) and 0.75 (0.60-0.93) respectively. 
5.3.2.3. Atazanavir plasma pharmacokinetics 
Eight participants provided data for ATV intake with and without EE/LNG (G1 n=4, 
G2 n=4). GMR (90% CI) of ATV Cmax, AUC0-24 and C24 were 0.75 (0.60-0.95), 0.78 
(0.64-0.96) and 0.89 (0.72-1.11) respectively. 
5.3.2.4. Cobicistat plasma pharmacokinetics 
Eight participants provided data for COBI intake with and without EE/LNG (G1 n=4, 
G2 n=4). GMR (90% CI) of COBI Cmax, AUC0-24 and C24 were 0.88 (0.8-0.97), 0.85 
(0.77-0.95) and 0.89 (0.66-1.21) respectively.  
 
LNG and EE drug concentrations vs time curves with and without ATV/COBI are 
illustrated in figures 5.2 and 5.3 respectively. Table 5.3 summarises the results in this 
study together with currently reported findings of COCP interaction studies involving 
ATV/RTV and/or COBI. 
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Table 5.2: Summary of pharmacokinetic data for all four drugs. EE = ethinylestradiol, LNG = levonorgestrel, ATV = atazanavir, COBI = cobicistat, CV = coefficient of 
variation, GM = geometric mean, GMR = geometric mean ratio, CI = confidence interval, Cmax = maximum concentration, AUC0-24 = area under the curve from 0 to 24 hours, 
C24 = concentration at 24 hours post-dose. 

































LNG (n=6)  
Total 6.5 (3.5-9.6) 60 5.4 (3.7-7.2) 43 0.83 (0.68-1.02) 92 (41-143) 67 84 (57-111) 43 0.92 (0.71-1.18) 2.83 (1.2-4.5) 67 2.85 (1.9-3.8) 45 1.01 (0.73-1.38) 
Group 1 (n=4) 8.8 (5.9-12) 46 7.2 (6.1-8.3) 23 0.82 (0.61-1.11) 130 (81-180) 50 111 (93-129) 23 0.85 (0.64-1.12) 4.2 (2.7-5.7) 47 3.8 (3.2-4.5) 25 0.90 (0.64-1.27 
Group 2 (n=2) 3.6 (1.5-5.7) 47 3.09 (2.1-4.1) 26 0.86 (0.66-1.12) 45 (3.2-87) 69 48 (36-61) 23 1.07 (1.74-2.69) 1.3 (-0.05-2.6) 75 2.6 (1.0-4.2) 59 0.9 (0.64-1.27) 
EE (n=6)  
Total 40 (28-53) x10-3 43 42 (32-52) x10-3 34 1.05 (0.92-1.19) 407 (259-555) x10-3 49 410 (318-501) x10-3 32 1.01 (0.83-1.22) 7.4 (3-12) x10-3 72 5.6 (3.9-7.3) x10-3 42 0.75 (0.6-0.93) 
Group 1 (n=4) 43 (28-58) x10-3 47 46 (32-60) x10-3 35 1.07 (0.88-1.3) 446 (281-612) x10-3 50 440 (335-544) x10-3 33 0.98 (0.77-1.26) 8.2 (3-13) x10-3 76 5.5 (3.7-7.3) x10-3 45 0.67 (0.50-0.89) 
Group 2 (n=2) 36 (29-42) x10-3 26 36 (32-39) x10-3 15 1 (0.88-1.13) 338 (202-475) x10-3 55 356 (302-411) x10-3 22 1.05 (0.7-1.59) 6.1 (3.2-9) x10-3 63 5.7 (3.5-8) x10-3 53 0.94 (0.82-1.08) 
ATV (n=4)  
Total 4157 (3151-5163) 39 3133 (2472-3795) 34 0.75 (0.60-0.95) 48998 (37387-60608) 38 38293 (27206-49380) 45 0.78 (0.64-0.96) 1061 (614-1507) 62 949 (527-1371) 66 0.89 (0.72-1.11) 
Group 1 (n=4) 4447 (2692-6201) 45 2861 (2158-3565) 29 0.64 (0.46-0.90) 49455 (35411-634500) 33 33680 (24048-43312) 32 0.68 (0.51-0.91) 930 (348-1510) 65 787 (543-1031) 35 0.85 (0.59-1.21) 
Group 2 (n=4) 3886 (2692-5080) 36 3432 (2286-4577) 38 0.88 (0.65-1.21) 48544 (27777-69312) 48 43539 (23393-63684) 50 0.90 (0.69-1.17) 1211 (467-1954) 65 1145 (341-1949) 71 0.95 (0.71-1.27) 
COBI (n=4)  
Total 1760 (1604-1917) 15 1554 (1325-1782) 25 0.88 (0.8-0.97) 16456 (13863-19049) 26 14054 (10703-17405) 39 0.85 (0.77-0.95) 70 (27-113) 84 62 (13-112) 101 0.89 (0.66-1.21) 
Group 1 (n=4) 1810 (1669-1952) 9 1414 (1173-1655) 20 0.78 (0.7-0.87) 15834 (13044-18624) 21 11820 (9572-14069) 23 0.75 (0.65-0.86) 49 (25-73) 53 44 (26-61) 44 0.89 (0.47-1.67) 





Figure 5.2: Levonogestrel (LNG) GM (95% CI) plasma concentration vs time curves, with and without ATV/COBI, GM (95% CI) n=6. LNG = levonorgestrel, ATV = 
atazanavir, COBI = cobicistat, GM = Geometric Mean, CI = Confidence Interval
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Figure 5.3: Ethinylestradiol EE GM (95% CI) plasma concentration vs time curves, with and without ATV/COBI, GM (95% CI) n=6. EE = ethinylestradiol, ATV = atazanavir, 
COBI = cobicistat, GM = Geometric Mean, CI = Confidence Interval 
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Progestogen AUC 8% 50% 85% 110% 130% (AUC0-∞) 
 Cmax 17% 33% 68% 60% 12% 
 Cmin 1% 26% 102% N/A N/A 
EE AUC 1% N/A 19% 20% 22%  (AUC0-∞) 
 Cmax 5% N/A 16% 10% 18% 
 Cmin 25% N/A 37% N/A N/A 
Table 5.3: Summary of COCP drug interactions studies with atazanavir, ritonavir & cobicistat. Legend: 
AUC = Area Under the Curve; Cmax = maximum concentration reached; Cmin = trough concentration; 
ATV= atazanavir; COBI = cobicistat; EE = ethinylestradiol; LNG = levonogestrel; PI = protease 
inhibitor; RTV = ritonavir; NET: norethindrone; NGM = norgestimate; TDF = tenofovir; FTC = 
emtracitabine; EVG = elvitegravir; DRSP = drospirenone; N/A: not applicable. 
a: Atrio et al. J Acquir Immune Defic Syndr. 2014337 b: Zhang et al. Antivir Ther. 2011338 c: Squires et 
al. Asia Pacific AIDS Conference. 2016344 d: Majeed et al. IWCPAT. 2017340 
5.3.3. Safety and tolerability 
Five participants withdrew consent from the study secondary to side effects; of those, 
data on the reason are available for three and are listed in table 5.1. Full adherence 
was confirmed through regular direct questioning and pill counts in the women who 
completed the study and no grade 3 or 4 adverse events or laboratory abnormalities 
were observed in this group. 
5.4. DISCUSSION 
This was the first study to investigate the steady state PK of Microgynon® co-
administered with ATV/COBI (Evotaz®). The hormonal components of the COCP 
undergo extensive first-pass metabolism by phase I and II microsomal enzymes in the 
small intestinal mucosa and the liver before reaching the systemic circulation, meaning 
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that they are highly susceptible to DDI.345, 346 LNG is first hydroxylated in the liver, 
mainly by CYP3A4, and its metabolites are then excreted as glucuronide conjugates.347 
The results of this study showed only a small reduction in steady state LNG Cmax 
(17%) and no changes in C24 or AUC0-24 when it is administered with ATV/COBI 
(GMR range 0.92-1.01). Majeed et al. had also reported little interaction with 
progestogens, with only a 12% increase seen in DRSP Cmax when co-administered as 
a single dose with ATV/COBI. Both studies therefore suggest that ATV/COBI has a 
lesser impact on progestogen peak concentrations than ATV/RTV does when co-
administered with NGM or NET (GMR 1.33-1.68)337, 338, 340 and when NGM is co-
administered with COBI as part of Stribild® (TDF/FTC/EVG/COBI; GMR 2.08; 
Polina et al. 12th Clin Pharm of HIV Therapy Workshop 2011). Whilst the number of 
participants completing the relevant phases in our study (n=6) was small and our data 
cannot be conclusive, a lack of clinically significant decrease in LNG minimum 
concentration and exposure is cautiously reassuring. This is because the progestogen-
mediated suppression of the luteinising hormone (LH) surge is one of the main 
contraceptive mechanisms of the COCP and LNG is also the progestogen contained in 
the most commonly prescribed form of the emergency contraceptive pill.347-349 
Furthermore, the lack of meaningful rise in progestogen C24 and AUC0-24 in the study 
presented here differs to the increases seen with ATV/RTV co-administration (GMR 
1.85 and 2.02 respectively) or with COBI co-administration when combined with DRV 
or EVG (GMR range 1.58-2.67; Majeed et al., IWCPAT 2017 and Polina et al. 12th 
Clin Pharm of HIV Therapy Workshop 2011). This finding is important since 
progestogen overexposure can lead to a number of significant side effects, as described 
above, that include nausea, weight gain and acne amongst others and that may impact 




This study showed that EE C24 decreased by 25% with ATV/COBI compared to a 37% 
decrease reported with ATV/RTV. Moreover, no clinically significant changes were 
found in Cmax or AUC0-24 (5% and 1% increases respectively), compared to the 
decreases seen with ATV/RTV (19% and 16% respectively).338 This may be explained 
by the fact that, unlike RTV, COBI does not induce UGT1A1 or CYP2C9, both of 
which are involved in EE clearance.198 As the EE component of the COCP is mainly 
responsible for endometrial stability and a significant reduction in C24 can lead to 
breakthrough bleeding potentially impacting adherence to contraception,319 smaller 
decreases in PK parameters are likely to optimise tolerability and adherence. Our 
findings also compared well to data on EE co-administration with DRV/COBI in the 
Majeed et al. study, which lead to a 30% and a 14% decrease in EE AUC0-∞ and Cmax 
respectively, secondary to DRV-mediated induction of CYP2C9 and CYP2C19.336, 340 
EVG-mediated induction of CYP2C9 and UGT appears to overcome general COBI-
mediated enzyme inhibition, leading to a decrease in EE PK parameters when it is co-
administered with Stribild (GMR range 0.66-0.94; Polina et al. 12th Clin Pharm of 
HIV Therapy Workshop 2011). 
 
As previously described, EE concentrations increase with unboosted ATV (AUC, Cmax 
and Cmin 48%, 15% and 91%, respectively), as do progestogen concentrations, through 
ATV mediated CYP3A4 and UGT1A1 inhibition.339  Yet, when co-administered with 
ATV/COBI in this study, EE AUC0-24, EE Cmax, LNG AUC0-24 and LNG C24 did not 
increase, whilst EE C24 and LNG Cmax even decreased. This is despite the lack of 
known COBI related enzyme or transporter induction (in-vitro) to counteract ATV and 
COBI-mediated enzyme inhibition. This highlights that COBI’s in-vivo metabolic 
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effects may not yet be fully elucidated and warrant further investigation.  
Of note, EE Cmax levels were consistently lower in this study (36-46 pg/mL regardless 
of the study phase), than in a majority of other EE PK studies (mean levels 80 pg/mL 
following a 30ug EE dose).350 This could be explained by the sampling schedule used 
- EE tmax is usually reached at an average of 1.5 hours; it is therefore possible that the 
maximum concentration reached for some subjects was missed by sampling 1- and 2-
hours post-dose. Additionally, levels of EE have been shown to steadily increase 
within the first treatment cycle,341 therefore concentrations measured at the end of the 
cycle (day 21) may be higher than mid-cycle (day 14), which is when subjects in this 
study underwent intensive PK sampling. It may also be higher again in subsequent 
cycles. This is however offset by the study design, which allowed for the intra-
individual effect of co-administration to be measured. LNG PK parameters in this 
study were comparable to previously published data.320, 323 
 
ATV and COBI concentrations were slightly reduced during the co-administration 
period (table 5.2). For ATV, the changes in both groups combined were small and 
within the no-effect boundary (GMR Cmax was 0.79 and GMR C24 0.89). Interestingly, 
there was a significant decrease in ATV/COBI Cmax and AUC0-24 when combined with 
EE/LNG (GMR 0.64 and 0.68 respectively) in group 1 subjects only (i.e. those who 
received Microgynon30 alone for 21 days prior to combining with ATV/COBI) 
whereas no interaction was present with the group 2 subjects. Whilst this could be 
interpreted as being due to enzyme induction by EE, it is an observation and it is not 
possible to come to any conclusions based on the very small number of subjects in a 
sub-group (n=4); C24 remained unchanged.  Importantly, ATV concentrations in both 
groups remained reassuringly above the in-vivo suggested minimum effective 
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concentration for wild type HIV  (MEC = 150 ng/mL).335 
The target recruitment was not reached and five/11 participants (45%) withdrew from 
the study secondary to side effects, 3 of which disclosed information on the reason 
(rash, deranged liver function tests and gastrointestinal symptoms). This is a higher 
dropout rate than seen in Majeed et al. (22%), although participants in that study had 
only received one dose of COCP. Whilst high, it is in keeping with the combined 
published discontinuation rates secondary to any AE for boosted atazanavir (15%) and 
the COCP (29%).349, 351 Both are drugs with relatively common side effects in the 
initial period and it is important that patients are counseled accordingly.  
 
There are limitations to this study. The subjects were HIV negative healthy volunteers. 
As such, PK or pharmacodynamic comparisons with HIV positive women must be 
made cautiously and the practical implications of these PK observations are unknown. 
Clinical outcome data are required in large cohorts of HIV infected participants, and 
studies investigating pharmacodynamic endpoints (such as failure of viral suppression, 
HIV-related clinical disease progression or unintended pregnancy) are needed in order 
to draw definite conclusions on how likely a contraceptive or an ARV is to fail in the 
context of co-prescription. It is also important to remember that efficacy rates of user 
dependent contraception differ between perfect use (as seen in a clinical study) and 
real-life use. The fact that this study involved healthy volunteers may also explain the 
low number of participants completing the study.  In real-life settings, mild side effects 
associated with the initiation of COCP and/or of ARVs do not normally persist beyond 
three to six months, at which point an alternative would usually be offered. The option 




Nonetheless, this study provides the first steady state PK data on EE/LNG co-
administered with ATV/COBI, demonstrating minimal changes in LNG 
concentrations and a smaller decrease in EE than seen with ATV/RTV.  Whilst 
preliminary, these data are important in informing physicians, who need to discuss and 
choose safe and reliable contraception with their female patients living with HIV. 
Whether this minor difference between ATV/RTV and ATV/COBI will be clinically 




Genetic Influence Of ABCG2, UGT1A1 






























Emilie ER, Neary M, Else L, Khoo S, Moyle G, Carr DF, Wang X, Mcclure M, Boffito M, Owen A. 
Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics, 





6.1 INTRODUCTION ..…………………………………...…...…......... 137 
6.2. METHODS ..………………............................ 140 
 6.2.1. Clinical study and participant selection .........……......... 140 
 6.2.2. PK sample and data collection  ........……...…………… 141 
 6.2.3. Pharmacogenetics sampling, DNA extraction and 
genotyping  ................................................................................. 142 
 6.2.4. Covariates  ...................................................................... 143 
 6.2.5. Statistical analysis  .....................................................…. 143 
6.3. RESULTS  ……………………………………………....………….. 144 
 6.3.1. Participants  ..………………………....……….............. 145 
 6.3.2.  DTG pharmacokinetics  ................................................. 145 
 6.3.3. DTG pharmacogenetics  ................................................. 145 
 6.3.4. Covariates  ................................….................................. 146 
 6.3.5. ABCG2 c.421C>A (rs2231142)  .................................... 146 
 6.3.6. NR1I2 c.63396C>T (rs2472677)  ................................... 148 
 6.3.7. UGT1A1*28 (rs8175347)  .............................................. 148 
 6.3.8. Composite Scores  ...............................................…....... 148 




DTG is now a preferred agent in major guidelines and a drug of choice for many HIV 
healthcare providers worldwide.352 It has replaced EFV as the preferred first-line agent 
in the WHO ARV guidelines and has been recommended by PEPFAR (Emergency 
Programme on AIDS Research) for rapid introduction in its key target countries, 
meaning that it is a major player in the worldwide ARV scale up.65 Despite a signal 
raised for a possible increased risk of NTD in women who conceive on DTG (0.3% vs 
0.12% on other ARVs),167 the WHO still recommends DTG in women who do not 
plan to conceive, provided that those of childbearing age are well informed and have 
access to reliable contraception, until further data is available.63-65, 164 Overall, up to 
60 LMICs have adopted DTG into their national treatment guidelines and it is 
estimated that 15 million people could be taking DTG by 2025, which stresses the 
importance of understanding how its pharmacology behaves in diverse and wide-
ranging populations.7, 65 
 
The real-life rates of DTG-related AEs and discontinuation rates secondary to AEs, 
particularly NP-AEs, have been discussed in details in chapters 1 and 2. A number 
of cohort studies have suggested an association between DTG PK and neurotoxicity, 
although this remains to be confirmed.149-151 Other risk factors such as age, gender, 
evening dosing and ABC co-administration, have also been suggested in some cohorts, 
whilst being altogether disproved in others.129-135, 146 More recently, reports of drug 
associated weight gain have emerged with InSTIs, particularly DTG and particularly 
in women and persons of black origin, raising concerns around potential metabolic 
sequelae.140-144 Despite TAF being identified as a co-factor and suggestions of possible 
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DTG-mediated disruptions of adiponectin and/or melanocortin receptor 4 (MCR4) 
pathways, the aetiology remains poorly understood.145, 353  
 
Overall, whilst a relation with DTG Cmin is suggested, mechanisms of DTG-related 
AEs, particularly neurotoxicity, are likely to be more complex than a simple linear or 
threshold-defined PK relationship and may relate to a combination of factors that also 
include pharmacogenetic, immune and/or functional predispositions.241, 354 
 
The PK and PD properties of DTG have already been extensively described in the 
literature and are discussed in chapters 1 and 2 of this thesis.57 To summarise, DTG 
is primarily metabolised via the phase II enzyme UGT1A1 and, to a minor extent, by 
phase I CYP3A4 (~ 15%; and UGT1A3, UGT1A9 in vitro), whilst being a substrate 
for the efflux transporters BCRP and P-gp, which are found on gastrointestinal 
epithelial cells, liver cells and on endothelial cells within the blood brain barrier.172 
DTG displays no significant CYP enzyme inhibition or induction and thus is a minor 
DDI perpetrator.76 Notably, it has a long PK tail (chapter 3) and its PK inter-individual 
variability was moderate in pre-licencing trials (CV%, 24-26%) although greater in 
subsequent studies (CV% up to 85%).354-356  
 
PK data have also become available in populations underrepresented in clinical trials.57 
For instance, in chapter 2, a 25% higher Cmax was demonstrated in PLWH aged 60 
years and over and a 25-50% lower exposure (AUC) and Cmin have been described in 
women in the 3rd trimester of pregnancy.65, 160, 354 The DTG SPC reports no ethnicity 
or gender differences in DTG exposure235 but this remains to be confirmed more 




Pharmacogenetics data for DTG to date are relatively limited. Chen et al., in a pooled 
analysis of pharmacogenomics samples collected from pre-licencing clinical studies 
in healthy subjects, found a 34% lower CL/F, 31% higher AUC0-t  and 22% higher Cmax 
in homozygous carriers of UGT1A1 (rs8175347) poor function variants (*28/*37/*6) 
compared with subjects with normal enzyme activity (*1/*1 and *1/*36).230 This data 
is referred to in the DTG SPC. Furthermore, in smaller studies, Yagura et al. found an 
association between UGT1A1*6 (rs4148323) and UGT1A1*28 (rs8175347) variants 
and higher Cmin, whilst Tsuchiya et al. reported that DTG Cmax was significantly higher 
(50%) in individuals homozygous for ABCG2 c.421C>A (rs2231142), which may be 
particularly important if supratherapeutic DTG concentrations are shown to correlate 
with DTG side-effects.148-150, 357 At the time of writing, there were no other published 
studies investigating the impact of polymorphisms on DTG pharmacokinetics. Of note, 
however, Borghetti et al. recently reported an association between a variant within the 
encoding gene for OCT2 (SLC22A2) and sub-clinical neuropsychiatric 
pharmacodynamic  measurements in a European cohort.232 DTG inhibits OCT2 but is 
not a substrate; variants would therefore not be expected to impact DTG plasma 
concentrations.  
 
Common UGT1A1 polymorphisms were discussed in chapter 1. DTG is also a known 
substrate of the BCRP efflux transporters. ABCG2 c.421C>A (rs2231142) is one of 
the most studied SNPs for the BCRP encoding gene; the variant allele is most common 
in East Asian populations (29.1%; Caucasians 10%). It is associated with a loss of 
protein function and a reduction of drug efflux transport leading to increased substrates 
plasma and cellular concentrations.150 Of additional interest, CYP3A4*22 (522-
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191C>T; rs35599367) is associated with lower CYP3A4 expression and activity 
within the liver,358 as well as increased lopinavir concentrations.359 The CYP3A5*3 
(6986A>G, rs776746) variant allele, whilst not directly involved in DTG metabolism, 
is known to be in linkage disequilibrium with CYP3A4*1B and has been independently 
associated with higher NVP AUC and reduced ATV clearance.222, 360, 361 NR1I2 
encodes the PXR nuclear receptor, which regulates the expression and activity of 
several enzymes, including CYP3A4 and UGT1A1.222, 362 NR1I2 c.63396C>T 
(rs2472677) has been associated with the PK of unboosted atazanavir.363, 364 
Accordingly, the objective of this study was to investigate the role of common 
UGT1A1, ABCG2, CYP3A and NR1I2 SNPs on plasma DTG concentrations in pooled 
subjects from four clinical trials investigating the PK of 50mg DTG taken OD. Of note, 
ABCB1 SNPs, coding for P-gp, were not selected since there are many known 
compensatory mechanisms for any potential ABCB1 polymorphism related PK/PD 
effects. 
6.2. METHODS 
6.2.1. Clinical study and participant selection 
Pooled samples from three Phase I (SSAT061 (NCT02219217), SSAT064 
(NCT02509195) and SSAT073 (NCT03094507)) and one Phase III (SSAT066 
(NCT02351908)) clinical trials carried out at the St Stephen’s AIDS Trust clinical trial 
unit, London, between 2014 and 2017 were collected and saved for genetic analysis. 
All Phase I trials were clinical pharmacology repeat-dose studies involving intensive 
PK assessments. The Phase III trial included a PK sub-study involving a timed DTG 
C24 at steady state.  All studies used a 50mg dose of DTG OD, taken as a tablet 
formulation either alone (healthy volunteers) or co-formulated with 
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abacavir/lamivudine as part of Triumeq® in the Phase I studies and with 
emtracitabine/tenofovir (Truvada®) in the Phase III study (HIV infected participants). 
All clinical studies are registered. 
 
The studies selected for inclusion were conducted in accordance with good clinical 
practice procedures, all applicable regulatory requirements and the guiding principles 
of the Declaration of Helsinki. The study protocols for each clinical study were 
reviewed and approved by the applicable National Research Ethics Service (NRES) 
committees and MHRA UK. Pharmacogenetic samples were collected under separate 
written informed consent to the main clinical study and were optional for participants 
in each study. The respective NRES committees for each study approved the 
pharmacogenetic sub-study for each trial as part of the main study protocol approval.  
No individual subject took part in more than one study.  
6.2.2. PK sample and data collection 
Within each of the Phase I studies, subjects underwent steady state intensive DTG 
plasma PK determinations, following witnessed drug intake (on study day 14 or 28).  
Blood samples were collected pre-dose, 1, 2, 3, 4, 8, 12- and 24-hours post-dose. The 
Phase III study involved a one-off PK sample taken 24-hour post-dose. This was 
carefully timed, with research staff instructing participants over the phone to take the 
medication the morning of dosing and with participants attending the clinical research 
unit the following day to allow for PK sampling exactly 24-hours post-dose, as timed 
by research staff. Overall, medication adherence was assessed through direct 
questioning and pill count in all studies. Steady-state plasma concentrations were 
determined using high-pressure liquid chromatography–tandem mass spectrometry 
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methods for samples from three of the clinical trials (HPLC-MS/MS; completed at the 
Bioanalytical Facility, University of Liverpool) or using ultra-performance liquid 
chromatography coupled with UV detection for one clinical trial (UPLC; Jefferiss 
Trust Laboratory, Imperial College London). Both are validated and have been 
previously described in the literature.247, 273 The lower limits of quantification (LLOQ) 
were 10 ng/mL and 80 ng/mL, respectively. For concentrations below the assay 
LLOQ, a value of one-half of the quantification limit was used. Accuracy (percentage 
bias) was between 92.5% and 96.2% and precision was between 2.6% and 4.1% for 
the HPLC-MS/MS method, whilst the reported accuracy for the UPLC method was 
between 90.7% and 97.7%, intra-assay variability was 3.3–6.1%, and inter-assay 
variability was 4.5–5.7%.247, 273 The two methods have not been cross-validated as 
their respective calibration ranges vary widely. The calculated PK parameters for 
plasma DTG in the three phase I studies were C24, Cmax, AUC0-24 and half-life (t1/2). 
For the phase III study, only C24 was determined. PK parameters were calculated using 
actual blood sampling time and non-compartmental analysis techniques (WinNonlin 
Phoenix; version 6.1 or above; Pharsight, Mountain View, CA). 
6.2.3. Pharmacogenetics sampling, DNA extraction and genotyping 
Venous blood was collected at baseline, from subjects consenting to pharmacogenetics 
research, into an EDTA vacutainer. Samples were then shipped on dry ice to the 
Pharmacology Research Laboratories at the University of Liverpool, UK, and stored 
at -80°C. Genomic DNA was extracted from whole blood using a spin-column based 
kit according to the manufacturer’s protocol (E.Z.N.A Blood DNA Mini Kit; Omega 
bio-tek; Norcross, GA). Extracted DNA was quantified using NanoDrop 
(ThermoFisher Scientific, Wilmington, DE). Genotyping was completed using real 
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time allelic discrimination polymerase chain reaction (PCR) assays on a DNA Engine 
Chromo4 system (Bio-Rad Laboratories, Hercules, CA). The PCR protocol followed 
denaturation at 958°C for 10 min, followed by 50 cycles of amplification at 928°C for 
15 sec and annealing at 608°C for 1 min 30 sec.  
 
Taqman Genotyping Master mix and assays were purchased from Thermofisher 
Scientific (Life Technologies Ltd, Paisley, Renfrewshire, UK) and were as follows: 
CYP3A4*22 c.522-191C>T (rs35599367, catalogue number C_59013445_10), 
CYP3A5*3 c.6986A>G (rs776746, catalogue number C_26201809_30), ABCG2 
c.421C>A (rs2231142, catalogue number C_15854163_70), ABCG2 c.34G>A 
(rs2231137, made to order), NR1I2 c.63396C>T (rs2472677, catalogue number 
C_26079845_10), NR1I2 c.44477A>G (rs1523130, catalogue number 
C_9152783_20) and UGT1A1*6 c.211G>A (rs4148323, catalogue number 
C_559715_20). Opticon Monitor V3.1 software (Bio-Rad Laboratories) was used to 
obtain allelic discrimination plots and identify genotypes. The UGT1A1 promoter 
region (*1, *28, *36 and *37) was genotyped using an Agena MassArray iPLEX assay. 
6.2.4. Covariates 
Subjects age, gender, height, weight, ethnicity, HIV status and accompanying drug to 
DTG were extracted from each study. Covariates were then included in the univariate 
and multivariate linear regressions described below.  
6.2.5. Statistical analysis 
In order to determine assay performance, genotypes for each marker were evaluated 
for compliance with Hardy–Weinberg equilibrium (p >0.05) using validated and 
previously outlined methods.365 Allele frequencies were also compared to published 
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and publicly available British and European allele frequencies.242  
Genotypes were coded for regression analyses as 0 for the homozygous common 
allele, 1 for the heterozygous and 2 for the homozygous variant allele. For SNPs 
displaying a dominant or recessive allele effect, coding was dichotomized and 
weighted appropriately (e.g. if using a recessive genotypic test model, the homozygote 
common variant and the heterozygote allele were grouped into a single category and 
were coded as 0 whilst the homozygote variant was coded as 2).366 The SNPs selected 
for the study were analyzed individually. SNPs found to correlate with any PK 
parameter were then also combined in pairs to create scoring algorithms consisting of 
the sum of each genotype code.  
 
Categorical variables were described using relative frequencies, while continuous 
variables were described using medians and interquartile ranges (IQR). Drug PK 
parameters were described using GM (95% CI). Inter-individual variability in PK 
parameters was expressed as CV%. The Shapiro–Wilk test was applied to test 
continuous variables for normality, with p <0.05 considered statistically significant; 
variables were Log10 transformed if the normality test failed.  
 
Associations between participant covariate characteristics or genotypes and DTG 
concentrations were determined through univariate and multivariate linear regressions. 
Univariate linear regression with a p value of <0.2 were carried through to multivariate 
linear regression analysis where a p value of <0.05 was classed as statistically 
significant. Results were checked with the Benjmini-Hochberg procedure to account 
for multiple comparisons, using a false positivity rate (Q value) of 10%. All statistical 
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analyses were carried out using IBM SPSS Statistics v.22 (IBM, Armonk, NY). Charts 
were produced using GraphPad Prism 8 (GraphPad Software, La Jolla, CA). 
6.3. RESULTS 
6.3.1. Participants 
One hundred participants attended the baseline visit of one of the four clinical trials. 
Two subjects declined participation to a genomic sub-study and 5 withdrew from their 
trial before PK data were collected. Ninety-three subjects with paired pharmacogenetic 
and PK data were pooled for analysis (57 HIV-infected and 36 healthy volunteers; 67 
men and 26 women). Subject characteristics and genotype frequencies are summarised 
in table 6.1. The median (IQR) age and weight were 51 years (35–64 years) and 77 kg 
(67-84); 71% self-described as Caucasian and 17% as Black African or Black 
Caribbean.  
6.3.2.  DTG pharmacokinetics 
76 participants provided intensive PK data collected over 24 hours and 17 provided a 
single PK sample 24 hours post-dose (C24). 53 samples were analysed using HPLC-
MS/MS and 40 using UPLC. All participants received 50mg OD DTG, taken in the 
morning of the intensive PK day or the morning before the one-off PK measurement.  
DTG GM (95% CI) for Cmax, AUC0-24, C24 and t1/2 were 3974 ng/mL (3864 - 4357), 
51846 ng*h/mL (48607- 55085), 1182 ng/mL (994 - 1371) and 13.0 hours (12.1 - 
14.0). DTG PK parameters are summarised by SNP in table 6.2. 
6.3.3. Genotypes overview 
All SNPs were in Hardy–Weinberg equilibrium, except for CYP3A5*3 c.6986A>G 
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(rs776746; X2 = 33.36; p=0.001) and CYP3A4*22 c.522-191C>T (rs35599367; X2 = 
33.13; p=0.001), which may compromise their interpretation (although both still 
mirrored European genotype distributions). Genomic data were missing in 1 case for 
CYP3A5*3, in 1 case for UGT1A1*6 and in 9 cases for UGT1A1*28 due to assay 
failure. Univariate and multivariate regression analyses with significant associations 
for DTG PK parameters are presented in table 6.3 whilst figure 6.1 shows scatter plots 
for each statistically significant genotype, plotting DTG PK data (GM) versus 
genotype for each SNP. The totality of the regression results can be found in table 6.4. 
6.3.4. Covariates 
Weight and Log10 height were associated with lower DTG Log10 Cmax (β=-1.649 
p=0.012 and β=-0.003; p=0.009, respectively) whilst DTG administration with 
ABC/3TC was associated with a higher DTG Log10 Cmax than intake alone (GM Cmax 
(95% CI) 4246 (3872-4620) vs 3692 (3414-3971) ng/mL, p=0.001). TDF/FTC co-
administration with DTG was associated with a higher DTG Log10 C24 than 
administration alone or with ABC/3TC (GM C24 (95% CI): 1791 (975-2607) vs 1106 
(976-1236) & 1052 (876-1228) ng/mL, respectively; β=0.069; p=0.034).  Finally, 
higher weight was also associated with lower DTG Log10 AUC0-24 (β=-0.002; 
p=0.02), with an 8-10% lower GM AUC0-24 for every 10kg increase in weight bracket 
between 40 and 80kg. 
6.3.5. ABCG2 c.421C>A (rs2231142)  
After multivariate analysis, ABCG2 c.421C>A (rs2231142) was independently 
associated with a 28% higher DTG Cmax (β=0.053, p=0.047) in the homozygous 
variant carriers. GM Cmax (95% CI) was 3893 (3774-4240), 4346 (3629-5531) and 
4994 (single value) ng/mL in the CC, CA and AA genotype groups, respectively.  
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  Total N 
 93 
 Median (IQR) 
Age (years) 51 (36-64) 
Weight (kg) 77.6 (67-84.4) 
Height (cm) 173 (168-177) 
ARV Regimen N (%) 
• ABC/3TC/DTG 40 (43) 
• TFV/FTC + DTG 17 (18) 
• DTG alone 36 (39) 
Ethnicity N (%) 
• Caucasian  70 (75) 
• Black 16 (17) 
• Asian 3 (3) 
• Mixed race 1 (1) 
• Other 3 (3) 
Female gender 26 (28) 
 PK parameters GM (95% CI) – IQR 
DTG GM Cmax (ng/mL) 3974 (3864 – 4357) – IQR 3462-4611 
DTG GM AUC0-24 (hr*ng/mL) 51846 (48607- 55085) – IQR 53190-57191 
DTG GM C24 (ng/mL) 1182 (994 – 1371)) – IQR 873-1612 
DTG GM t1/2 (hrs) 13 (12.0- 14.0) – IQR 11.0-15.3 
 Genotypic frequencies % 






46 43 11 






37 63 0 
CYP3A4*22 G>A (rs35599367) GG GA AA 
88 6 5 
CYP3A5*3 C>T (rs776746) CC TC TT 
76 12 12 
ABCG2 421C>A (rs2231142) CC CA AA 
82 17 1 
ABCG2 34C>T (rs2231137) CC CT TT 
83 17 0 
NR1I2 63396C>T (rs2472677) CC CT TT 
17 42 41 
NR1I2 44477T>C (rs1523130) TT CT CC 
19 39 42 
Table 6.1: Characteristics of participant population are shown as medians (interquartile range) or count 
(N), percentage of population (%). PK values are shown as geometric means (GM) (95% Confidence 
Interval, 95% CI). CV% = percentage coefficient variation. **Clinical Pharmacogenetics 
Implementation Consortium (CPIC) classification for UGT1A1 genotype-predicted phenotypic 
function: extensive metabolisers (*1/*1; *1/*36; *36/*36), intermediate metabolisers (*1/*28; *1/*37; 
*36/*28; *36/*37; *1/*6) and poor metabolisers (*28/*28; *28/*37; *37/*37; *6/*6
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6.3.6. NR1I2 c.63396C>T (rs2472677) 
NR1I2 c.63396C>T (rs2472677) was associated with higher DTG Log10 Cmax 
(β=0.032; p=0.033) and higher DTG Log10 AUC0-24, (β= 0.042; p=0.029).  GM Cmax 
(95% CI) was 3445 (3176-3822), 3938 (3705-4480) and 4278 (3992-4817) ng/mL and 
GM AUC0-24 (95% CI) was 42750 (38002-52263), 54138 (50998-61344) and 54170 
(51019-60413) ng*h/mL in the CC, CT and CC genotype groups, respectively. This 
represents a 24% difference in Cmax and a 27% difference in AUC0-24 between 
homozygote groups. 
6.3.7. UGT1A1*28 (rs8175347) 
The UGT1A1*28 variant allele displayed a recessive allele effect (figure 6.1). Coding 
was therefore dichotomized and weighted appropriately (extensive and intermediate 
metabolisers were grouped as a single category coded as 0 and poor metabolisers were 
coded as 2). The UGT1A1*28 poor metaboliser genotype was independently 
associated with higher DTG Log10 AUC0-24 (β=0.042; p=0.02). GM AUC0-24 (95% 
CI) were 52639 (47956-57321), 51818 (46866-56771) and 66281 (57162-75401) 
ng*h/mL for the extensive, intermediate and poor metaboliser genotypes respectively 
(27% difference between homozygote groups).  When UGT1A1*28 was combined 
with UGT1A1*6, genotypic scores ≥three/4 were associated with a 36% increase in 
DTG AUC0-24 and a 44% increase in DTG C24 (β=0.041; p=0.023 and β=0.042; 
p=0.009 respectively). GM AUC0-24 (95% CI) was 48500 (43417-53583) ng*h/mL in 
participants who scored 0 and 66085 (54917-77253) ng*h/mL in those who scored 
three/4 (no individual scored four/4). GM C24 (95% CI) was 1109 (885-1334) and 1594 
(1247-1941) ng/mL respectively.  
6.3.8. Composite Scores 
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6.3.8.1. UGT1A1*28 + NR1I2 c.63396C>T  
Participants carrying the homozygous variant alleles for both NR1I2 c.63396C>T 
(rs2472677) and UGT1A1*28 displayed a statistically significant 79% higher AUC0-
24 (β=0.42, p=0.005). GM AUC0-24 (95% CI) in those who carried the common allele 
for both genotypes was 42306 (36990-52278) vs 75807 (69714-82166) ng*h/mL in 
those who carried the variant allele for both. This was the largest magnitude of SNP 
effects seen in this study. Variability in the two groups as reflected by IQR was 41921-
47692 and 73180-74542 ng*h/mL respectively. There was also a significant 47% 
increase in Cmax and a 78% increase in GM C24. The latter was not statistically 
significant (p=0.436). 
6.3.8.2. ABCG2 c.421C>A (rs2231142) and NR1I2 c.63396C>T 
When combined into a scoring algorithm, a statistically significant 43% higher Cmax 
and 39% higher AUC0-24 were seen in participants who scored ≥three/4 relative to 
participants who scored 0 (β=0.038; p=0.002 and β=0.038; p=0.002 respectively). GM 
Cmax (95% CI) were 3450 (3102-3799) vs 4924 (3555-6293) ng/mL and GM AUC0-24 
(95% CI) were 42768 (35078-50457) vs 59335 (48362-70308) ng*h/mL in the two 
groups respectively. Only one person scored four/4 and they were categorised with 
those who scored three/4. A genotypic score-dose effect was seen. 
 
There were no significant differences in genotypic distribution for ABCG2, UGT1A1 
and NR1I2 between groups analysed with either HPLC-MS/MS or UPLC for PK. 
Remaining genotypes  
No clinically significant association was found with the remaining genotypes studied.
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 Allele Cmax (ng/mL) AUC0-24 (ng*h/mL) C24 (ng/mL) t1/2 (hrs) 
CYP3A4*22 
(rs35599367) 
GG 3942 (3816- 4356) 50689 (49364- 56391) 1153 (1133-1548) 12.96 (12.52-14.56) 
GA 3820 (3761-4284) 57590 (42549- 63889) 1426 (647-2124) 12.67 (10.11-17.13) 
AA 4571 (3745-5581) 64494 (57914-71837) 1430 (1253-1634) 14.20 (11.70-17.26) 
CYP3A5*3 
(rs776746) 
TT 4011 (3526-4722) 57328 (51748- 64881) 1295 (1167-1475) 13.40 (11.92-15.37) 
TC 4333 (3544-5545) 57339 (51437-65205) 1313 (1014-1838) 13.48 (11.87-15.66) 
CC 3898 (3753-4294) 49972 (48290-56523) 1159 (1129-1611) 13.03 (12.47-14.83) 
ABCG2 c.421C>A 
(rs2231142) 
CC 3893 (3774-4240) 51179 (49757-56852) 1037 (1156-1578) 13.15 (12.72-14.51) 
CA 4346 (3629-5531) 54765 (48083-65483) 1122 (882-1801) 12.29 (9.75-16.81) 




CC 3936 (3812-4310) 51381 (49992-57307) 1021 (1148-1585) 12.90 (12.43-14.57) 
CT 4163 (3543-5153) 54158 (48523-62306) 1230 (1020-1662) 13.75 (12.35-15.63) 
TT - - - - 
NRI1/2 c.63396C>T  
(rs2472677) 
 
CC 3445 (3176-3822) 42750 (38002-52263) 1094 (910-1539) 11.93 (10.63-13.95) 
CT 3938 (3705-4480) 54138 (50998-61344) 946 (1171-1632) 13.05 (12.20-14.98) 
TT 4278 (3992-4817) 54170 (51019-60413) 1165 (1002-1757) 13.51 (12.50-15.72) 
NRI1/2 c.44477A>G  
(rs1523130) 
TT 3830 (3581-4191) 53505 (49786-59019) 1158 (1047-1387) 12.68 (11.51 -14.62) 
CT 3933 (3636-4537) 50105 (46431-57750) 1031 (1049-1904) 13.14 (11.85 -15.79) 
CC 4087 (3826-4677) 52298 (49481-60752) 1031 (1119-1528) 13.15 (12.34 -15.03) 
UGT1A*28  
(rs8175347) 
Extensive 4152 (3731-4573) 52639 (47956-57321)) 1115 (934-1297) 12.43 (11.22 -13.65) 
Intermediate 4015 (3665-4364) 51818 (48966-58871) 1212 (973-1452) 13.57 (11.82 -15.32) 
Poor 4512 (3733-5291) 66281 (57162-75401) 1600 (1294-1906) 14.85 (11.91 -17.79) 
UGT1A1*6  
(rs4148323) 
GG 4205 (3946-4767) 51735 (48953-597470 1085 (1015-1399) 13.00 (11.76-14.24) 
GA 3797 (3622-4201) 51935 (49667-57553) 1221 (1147-1690) 13.06 (11.73-14.39) 




and *28 scores  
0 3966 (3639-4294) 48500 (43417-53583) 1109 (885-1334) 12.72 (11.93-14.40) 
1 4189 (3765-4613) 55837 (51521-60152) 1208 (1008-1407) 13.53 (12.50-15.89) 
2 - - -  





0 3626 (3361-3950) 42306 (34990-52278) 1097 (868-1619) 10.97 (9.64-12.54) 
1 4151 (3855-4737) 57502 (53574-64634) 1366 (1253-1801) 13.76 (12.23-15.29) 
2 4207 (3887-4774) 52718 (49568-58223) 1027 (954-1230) 13.17 (11.51-14.83) 
3 3844 (3238-4477) 53789 (53659-53918) 1132 (973-1304) 16.88 (12.15-21.60) 
4 5333 (4570-6159) 75807 (69714-82166) 1958 (1703-2253) x 
Combined ABCG2 
c.421C>A and NRI1/2 
c.63396C>T scores 
0 3450 (3102-3799) 42768 (35078-50457) 1124 (795-1453) 11.98 (10.19-13.78) 
1 3915 (3528-4301) 53948 (48733-59162) 1204 (980-1429) 13.38 (11.95-14.80) 
2 4077 (3763-4392) 52720 (47997-57443) 1217 (217-791) 13.05 (11.73-14.36) 
3 4924 (3555-6293) 59335 (48362-70308) 1067 (740-1394) 13.72 (8.15-19.29) 
Table 6.2: Dolutegravir (DTG) pharmacokinetic parameters shown as Geometric Means (GM) 95% Confidence Interval (95% CI), summarised by single or combined genotype. 
NB: UGT1A1*28 was coded as binary 
Log10 Cmax 
Univariate Linear Regressions Multivariate Linear Regressions 
p value β value (95% CI) r2 p value β value (95% CI) r2 
Log10Height (Log10cm) 0.008 -1.716 0.092 0.012 -1.649 0.394 
Weight (kg) 0.000 -0.004 0.175 0.009 -0.003 0.394 
Accompanying Drug 0.019 0.061 0.072 0.001 0.074 0.394 
UGT1A1*6 (rs4148323) 0.091 -0.044 0.038 0.355 0.039 0.402 
ABCG2 c.421C>A (rs2231142) 0.111 0.050 0.034 0.047 0.053 0.394 
NR1I2 c.63396C>T (rs2472677) 0.010 0.045 0.086 0.033 0.032 0.394 
Combined NRI1/2 and UGT1A1*28 
scores 
0.030 0.029 0.071 0.023 0.026 0.311 
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Combined ABCG2 and NRI1/2 scores 0.011 0.057 0.291 0.005 0.054 0.377 
Log10 C24 
Univariate Linear Regressions Multivariate Linear Regressions 
p value β value (95% CI) r2 p value β value (95% CI) r2 
Log10 Age (Log10years) 0.125 -0.236 0.026 0.029 -0.310 0.104 
Accompanying drug 0.008 0.084 0.076 0.114 0.048 0.133 
UGT1A1*28 (rs8175347) 0.045 0.070 0.049 0.083 0.059 0.140 
Combined UGT1A1*6 and *28 scores 0.009 0.067 0.082 0.009 0.067 0.082 
AUC0-24 
Univariate Linear Regressions Multivariate Linear Regressions 
p value β value (95% CI) r2 p value β value (95% CI) r2 
Log10Height (Log10cm) 0.011 -1.866 0.066 0.323 -0.871 0.282 
Weight (kg) 0.017 0.003 0.075 0.03 -0.002 0.228 
Ethnicity 0.044 0.036 0.054 0.143 0.025 0.256 
CYP3A4*22 (rs35599367) 0.059 0.053 0.047 0.295 0.027 0.270 
CYP3A5*3 (rs776746) 0.097 -0.034 0.037 0.033 -0.040 0.228 
NR1I2 c.63396C>T (rs2472677) 0.033 0.043 0.060 0.029 0.042 0.228 
UGT1A1*28 (rs8175347) 0.020 0.058 0.060 0.020 0.116 0.228 
Combined UGT1A1*6 and *28 scores 0.075 0.046 0.048 0.041 0.050 0.231 
Combined UGT1A1*28 and NRI1/2 
scores 
0.011 0.039 0.095 0.002 0.048 0.025 
t1/2 
Univariate Linear Regressions Multivariate Linear Regressions 
p value β value (95% CI) r2 p value β value (95% CI) r2 
Ethnicity 0.057 0.031 0.058 
   
Table 6.3: Significant results from univariate (p <0.2) and multivariate (p <0.5) linear regression analysis per PK parameter (significant SNP associations are boxed in bold) 
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Figure 6.1: Scatter 
plots of statistically 
significant relationships 
between genotypes and 












p value β value r2 p value β value r2  
Log10 Age (Log10years) 0.252 0.104 0.018     
Log10Height (Log10cm) 0.008 -1.716 0.092 0.012 -1.649 0.394 - 
Weight (kg) 0.000 -0.004 0.175 0.009 -0.003 0.394 - 
Ethnicity 0.297 0.002 0.015     
Accompanying drug 0.019 0.061 0.072 0.001 0.074 0.394 - 
CYP3A4*22 (rs35599367) 0.309 0.025 0.014     
CYP3A5*3 (rs776746) 0.514 - 0.012 0.006     
ABCG2 c.421C>A (rs2231142) 0.111 0.050 0.034 0.047 0.053 0.394 28% 
ABCG2 c.34C>T (rs2231137) 0.487 0.024 0.007     
NR1I2 c.63396C>T (rs2472677) 0.010 0.045 0.086 0.033 0.032 0.394 24% 
NR1I2 c.44477A>G (rs1523130)  0.384 0.014 0.010     
UGT1A1*6 (rs4148323) 0.091 -0.044 0.038 0.355 0.039 0.402  
UGT1A1*28 (rs8175347) ** 0.332 0.044 0.014     
Combined NRI1/2 and UGT1A1*28 
scores  
0.030 0.029 0.071 0.023 0.026 0.311 47% 
UGT1A1*6 and UGT1A1*28 0.797 0.004 0.001    18% 
Combined ABCG2 c.421C>A and 
NRI1/2 c.63396C>T scores 








p value β value r2 p value β value r2  
Log10 Age (Log10years) 0.125 -0.236 0.026 0.029 -0.310 0.104 - 
Log10Height (Log10cm) 0.363 1.033 0.009     
Weight (kg) 0.454 -0.001 0.006     
Healthy volunteer 0.697 -0.047 0.011     
Ethnicity simplified coding 0.526 0.004 0.017     
Accompanying drug 0.008 0.084 0.076 0.114 0.048 0.133  
CYP3A4*22 (rs35599367) 0.221 0.057 0.016     
CYP3A5*3 (rs776746) 0.390 -0.029 0.008     
ABCG2 c.421C>A (rs2231142) 0.766 -0.016 0.001     
ABCG2 c.34C>T (rs2231137) 0.735 0.021 0.001     
NR1I2 c.63396C>T (rs2472677) 0.847 0.006 0.000     
NR1I2 c.44477A>G (rs1523130)  0.922 0.003 0.000     
UGT1A1*6 (rs4148323) 0.281 0.051 0.013     
UGT1A1*28 (rs8175347)** 0.045 0.070 0.049 0.083 0.059 0.140 38% 
Combined UGT1A1*6 and *28 0.009 0.067 0.082 0.009 0.067 0.082 44% 
Combined ABCG2 c.421C>A and 
NRI1/2 c.63396C>T scores 
0.436 0.017 0.008    39% 
Combined NRI1/2 c.63396C>T and 
UGT1A1*28 scores 








p value β value r2 p value β value r2  
Log10 Age (Log10years) 0.291 -0.110 0.015     
Log10Height (Log10cm) 0.011 -1.866 0.066 0.323 -0.871 0.282  
Weight (kg) 0.030 -0.002 0.075 0.03 -0.002 0.228  
Healthy volunteer 0.978 0.001 0.000     
Ethnicity simplified coding 0.044 0.036 0.054 0.143 0.025 0.256  
Accompanying drug 0.978 -0.001 0.000     
CYP3A4*22 (rs35599367) 0.059 0.053 0.047 0.295 0.027 0.270  
CYP3A5*3 (rs776746) 0.097 -0.034 0.037 0.033 -0.040 0.228 -12% 
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ABCG2 c.421C>A (rs2231142) 0.376 0.032 0.011     
ABCG2 c.34C>T (rs2231137) 0.566 0.023 0.004     
NR1I2 c.63396C>T (rs2472677) 0.033 0.043 0.060 0.029 0.042 0.228 27% 
NR1I2 c.44477A>G (rs1523130)  0.893 -0.003 0.000     
UGT1A1*28 (rs8175347)** 0.020 0.058 0.060 0.020 0.116 0.228 27% 
UGT1A1*6 (rs4148323) 0.956 0.002 0.000     
Combined UGT1A1*6 and *28  0.035 0.041 0.067 0.023 0.041 0.243 36% 
Combined ABCG2 c.421C>A and 
NRI1/2 c.63396C>T scores 
0.031 0.035 0.061 0.008 0.042 0.257 43% 
Combined NRI1/2 c.63396C>T and 
UGT1A1*28 scores 








p value β value r2 p value β value r2  
Log10 Age (Log10years) 0.506 -0.069 0.006     
Log10Height (Log10cm) 0.495 0.529 0.007     
Weight (kg) 0.484 0.001 0.007     
Healthy volunteer 0.637 0.014 0.003     
Ethnicity 0.437 0.008 0.003     
Accompanying drug 0.637 -0.014 0.003     
CYP3A4*22 (rs35599367) 0.561 0.016 0.005     
CYP3A5*3 (rs776746) 0.719 -0.008 0.002     
ABCG2 c.421C>A (rs2231142) 0.744 -0.011 0.002     
ABCG2 c.34C>T (rs2231137) 0.487 0.028 0.007     
NR1I2 c.63396C>T (rs2472677) 0.212 0.025 0.022     
NR1I2 c.44477A>G (rs1523130)  0.707 0.007 0.002     
UGT1A1*28 (rs8175347)** 0.274 0.058 0.020     
UGT1A1*6 (rs4148323) 0.950 0.002 0.000     
Combined UGT1A1*6 and *28  0.302 0.021 0.017     
Combined ABCG2 c.421C>A and 
NRI1/2 c.63396C>T scores 
0.391 0.014 0.011     
Combined NRI1/2 c.63396C>T and 
UGT1A1*28 scores 
0.057 0.031 0.058     
Table 6.4 Univariate and Multivariate regressions – complete analysis. Results in bold = above cut off; 
**UGT1A1*28 dichotomised throughout, using a recessive genotypic test model  
6.4. DISCUSSION 
The impact on DTG PK parameters of key common SNPs coding for the four main 
enzymes and transporters involved in its disposition were investigated.172 For the first 
time, to the best of our knowledge, these were brought together in a multivariate 
analysis model, which also controlled for important demographic covariates and were 




A statistically significant increase in DTG exposure was found in carriers of the 
UGT1A1*28 (rs8175347) poor metaboliser genotype (28%). Our results are in keeping 
with findings from the Chen et al. study albeit with a smaller effect size (28% vs 
46%).230 As previously discussed, Yagura et al. reported an association between the 
*28 heterozygote status (intermediate metaboliser) and an increase in Cmin but not for 
the homozygote (poor metaboliser) genotype, which the authors related to lack of 
statistical power.148 Contrastingly, our study demonstrated higher DTG PK parameters 
in the UGT1A1*28 poor metaboliser group and not the intermediate group, consistent 
with a recessive genotype model. Whilst this may also relate to a potential lack of 
statistical power, other studies have reported a lack of PK or PD effect with the 
UGT1A1*28 intermediate metaboliser genotype with drugs such as irinotecan or 
raloxifene.367, 368 Of note, the impact of UGT1A1*28 alone on DTG concentrations 
seemed modest compared to that seen for raltegravir concentrations, where C12 was 
110% higher in individuals carrying UGT1A1*28 poor metaboliser genotype.369 
However, when UGT1A1*28 and NR1I2 c.63396C>T were combined in our study, a 
79% higher AUC0-24 and a 47% higher Cmax, were seen in those with a maximum score 
(C24 was 78% higher but this was not statistically significant). Additionally, when 
UGT1A1*28 and UGT1A1*6 were combined, genotypic scores ≥three/4 were 
associated with a 36% higher DTG AUC 0-24 and a 44% higher DTG C24. Overall, this 
indicates that genomic biomarkers of DTG plasma exposure may be better based on 
carefully defined sets of SNPs or scoring algorithms rather than on single SNP 
characterisation.228, 370-373 
 
A statistically significant, but moderate, 28% higher DTG Cmax was found in subjects 
carrying the ABCG2 c.421C>A (rs2231142) homozygous variant genotype (AA) 
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compared to those homozygous for the common allele (CC).  This therefore confirms, 
results previously reported by Tsuchiya et al. but in a very different population (75% 
Caucasian and 17% Black participants (n=76) vs 100% Japanese participants (n=42) 
respectively).357 The higher DTG Cmax may reflect a decrease in first pass metabolism, 
for instance through reduced expression of efflux BRCP transporters in intestinal 
epithelial cells leading to increased absorption and/or through reduced hepatic 
clearance.357, 374 Higher exposures to sunitinib, rosuvastatin and atorvastatin have 
similarly been described in individuals carrying the ABCG2 c.421C>A (rs2231142) 
variant.375, 376 Interestingly, when ABCG2 c.421C>A was combined with NR1I2 
c.63396C>T (rs2472677), participants homozygous for the variant in both genes 
showed a significant 43% increase in DTG Cmax, once again suggesting a composite 
of SNPs may represent a more useful genomic biomarker of DTG PK parameters. 
 
The NR1I2 c.63396C>T (rs2472677) variant was independently associated with higher 
Cmax (24%) and AUC0-24 (27%).  This is converse to the effects seen with unboosted 
atazanavir363, 364 and is surprising since the TT genotype is thought to be associated 
with higher basal expression of the nuclear receptor PXR, which in turn would be 
expected to result in higher UGT1A1, BCRP and CYP3A4 expression and lower DTG 
concentrations.212, 222 Therefore, this observation should be interpreted with caution 
and needs to be confirmed. 
 
There are limitations to this work. The use of pooled data means drug intake 
conditions, such as time of day, accompanying food and backbone regimen were 
standardised within but not necessarily across trials. Moreover, a number of studies 
involved healthy volunteers whilst others investigated HIV infected individuals, 
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although this was included as a covariate in the multivariate analyses. Whilst the 
majority of studies contributing data were Phase I clinical trials, one study was a Phase 
III trial (n=17) and only contributed DTG trough concentrations rather than intensive 
PK data, meaning the sample sizes for Cmax/AUC0-24 and for C24 differed (N=76 and 
N=93 respectively). Additionally, two different assay methodologies were used for the 
PK analysis, potentially introducing variability. However, reassuringly, there was no 
significant difference in genotypic distribution for ABCG2, UGT1A1 and NR1I2 
between groups analysed by either method. Findings need to be interpreted in the 
context of the limited population size and statistical power of this study. Finally, our 
population was predominantly Caucasian (75%) and whilst the genetic associations 
found were preserved when the analyses were restricted to Caucasians only, we could 
not conduct any other ethnicity sub-analyses due to the small numbers representing 
other ethnic groups, therefore clinical findings should be verified further in population-
specific studies.  
 
In conclusion, since there is evidence of concentration-dependent DTG side effects 
and given that DTG-based regimens are increasingly replacing preferred first line 
therapy in ARV naïve HIV patients worldwide, searching for genomic biomarkers of 
plasma exposure may help tailor DTG-based HIV therapy at individual and population 
levels. This study showed a pharmacogenetic association between DTG 
pharmacokinetics and variants in the ABCG2, UGT1A1 and NRI1/2 genes, particularly 
when combined.  Further studies in large and diverse populations are warranted, 
particularly examining pharmacodynamic endpoints such as neuropsychiatric AEs, in 
order to further determine the clinical validity and population impact of 







Dolutegravir and cobicistat were approved for the treatment of HIV in 2013-14. Both 
addressed unmet clinical needs at the time and are now widely used. Their licences 
coincided with an intensification in the global ARV scale-up and, separately, a general 
paradigm shift in HIV research towards individualising therapy.100, 101 Both drugs have 
played a significant role in these latest developments, particularly DTG, which 
replaced EFV as preferred first line agent in universal guidelines alongside the newly 
introduced recommendation to adopt a ‘test and treat’ approach.64 It is estimated that 
at least 35 million people, including newly infected individuals, would need to be on 
treatment to meet in the 90–90–90 targets, meaning that, regardless of the target being 
reached and the residual need for further key population data (pregnancy, TB co-
infection), the worldwide implementation of DTG is likely to be widespread, across 
many different settings and across very diverse populations.65-68, 377 This highlights the 
importance of characterising the pharmacological behaviour of these drugs in real life 
settings and in commonly encountered clinical scenarios, in order to guide physicians 
in prescribing. It is particularly salient since data from licencing programs often only 
reflect drug use in highly selected groups of individuals under stringent trials 
conditions.127 
 
The goal of HIV therapy is to achieve and maintain virological suppression. Whilst 
clinical developments in novel formulations such as long active (LA) injectables and 
implantables are currently at the forefront of research and results are promising, 
treatment today still requires lifelong daily oral ARV dosing.378 Most agents now have 
near-perfect efficacy (>90%) in clinical trials in ARV naïve individuals, the chances 
of success of therapy therefore fall heavily on optimising adherence, itself dependent 
on a large number of factors (figure 7.1). The data presented in this thesis has 
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addressed gaps in knowledge within the domain of therapy-related factors that impact 
adherence, efficacy and tolerability of treatment, with the aim of assisting clinicians 




Figure 7.1: Non-exhaustive list of factors that influence adherence to and efficacy of ARVs. HCP: 
healthcare provider; CDC: Centre for Disease Control and Prevention; BMI: body mass index; PK: 
pharmacokinetics; ARV: antiretrovirals; HAND: HIV Associated Neurocognitive Disorder 
As discussed in chapter 2, both high and low-to-middle income settings have seen an 
ageing of the HIV population as a result of greater survival and of increasing rates of 
infection in later life.234-238 HIV physicians are now commonly faced with managing 
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ARVs in the context of multiple comorbidities and polypharmacy, both strongly 
associated with older age.235-238, 379-385 Additionally, in advancing age, several 
physiological changes affect drug pharmacokinetics and pharmacodynamics.239 Since 
DTG is a fitting candidate for therapy in this population, the study in chapter 2 
characterised DTG’s intensive PK in PLWH ≥ 60 years, showing a significantly higher 
DTG Cmax (25%) vs younger subjects (median age 36 years). 
 
Changes in sleep and cognition were also evaluated over six months of DTG in this 
population. There were two discontinuations secondary to NP-AEs, matching 
published rates.127 The one participant with PK data available had a Cmax, AUC0-24 and 
Cmin above the 95th centile for the study group, suggesting a PK contribution. This is in 
keeping with cohort data from the groups of Borghetti, Menard and Yagura, all of 
whom found an association between Cmin and NP-AEs.146, 148, 149, 232 However, there 
was no association between DTG PK parameters and changes in PD scores in the 
remaining subjects over time, in our study, which is in keeping with observations from 
Riva and Hoffman.259, 151 More specifically, there were no changes in sleep scores in 
some subjects with very high drug concentrations (>95th centile) in whom, 
surprisingly, cognition improved significantly, suggesting that the mechanisms of 
DTG-related neurotoxicity are more complex than a simple linear or threshold-defined 
PK relationship. It may relate, as already discussed, to a combination of factors that 
include pharmacogenetic, immune and/or functional predispositions.138 Further 
research is warranted in order to determine the role of DTG drug concentrations in its 
safety and tolerability profiles and to characterise other contributing factors more 
precisely. This will be crucial to minimising the personal and financial impacts of DTG 




As previously mentioned, there has been a recent drive to investigate treatment 
simplification strategies and challenge the use of conventional triple therapy, which 
has been the staple of HIV treatment since 1996. This aims to lessen toxicity, cost and, 
potentially, drug interactions through reducing the number of agents in any single 
regimen.100 Treatment simplification is especially relevant in today’s ageing HIV 
patient population.236 One recent study conducted in France, demonstrated that DDIs 
are common in people over the age of 65 living with HIV and substantially increase 
healthcare cost by as much as $2693 per patient per year.386 A number of simplification 
strategies have been examined, however, following the historically mixed success of 
PI/RTV monotherapy, concerns over CSF viral escape and poor quality data on DTG 
monotherapy, current data firmly favours dual therapy over monotherapy.100-103, 387 Of 
note, phase 3 trials for long-acting dual therapy maintenance are on-going 
(cabotegravir + RPV).388 RCT and cohort data available for some of the main dual 
combinations studied to date are discussed in chapters 1 and 4. The latter focuses on 
DTG combined with boosted DRV, which offers a simplified and safe regimen with a 
high genetic barrier and can particularly assist in cases where treatment simplification 
is desired but NRTI or NNRTI based dual therapy is not possible (e.g. cases of 
complex resistances).101, 102 The DUALIS study and a number of cohort studies have 
already demonstrated high efficacy and safety of this combination as maintenance 
therapy, including in highly treatment experienced patients with resistance.118-121 PK 
and efficacy data, however, were mainly available for DTG with DRV when boosted 
with RTV. In chapter 4, co-administration of DTG with DRV when boosted with 
COBI was therefore investigated; minimal intra-individual variance in DTG and 
DRV/COBI PK parameters when administered together was demonstrated (<10%) 
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compared to alone. Concentrations of both active agents remained manifold above the 
PA-IC90/PA-EC90 in all participants, suggesting that no dose adjustment is required in 
either agents and that this combination can be prescribed safely, at standard doses, in 
the treatment of HIV-1, including in patients harbouring resistance. DTG/DRV/COBI 
thus offers a potent dual regimen that is taken as two tablets rather than three with 
RTV and is likely to become a strong addition to the HIV therapy armamentarium in 
future.  
 
Despite advances to improve adherence such as single tablet regimens, smaller tablets, 
adherence support and purpose-designed technology, delayed or omitted doses still 
occur, potentially compromising virological control and risking the emergence of drug 
resistance. In chapter 3, the plasma PK of oral DTG and COBI-boosted EVG, DRV 
and ATV following cessation of drug intake were investigated, in order to understand 
and guide the management of late and missed doses for these drugs. A marked 
difference in the elimination rates of DTG and EVG was seen following treatment 
interruption. There was a significant decline in EVG GM concentration after 24 hours, 
paralleling a rapid COBI decay; EVG levels dropped to below the PA-IC95 shortly 
after the 36 hours mark. Conversely, DTG was persistent in systemic circulation for a 
very prolonged period, with GM concentrations remaining above the suggested plasma 
PA-IC90 for up to 72 hours and above the suggested MEC for over 48 hours post-drug 
intake cessation. These discrepancies in PK forgiveness may influence drug choices 
in patients who have suboptimal adherence, as clinical difference may emerge in this 
population. There was also an increase in rates of decline for ATV and DRV as COBI 
concentrations diminished. All 16 subjects in the study had ATV concentrations above 
or very close to the suggested MEC 30 hours post-dose, suggesting that a 6-hour drug 
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intake delay would not compromise optimal drug exposure and efficacy. DRV 
concentrations, however, appeared to drop below the MEC shortly after the 24-hour 
mark and 3/16 study individuals had concentrations below the suggested MEC cut-off 
24 hours post-dose. DRV is a robust agent and whether this is clinically significant is 
unclear. PD data in patients who are poorly adherent to DRV/COBI are therefore 
needed. Overall, the findings contribute to the understanding of whether oral doses, 
for the specific drugs investigated, can be delayed or missed and, if so, to what extent. 
This is particularly important as DTG and the PIs are the agents used in patients who 
are susceptible to poor compliance or harbour viral resistance.56, 260, 261 
 
PK tail data will be particularly important in the era of LA compounds, not only to 
determine optimal dosing intervals but also for clinicians to assess the suitability of 
certain patients for available options. There remains an ongoing debate on whether 
patients who struggle with adherence to medication and attendance to clinic would be 
suitable candidates for LA formulations of ARV agents with long PK tails. This is 
because of the risk of viral resistance in the context of prolonged exposure to 
subtherapeutic drug doses in those who do not attend their scheduled dosing.  
Consequently, strategies for the implementation of LA therapeutics in real life clinical 
settings is an important and actively evolving area.388  
 
Chapter 5 describes the intra-individual variance in the PK of EE/LNG in one of the 
most commonly used oral contraceptive pill (Microgynon®) and of ATV/COBI co-
formulated in Evotaz®, when they are administered together compared to alone. 
Evotaz® may be preferentially used over ATV + RTV in some patients in order to 
reduce pill burden.208 With (TG)WLWH living longer and healthier lives, U=U 
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(undetectable = untransmittable) and the markedly minimised rates of mother-to-child 
transmission (MTCT) in the context of planned pregnancy with optimal viral 
suppression, access to safe and reliable contraception and ART is a priority on the HIV 
care agenda. As discussed comprehensively in chapter 5, oestrogen and progestogen 
have relatively narrow therapeutic indices and the tolerability, safety and efficacy 
sequalae of underexposure or overexposure to either are all potentially significant. 
This study demonstrated minimal changes in LNG concentrations and a smaller 
decrease in EE Cmin than seen with ATV/RTV (25% vs 37%).338, 339 There were no 
clinically significant changes in EE Cmax or AUC0-24 (5% and 1% increases 
respectively). The disparity in DDI between the two pharmacological boosters is likely 
to relate to the fact that unlike RTV, COBI does not induce CYP2C9 and 
glucuronidation, both responsible for EE clearance.198, 199, 338  ATV has fallen out of 
favour in high income countries but it remains in the WHO guidelines and large 
numbers of patients stable on ATV continue to take it. Whilst preliminary, these data 
are therefore important in informing physicians, who need to discuss and choose safe 
and reliable contraception with their female patients living with HIV. Whether this 
difference between ATV/RTV and ATV/COBI will be clinically significant, however, 
demands further characterisation. 
 
Finally, considering that DTG is fast becoming the leading agent for naïve HIV 
patients in the transition to global ARV access, searching for genomic biomarkers of 
plasma exposure may help tailor DTG-based HIV therapy at individual and population 
level.64, 65 Chapter 6 therefore evaluated the impact of genetic variability in drug 
disposition genes on the PK of DTG, showing an independent pharmacogenetic 
association between DTG PK and variants in the ABCG2, UGT1A1 and NR1I2 genes, 
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particularly when combined. Most significantly, co-occurring UGT1*28 and NR1I2 
c.63396C>T homozygosity was associated with a statistically significant 79% increase 
in AUC0-24 and a 47% increase in Cmax whilst combined ABCG2 c.421C>A and NR1I2 
c.63396C>T variants were associated with a 43% increase in Cmax and a 39% increase 
in AUC0-24. The combination of UGT1A1*28 poor metaboliser and UGT1A1*6 
intermediate metaboliser statuses correlated with a 43% increase in AUC0-24. Overall, 
results indicate that genomic biomarkers of DTG plasma exposure may be best 
characterised with carefully defined sets of SNPs or scoring algorithms rather than 
with individual alleles. These findings warrant further research in large and diverse 
populations that particularly examine pharmacodynamic endpoints in order to 
determine the feasibility, clinical validity and population impact of pharmacogenetic 
testing for DTG.228, 370-373 
 
There remains a call in the field for tangible biomarkers of DTG toxicity, particularly 
with regards to NP-AEs and to weight gain, both of which are likely to be 
multifactorial.127, 144 From the studies of weight gain published so far, women and 
black people appear most likely to be at risk on InSTI-based regimen, particularly 
when compared with NNRTI-based regimen.144 Median gain has ranged from 1kg to 
4.9kg in RCTs that reported weight changes.144 Recent data from IAS 2019, showed 
that DTG-related weight gain was significantly associated with TAF co-
administration,389 but, interestingly, there has also been a suggestion that DTG binding 
to the MC4R receptor may be involved. In vitro, DTG inhibited the binding of 
radiolabelled α-melanocyte-stimulating hormone (MSH) to the human recombinant 
MCR4 receptor by 64% at a concentration equal to the clinical Cmax, when >50% is 
considered clinically significant by the EMA. MC4R is involved in the regulation of 
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energy homeostasis and food intake, and deficiency in MC4R is associated with 
monogenic obesity.390 It is not clear if these findings will be associated with changes 
in body weight in vivo and further studies are needed.144 If a mechanistic link is found, 
MC4R genetic variants may merit further investigations to assess their contribution to 
DTG-mediated weight gain. For NP-AEs, the literature to date remains suggestive 
rather than conclusive. A number of cohort studies have reported that co-
administration with ABC increases the risks of DTG discontinuation secondary to 
AEs, although this DDI has been refuted in a number of other studies, as have 
suggestions implicating PK, gender and age as risk factors.129-135, 146  As previously 
discussed, Borghetti et al. reported an association between a common SLC22A2 
genetic variants and a set of measured subclinical NP-AEs during DTG therapy, 
although none led to drug termination.232 In their study, two neuropsychiatric metrics 
were also associated with DTG Cmin, leading to the authors proposing a synergy 
between DTG PK and genetic neurological susceptibility.232 Yagura et al. similarly 
described an association between UGT1A1*28 and UGT1A1*6 gene polymorphisms 
and a higher cumulative incidence selected NP-AEs, mediated by Cmin in a Japanese 
cohort.148 These findings were furthered by data presented by the same authors in a 
poster at IAS 2019, showing an association between UGT1A1*28 and UGT1A1*6 
gene polymorphisms and AE related DTG discontinuation one to four years after DTG 
initiation in a similar cohort.149 There may be a genetic predisposition in the aetiology 
of DTG-mediated neurotoxicity. Further DTG NP-AE pharmacogenetic research is 
therefore warranted in order to investigate the role of SNPs, specifically in hard 
pharmacodynamic endpoints such as the discontinuation of DTG due to AEs with 
resolution of symptoms post-discontinuation. Genes involved in DTG transport across 
the BBB (e.g.BCRP) and in the susceptibility of neuronal receptors substrates 
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(e.g.OCT2) are of particular interest. This study is under-way and will characterise 
three SNPs in genes coding for DTG and BIC disposition (ABCG2 (BCRP, rs2231142) 
and UGT1A1*28) and coding for DTG target (SLC22A2 (OCT2, rs316019)), in a large 
cohort of patients on DTG or BIC who have discontinued the drug secondary to NP-
AEs (cases) compared to participants who have experienced no NP-AEs (controls) for 
over 1 year on either drug (the DOLBIC study). 
 
Lastly, as summarised above, chapter 3 reported a long DTG PK tail, with GM 
concentrations remaining above the in-vitro PA-IC90 for 3 days, above the suggested 
MEC for over 2 days and being detectable in plasma in 100% of participants at 4 days. 
Additionally, DTG C24 in all the DTG studies described in earlier chapters ranged 
between 1052 and 1324 ng/mL, for a 50mg OD dose, in various populations. This 
represents an inhibitory coefficient (IQ90) ranging between 16 and 21, which is high 
for wild type virus. The IQ90 is used in evaluating a drug’s efficacy at a given dose. It 
relates the in-vivo drug exposure to viral susceptibility, usually Cmin divided by IC90 or 
IC95, indicating the number of times the Cmin is greater than the IC90/IC95. DTG GM 
Cmin in the DTG SPC is 1110 ng/mL, giving an IQ90 within the same range as in our 
studies. For reference, the IQ95 for standard dose EFV is approximately 14 and NVP 
12.391 During the drug development phase for DTG, doses of 10 and 50 mg OD yielded 
Cmin values that were 3 and 13 times higher than the PA-IC90, in ARV naïve/ARV 
experienced, InSTI naïve patients, dosed with DTG monotherapy for 10 days.390 The 
subsequent dose finding phase II study, SPRING1, evaluated 10mg, 25mg and 50mg 
OD against the active control efavirenz 600 mg in ARV-naive subjects. All regimens 
contained a NRTI backbone of ABC/3TC or TDF/FTC. At 48 weeks, all 3 DTG dosing 
arms achieved more rapid and sustained virological suppression than EFV (88-91% vs 
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82%) and there was no difference in efficacy between arms.392 This raises the question 
of whether DTG could be considered for dose optimisation trials in first line therapy, 
particularly if PK is found to play a significant contributory role in DTG toxicity. 
Several dose optimisation trials have been conducted in the past to challenge approved 
supratherapeutic dosing of commonly used agents such at ATV, EFV and AZT.393-396 
In the ENCORE-1 study, for instance, lower dose of EFV, 400 mg OD, was non-
inferior in efficacy and showed lower risks of EFV-related AEs compared to the 
approved dose of 600 mg OD, in ARV naïve individuals.395, 396 Efficacy was consistent 
across different races and CYP2B6 polymorphisms, which are known to affect EFV 
concentrations. Efficacy results were subsequently replicated in patients with TB/HIV 
co-infection on rifampicin and in pregnant women and the WHO antiretroviral 
guidelines were updated to recommend EFV 400mg as the alternative first line option 
to DTG, aiming to reduce cost and overall toxicity of EFV-based therapy.397-399   
Consideration of DTG dose optimisation research aiming to reduce global cost and 
toxicity would depend on upcoming results from DTG toxicity aetiology studies, key 
population safety and efficacy data and overall cost-saving analyses, since DTG is 
already relatively competitively priced in LMIC (median price $30 per person per 
year; TDF/3TC/DTG is $75 per person-year).66  
 
In conclusion, on the back of the remarkable advances made in HIV pharmacotherapy 
in the last three decades, the field has been able to progress towards investigating and 
implementing the individualisation of treatment. Tailoring of therapy can be beneficial 
on an individual level but also on a population-level, where characteristics such as 
genomics or clinical circumstances (e.g. co-infection and pregnancy) are common to 
a population. DTG and, to a lesser degree, COBI have played a significant role in this 
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paradigm shift. DTG, in particular, is becoming a key player in the global ARV scale 
up, meaning that any findings related to DTG will be applicable to very large 
populations. The novel data presented in this thesis addresses gaps in knowledge on 
DTG and COBI’s pharmacological behaviour in important patient groups and clinical 
scenarios frequently encountered by physicians, namely older PLWH, women on 
contraception, patients who are poorly adherent, candidates for DTG/DRV/COBI dual 
therapy and genetically distinct populations. The findings provide data to assist 
clinicians in decision-making in clinically and genetically predefined sub-populations 
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Appendix 1: commercial nomenclature for individuals ARVs 
 
Molecule/combination UK commercial name 
Efavirenz + emtricitabine + tenofovir DF Atripla 
Bictegravir + TAF + emtricitabine Biktarvy 
Rilpivirine + emtricitabine + tenofovir DF Eviplera 
Rilpivirine + emtracitabine + TAF Odefsey 
Dolutegravir + abacavir + lamivudine Triumeq 
Elvitegravir + cobicistat+ emtracitabine + TAF Genvoya 
Darunavir + cobicistat + emtricitabine + TAF Symtuza 
Doravirine + lamivudine + tenofovir DF Delstrigo 
Dolutegravir + lamivudine Dovato 
Dolutegravir + rilpivirine Juluca 
Tenofovir DF + emtracitabine Truvada 
Tenofovir alafanemide (TAF) Descovy 
Abacavir + lamivudine Kivexa 
Efavirenz Sustiva 
Nevirapine Viramune 








Atazanavir + cobicistat Evotaz 





Appendix 2: Description of sleep questionnaires used in chapter 2 study:  
1. The Pittsburgh Sleep Quality Index (PSQI) is a well validated multidimensional 
tool with 19 scored questions (0-3 likert scale) covering 7 domains of subjective 
sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep 
disturbances, use of sleeping medications and daytime dysfunction. It aims to 
measure sleep quality and disturbances over the prior month and to discriminate 
between “good” and “poor” sleepers. The scoring range is 0-21. Score of 5 and 
above indicates poor sleep quality. 
2. The insomnia severity scale (ISS) is a self-questionnaire to measure the nature, 
severity and impact of any insomnia experienced including associated concerns 
and distress; The scaling of items is on a 5 point likert scale, with a total range 
from 0-28; Cut offs are 0-7: no insomnia, 8-14: subthreshold insomnia, 15-21: 
significant insomnia and 22-28: severe insomnia. 
3. The Epworth Sleepiness Scale (ESS) is an 8 question self reported tool to assess 
tendency for daytime sleepiness. It does not distinguish the cause and there is no 
recall period. The scoring range is between 0-24. Scores of 10 or higher indicate 
excessive daytime sleepiness. 
4. The Functional Outcomes of Sleep Questionnaire (FOSQ) is a 30-question tool to 
assess the impact of excessive sleepiness on functional outcomes relevant to daily 
behaviours and sleep-related quality of life. It contains 30 items in 5 factor 
subscales: activity level, vigilance, intimacy and sexual relationships, general 
productivity, social outcome and difficulty performing a given activity. The range 
goes from 5-10. Higher scores indicate better functional status. 
5. The Fatigue Severity Scale (FSS) is a 9-item questionnaire to assess the effect of 
fatigue on daytime function in a 7-point likert scale. There are no categories or 
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domains established and the recall period is 1 week. The scoring range goes from 
0-63. Scores of 36 or higher indicate fatigue. 
 
6. The SDQ is a 175-question extensive and comprehensive questionnaire, which 
assesses all of the sleep domains (this was only administered on days 1 and 180 
only). The recall period is 6 months.
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Appendix 2; Table A: Sleep questionnaire results by time point 
Sleep component, median (IQR) 
Baseline  
(n=43) 
Day 28  
(n=40) 
Day 90  
(n=38) 
Day 180   
(n=38) 
n Score n n' Score n n' Score n n' Score 
PSQI (Sleep Quality)                       
  Subjective sleep quality 43 1 (1,2) 40 40 1 (1,2) 37 37 1 (0,1) 38 38 1 (0,2) 
  Sleep latency 43 1 (0,1) 39 39 1 (0,2) 36 36 1 (0,1) 38 38 1 (0,2) 
  Sleep duration 42 1 (0,1) 39 38 1 (0,2) 37 37 1 (0,1) 36 35 1 (0,1.5) 
  Habitual sleep efficiency 40 0 (0,1.5) 38 35 1 (0,2) 37 35 0 (0,2) 35 32 1 (0,2) 
  Sleep disturbances 40 1 (1,2) 38 36 1 (1,2) 37 34 1 (1,2) 38 35 1 (1,2) 
  Sleeping medication 43 0 (0,0) 39 39 0 (0,0) 37 37 0 (0,0) 38 38 0 (0,0) 
  Daytime dysfunction 42 1 (0,1) 40 39 1 (0,1) 37 36 1 (0,1) 38 37 1 (0,1) 
Global PSQI 36 5 (3.5,7.5) 35 29 6 (4,9)** 36 30 5.5 (3,9) 35 28 6 (4,11) 
  Global PSQI >5a, n (%) 36 16 (44) 35 29 18 (51) 36 30 18 (50) 35 28 18 (51) 
ESS (Sleepiness)                       
Overall ESS 41 5 (3,10) 37 37 6 (4,8) 34 32 5 (2,7) 38 36 5 (3,8) 
  ESS ≥10b, n (%) 41 12 (29) 37 37 8 (22) 34 32 6 (18) 38 36 9 (24) 
ISI (Insomnia)                       
Overall ISI 42 5.5 (2,10) 40 39 6.0 (3,10.5) 35 35 6.0 (1,10) 38 37 6.5 (1,12) 









    ≤14 (none or subthreshold) 38 (90) 37 (93) 33 (94) 30 (79) 
    15-21 (moderate) 3 (7) 2 (5) 2 (6) 8 (21) 
    ≥22 (severe) 1 (2) 1 (3) 0 (0) 0 (0) 
FOSQ (Functional Outcomes)                       
  General productivity 42 3.88 (3.6,4) 40 39 3.88 (3.6,4) 37 36 3.75 (3.25,4) 38 37 3.88 (3.6,4) 
  Social outcome 42 4.00 (4,4) 40 39 4.00 (4,4) 37 36 4.00 (4,4) 38 37 4.00 (4,4) 
  Activity level 43 3.67 (3.3,3.9) 40 40 3.56 (3.4,3.8) 37 37 3.67 (3.3,3.9) 38 38 3.65 (3.2,3.9) 
  Vigilence 43 3.71 (3,4) 40 40 3.63 (3.3,3.9) 37 37 3.71 (3.4,4) 38 38 3.57 (3.3,4) 
  Intimacy 38 3.75 (3,4) 36 35 3.75 (3.1,4) 34 31 4.00 (3,4) 36 31 3.88 (3,4) 
Global FOSQd 42 18.36 (16.1,19.5) 40 39 18.55 (16.7,19.4) 36 35 18.81 (17.8,19.7) 38 37 18.01 (16.4,19.6) 
FSS (Fatigue)                       
Overall FSS 39 22 (14,19) 35 31 23 (16,34) 31 28 21 (14,31) 35 31 26 (14,34) 




              
 
SDQ (Sleep Disorders)                       
            
  Sleep apnea 23 29 (25,31)         31 19 26 (23,31) 
  Periodic leg movement 38 20 (18,24)         36 32 20 (17,24) 
  Psychiatric sleep disorder 35 17 (14,21)         35 29 16 (14,21) 
  Narcolepsy 28 19 (17,22)             30 23 18 (16,20)             
Scores are raw median (IQR) unless otherwise stated. N are number of individuals with results at time point. N' are number of individuals with baseline & timepoint results 
Significant testing using Wilcoxon matched pairs sign-rank test compared to baseline. *** p <0.001, ** p <0.01, * p <0.05 (no correction for multiple testing) 
EFV, efavirenz;  ESS, Epworth sleepiness scale; FOSQ, Functional outcomes of sleep questionnaire; FSS, Fatigue severity scale of sleep disorders; ISI, Insomnia severity index; IQR, Interquartile range; PSQI, Pittsburgh sleep quality index; 
SDQ, Sleep disorders questionnaire 
For all sleep components a higher score indicates poorer performance with the exception of FOSQ, for which a higher score indicates better performance. PSQI domain range 0-3, global range 0-21; FOSQ domain range 1-4, global range 5-
20; ESS range 0-24; ISI range 0-28; FSS range 9-63; SDQ, sleep apnea range 12-60, period leg movement range 9-45, psychiatric sleep disorder range 9-45, narcolepsy range 15-75. 
a Global PSQI >5 considered poor sleep quality; bESS ≥10 considered sleepy; cFSS ≥36 indicates possible fatigue; dGlobal FOSQ only calculated if ≥60% questions answered 
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Appendix 2: Table C: Sleep scores by previous efavirenz status 
Scores are raw median (IQR) unless otherwise stated. 
EFV, efavirenz; ESS, Epworth sleepiness scale; FOSQ, Functional outcomes of sleep questionnaire; FSS, Fatigue severity scale of sleep disorders; ISI, Insomnia severity index; IQR, Interquartile range; PSQI, Pittsburgh 
sleep quality index; SDQ, Sleep disorders questionnaire 
Note: At baseline, for all sleep components a higher score indicates poorer performance with the exception of FOSQ, for which a higher score indicates better performance. PSQI domain range 0-3, global range 0-21; 
FOSQ domain range 1-4, global range 5-20; ESS range 0-24; ISI range 0-28; FSS range 9-63; SDQ, sleep apnea range 12-60, period leg movement range 9-45, psychiatric sleep disorder range 9-45, narcolepsy range 15-
75. For difference scores, score sign is reversed for all outcome measures where increasing values indicate performance decline. Thus, for all measures, negative change values indicate performace decline & positive 
values indicate performance improvement 
aP-values are exact Mann-Whitney tests for difference between groups at baseline; bP-values are exact Mann-Whitney tests for absolute difference between groups (non-EFV versus EFV) for change from baseline to 




Baseline Change from baseline, mean (SD) 
Day 28 Day 90 Day 180 
No EFV EFV p-
valuea 
No EFV EFV p-
valueb 
No EFV EFV p-
valueb 
No EFV EFV p-
valueb 
PSQI, global 6 (4,11.3) 4 (1,6) 0.029* -1 (-2,1) -1  
(-2.3,0.3) 
0.923 -1 (-3,1) -1  
(-3,0) 
0.719 0 (-1,1) 0 (-5,1) 0.556 

















ESS 6 (4.5,11.5) 4 (3,7.5) 0.049* 0 (-2,2) -1  
(-1,0.5) 





ISI 8.5 (3.8,11.5) 3 (0,7) 0.015* 0 (-2,2.3) 0 (-3,2) 0.961 0.5 (-
1.3,3.5) 










SDQ, sleep apnea 31 (26,35) 26 (22,30) 0.024*   
 
    
 
  2 (-2.5,4.5) 0 (-2.3,1) 0.214 
SDQ, periodic leg 
movement 
20 (18,24) 20.5 (17,21) 0.953   
 
    
 







17.5 (14,22) 16 (14,20) 0.541   
 
    
 
  1 (-3,3) 1  
(-2.5,4.3) 
0.855 
SDQ, narcolepsy 18.5 (16,23.5) 20 (18,21) 0.651             -1.5 (-3,1.8) 3 (0,4) 0.007** 
 
 180 
Appendix 2; Table E: P-values for correlation between PK parameters 
and change in sleep scores (baseline-day 180) 
Correlations tested using Spearman correlation. *** p <0.001, ** p <0.01 * p <0.0 
Appendix 2; Table D: P-values for correlation between PK parameters 
at day 28 and sleep scores at day 180 
 
Sleep component Cmax Clast AUClast 
PSQI, global -0.04 -0.09 -0.12 
FOSQ, global -0.09 0.24 0.17 
ESS 0.17 -0.15 -0.02 
ISI 0.01 0.08 0.01 
FSS -0.06 0.17 0.45 
Correlations tested using Spearman correlation. *** p <0.001, ** p <0.01 * p <0.0 
 
Sleep component Cmax Clast AUClast 
PSQI, global -0.16 -0.1 0.15 
FOSQ, global 0.04 0.07 0.09 
ESS -0.1 -0.21 -0.12 
ISI -0.12 -0.15 -0.14 
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